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Zusammenfassung
1 Zusammenfassung
Laut der aktuellen weltweiten Statistik über Krebserkrankungen (GLOBOCAN 2008), ist Brust-
krebs nicht nur der am häufigsten diagnostizierte Krebs, sondern zudem die Krebsart mit der
höchsten Mortalitätsrate bei Frauen.
In den letzten Jahren hat sich die Anwendung einer tumorspezifischen Vakzinierung als eine
mögliche Behandlungsoption für bestimmte Krebsarten, unter anderem auch Brustkrebs, etablieren
können. Von besonderem Interesse ist es hierbei Vakzinierungen zu entwickeln, die nicht nur eine
fortschreitende Metastasierung von Tumorzellen verhindern, sondern im idealen Fall bestehendes
Tumorgewebe eliminieren. Klassische Immunzellen, welche eine tumorspezifische und zytotoxische
Immunantwort vermitteln sind natürliche Killerzellen (NK Zellen) und zytotoxische CD8+ T Zellen
(CTLs). Neben CTLs zeigen auch aktivierte CD4+ T Zellen tumorspezifische Aktivität. Zahlreiche
wissenschaftliche Abhandlung beschreiben die Notwendigkeit einer Aktivierung von tumorspezi-
fischen CD4+ Effektorzellen zur Induktion einer effizienten gegen den Tumor gerichteten Immu-
nantwort. Das Brustkrebs assoziierte Antigen NY-BR-1 ist in 60% aller invasiven Brusttumoren
exprimiert, zudem liegt eine deutlich erhöhte Expression des NY-BR-1 Proteins in malignem Brust-
gewebe, im Vergleich zu normalem Brustgewebe vor. Schlussfolgernd stellt das NY-BR-1 Antigen
somit möglicherweise ein optimales Zielantigen für eine T Zell basierte, tumorspezifische Im-
muntherapie dar.
Zielsetzung dieser Arbeit war die Identifizierung neuer “Major Histocompatibility Complex” MHC-
I- und MHC-II- restringierter, NY-BR-1-spezifischer T Zell Epitope in HLA-transgenen Mäusen.
HLA-DRB1*0301-transgenen Mäusen (DR3tg Mäuse) und HLA-DRB1*0401-transgener Mäuse
(DR4tg Mäuse) wurden mit einem NY-BR-1-kodierender Experssionsvektor immunisiert um eine
NY-BR-1-spezifische T Zell Antwort in den Mäusen zu induzieren. Mittels IFN-γ EliSpot Tests und
einer NY-BR-1-spezifischen synthetischen Peptidbibliothek, konnten insgesamt drei neue NY-BR-
1-spezifische, HLA-DRB1*0301-restringierte Peptide (BR1-1347, BR1-88, BR1-1238) und drei
neue NY-BR-1-spezifische, HLA-DRB1*0401-restringierte Peptide (BR1-537, BR1-1242, BR1-
656/-775) in DR3tg Mäusen bzw. in DR4tg Mäusen, identifiziert werden. Daraufhin wurden
stabile murine CD4+ T Zell Linien, spezifisch für die neu identifizierten NY-BR-1-spezifische
Epitope aus DR3tg und DR4tg Mäusen generiert. Die HLA-Restriktion der murinen CD4+ T
Zell Linien wurde auf Grund der spezifischen Erkennung von peptidbeladenden T2/DR3 und
T2/DR4 Zielzellen bestätigt. Die endogene Prozessierung der NY-BR-1-spezifischen Epitope
BR1-1347, BR1-88, BR1-537 und BR1-1242, konnte anhand der spezifischen Erkennung von
humanen Dendritischen Zellen, welche mit Zelllysaten von Ad5-NY-BR-1 infizierten Tumorzellen
beladen worden waren, gezeigt werden.
Um eine mögliche klinische Relevanz der neu identifizierten, NY-BR-1-spezifischen Epitope zu
1
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zeigen, wurden periphere mononukleare Zellen (PBMCs) von Brustkrebspatienten, mit passen-
dem HLA-Genotyp, auf das Vorhandensein von NY-BR-1-spezifischen CD4+ T Zellen untersucht.
CD4+ T Zellen, spezifisch für die neu identifizierten Epitope BR1-88, BR1-1347, BR1-1238,
BR1-537, BR1-1242 und BR1-656/-775, konnten in PBMCs von Brustkrebspatienten detektiert
werden.
Die in dieser Arbeit neu identifizierten NY-BR-1-spezifischen CD4+ T Zellepitope könnten zum
Beispiel für die Generierung von Tetrameren zum Nachweis NY-BR-1-spezifischer CD4+ T Zellen
in Brustkrebspatientinnen, oder zur Überwachung einer NY-BR-1-spezifischen Immunantwort in
Brustkrebspatientinnen genutzt werden. Des Weiteren eignen sich NY-BR-1-spezifische Tetramere
gegebenenfalls auch zur selektiven Gewinnung NY-BR-1-spezifischer CD4+ T Zellen, welche nach
in vitro Expansion für einen adoptiven T Zell Transfer verwendet werden könnten. Eine weitere
Möglichkeit wäre die Generierung autologer T Zellen, welche einen NY-BR-1-spezifischen T Zell
Rezeptor exprimieren und somit für einen adoptiven T Zell Transfer geeignet wären.
NY-BR-1-spezifischen Vakzinierung sollten im idealen Fall sowohl MHC-I als auch MHC-II-
restringierte T Zell Epitope beinhalten, so dass zusätzlich zu der Induktion von NY-BR-1-spezi-
fischen CD8+ T Zellen auch NY-BR-1-spezifische CD4+ T Zellen stimuliert werden. Neben
der Aufrechterhaltung einer spezifischen, von CD8+ T Zellen vermittelte Immunantwort, können
antigen-spezifische CD4+ T Zellen durch Interaktion mit antigenpräsentierenden Tumor assozi-
ierten Makrophagen (TAMs) im Tumorstroma, möglicherweise maßgeblich zu einer gegen den
Tumor gerichtete Immunantwort beitragen.
2
Abstract
2 Abstract
Out of all malignancies, breast cancer is the second most common cancer worldwide and the
leading cause of cancer related death in females. In recent years it has been shown that the
anti-tumor vaccination might be a feasible approach for the treatment of certain cancer types,
including breast cancer. It is of great interest to develop immunotherapies which not only prevent
further dissemination by the tumor cells, but also eliminate tumor tissue and impair the function
of immune-suppressive cells, such as regulatory T cells (Tregs), in the tumor microenvironment.
Not only antigen-specific cytotoxic CD8+ T cells (CTLs) but also CD4+ T cells show a great
capacity to facilitate a specific anti-tumor immune response. Furthermore, successful immuno-
logical eradication of tumors depends on the presence of activated tumor antigen-specific CD4+
effector T cells as documented by numerous reports. The differentiation antigen NY-BR-1 has
been described to be expressed in 60% of all invasive mammary carcinomas. Since NY-BR-1
protein levels are highly elevated in malignant breast tissues compared to healthy breast tissues,
NY-BR-1 might represent a suitable target antigen for T cell based immunotherapy approaches
against breast cancer.
The aim of this project was to identify novel MHC-I- and MHC-II-restricted T cell epitopes de-
rived from the breast cancer associated antigen NY-BR-1. A NY-BR-1-specific peptide library was
utilized to screen for the presence of MHC-I and MHC-II- restricted T cells in HLA-DRB1*0301-
transgenic mice (DR3tg mice) and HLA-DRB1*0401-transgenic mice (DR4tg mice), after global
NY-BR-1-DNA vaccination. Splenocytes of immunized mice were screened ex vivo for a NY-BR-
1-specific T cell response against a synthetic peptide library covering the entire NY-BR-1 protein.
So far, novel NY-BR-1-specific, HLA-A2-restricted CD8+ T cell epitopes could not be identified.
However, the first NY-BR-1-derived, HLA-DRB1*0301-restricted peptides (BR1-1347, BR1-88,
BR1-1238) and the first NY-BR-1 derived, HLA-DRB1*0401-restricted peptides (BR1-537, BR1-
1242, BR1-656/-775) were identified in DR3tg mice and DR4tg mice, respectively.
Stable murine CD4+ T cell lines specific for five new epitopes could be established from
peptide-immunized DR3tg mice / DR4tg mice, and HLA-DR-restriction of the cell lines was
confirmed on peptide loaded T2/DR3 and T2/DR4 target cells in vitro. Furhtermore, endoge-
nous processing of HLA-DRB1*0301-restricted NY-BR-1-derived epitopes BR1-88, BR1-1347 and
of the HLA-DRB1*0401-restricted NY-BR-1-derived epitopes BR1-537, BR1-1242 could be con-
firmed by specific recognition of human dendritic cells loaded with cell lysates of melanoma cell line
Ma-Mel73a infected with Ad5-NY-BR-1. CD4+ T cells specific for the NY-BR-1 derived, HLA-
DRB1*0301-restricted peptides BR1-88, BR1-1347, BR1-1238 and for the HLA-DRB1*0401-
restricted peptides BR1-537, BR1-1242, BR1-656/-775 were detected among PBMCs of breast
cancer patients stimulated with the respective peptide in vitro for 24 days. Furthermore, CD4+
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T cells with the same specificities were also detected among PBMCs of HLA-matched healthy
donors, however, frequencies of antigen-specific CD4+ T cells were higher in the peripheral blood
of breast cancer patients compared to healthy donors.
The findings of this thesis, such as the identified NY-BR-1-specific, HLA-DRB1*0301-/*0401-
restricted CD4+ T cell epitopes, might be used to generate NY-BR-1-specific tetramers which
could be applied to monitor immune-responses in breast cancer patients with a tumor expressing
the NY-BR-1 antigen. Moreover, the new NY-BR-1-specific, CD4+ T cell epitopes could be ap-
plied to expand NY-BR-1-specific autologous CD4+ T cells for an adoptive T cell transfer. Cloning
of high affinity TCRs, specific for the newly identified epitopes, to generate TCR-transduced CD4+
T cells for adoptive T cell transfer might be another application for the findings obtained in this
work. NY-BR-1-specific therapeutic vaccines could be designed by combination of CTL and CD4+
T cell epitopes to induce NY-BR-1-specific CD8+ T cells as well as NY-BR-1-specific CD4+ T
cells. Infect, CD4+ T cells are not only important to sustain a functional CD8+ T cell response,
but might also target MHC-II expressing tumor associated macrophages (TAMs) presenting NY-
BR-1-specific epitopes on MHC-II, thereby contributing to anti-tumor immunity.
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3 Introduction
3.1 Cancer
Based on the latest estimate of the worldwide burden of cancer (GLOBOCAN 2008), cancer
represents the leading cause of death (7.6 million cancer deaths in 2008) in the world [72]. An
estimate of 200 subtypes of malignant tumors are described, the most common ones in Europe
being: colorectal cancer (436.000 cases, 13.6% of total), breast cancer (421.000, 13.1% of the
total) and lung cancer (391.000, 12.2% of the total) [72].
Cancer is a single cell based disease which can arise in almost every tissue in the body. Due
to their origin, malignant tumors can be classified in three major groups; carcinomas, sarcomas
and lymphomas. Carcinomas develop from normal epithelial cells e.g in the breast, colon or
lung whereas adenocarcinoma originates in glandular epithelial cells. Sarcomas are arising from
mesenchymal tissue such as muscles, bones, fat and cartilage. The last major group of malignant
tumors is represented by lymphomas defined as cancers of the hematopoietic system, lymph nodes
or blood, respectively. Myeloma, originating from plasma B lymphocytes in the bone marrow can
also be classified as a cancer of the hematopoetic system.
One of the fundamental features of cancer is the tumor clonality described by the transforma-
tion of a normal single cell into a malignant cell which is characterized by abnormal proliferation
due to genetic mutations. The multistep process of cancer development can be accounted to the
accumulation of genetic mutations, often leading to uncontrolled cell cycle activity, one exam-
ple being the mutation of tumor suppressor genes such as BRCA1/BRCA2 (breast cancer 1/2)
which are fundamentally involved in DNA repair, DNA recombination, cell cycle control and DNA
transcription [258]. Furthermore, aberrant epigenetic information is known to trigger carcinogen-
esis, one example being hypermethylation of the BRCA1 gene promotor region leading to the
silencing of the BRCA1 gene [277]. Acquired mutations of pro-oncogenes, such as chromosome
rearrangements in the case of the BCR-ABL gene cause constitutive activation to the Bcr-Abl
tyrosinkinase, which subsequently leads to the development of chronic myeloid leukemia (CML)
[138]. Moreover, gain of function mutations, for example in the receptor tyrosine kinase c-kit,
inducing uncontrolled cell proliferation resulting in malignancies such as gastrointestinal stromal
tumors (GIST) [51], are commonly found to induce cancer.
Given the fact of genomic instability being an underlying mechanism for the development
of cancer, Hanahan and Weinberg defined the hallmarks of cancer [97] . The ten hallmarks of
cancer include - genome instability and mutation, sustained proliferative signaling, evading growth
suppressors, resisting cell death, induction of angiogenesis, activating invasion and metastasis,
enabling replicative immortality, deregulating cellular energetics, tumor promoting inflammation
and evasion of immune destruction, all promoting the development of malignant tumors being the
13
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Figure 1: Hallmarks of cancer. This figure illustrates the ten hallmarks of cancer and some of the many approaches employed in
developing therapeutics targeted to the known and emerging hallmarks of cancer [97].
attributes of cancer cells [97].
“Evading of immune destruction” being one hallmark of cancer indicates the great importance
of the immune system to prevent malignant cell growth in the first place, thus investigation on
overcoming the evasion of tumor cells from anti-tumor immunity, as well as promoting a more
sustained immune responses, present two attractive strategies in how to interfere with cancer
progression and established cancers.
3.2 Breast Cancer
3.2.1 Incidence and risk factor
Based on the latest cancer statistics world wide (GLOBOCAN 2008), breast cancer resembles the
most common overall diagnosed cancer in women (1.38 million, 18.2% of total) and the leading
cause of cancer related deaths in women (13.7% of total cancer related deaths in women) [72]. In
the year 2011, 39.520 breast cancer deaths are expected in women in the United States of America
representing the leading cause of death among US women [53]. Important to notice, since 1990
breast cancer related death decreased by 34% among women in the United States [53]. Reduction
of breast cancer related death in women is mainly due to mammography screening programs
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which invite women at the age of 50-69 to a biannual mammography screening. A comprehensive
analysis indicates that the entry age of women included in the screening program is relevant for the
overall beneficial effect of mammography screening. Even though the mean reduction of breast
cancer related mortality due to mammography screening programs was calculated as 12%, women
entering the screening program between the age of 65-70 years statistically reduce their risk of
breast cancer related mortality up to 30% [18]. Nevertheless, mammography screening programs
have to be evaluated critically since 30% of women enrolled in the breast cancer screening programs
are over-diagnosed for breast cancer [90].
The overall likelihood of ones risk for the development of breast cancer can be analyzed due
to a number of known personal and familial risk factors. Risks for breast cancer development
are elevated if breast cancer cases were diagnosed in close female relatives (mother) before the
age of 40 years [42]. Familial risk factors also include inherited breast cancer associated germ
line mutations one example being mutations in the BRCA1 tumor-suppressor gene [68]. BRCA1
mutation carriers at the age of 60 were found to have an elevated breast cancer risk of 54%
[65]. Furthermore, an increased risk for the development of breast cancer was observed in BRCA1
mutation carriers due to diagnostic radiation exposure thus other imagine techniques e.g. magnetic
resonance imaging (MRI), should be considered as an alternative imaging technique in this group
of patients [195]. Nulliparity increases the risk of developing breast cancer in women aged 40 years
and older whereas on the other hand a full-term pregnancy significantly decreases the occurrence
of breast cancer in women, the underlying mechanism still being under investigation [122].
A modifiable risk factor for the disease of breast cancer is obesity in postmenopausal women
which is described to correlated with breast cancer incidence [123]. One mechanism underlying
elevated risk for the development of breast cancer in obese postmenopausl women might be
increased serum levels of secreted insulin and circulating free insulin-like growth factor (IGF-1)
often found in obese people [75]. Downstream signaling of the insulin receptor and IGF-1 involves
the pro-survival phosphatidylinositol-3 kinase (P13K)/Akt pathway already often unregulated in
breast cancers and further stimulated by high levels of insulin and free insulin-like growth factor
in obese breast cancer patients [75]. Secondly, in postmenopausal women, estrogen is primarily
produced in adipose tissue by aromatization of androgens, hence due to greater availability of
adipose tissue, levels of estrogen are highly elevated in obese postmenopausal patients [123].
In consequence, elevated levels of free estrogen in obese breast cancer patients, might induce
increased signaling via the estrogen-receptor (ER) in estrogen-receptor positive breast cancers,
leading to an enhanced cell proliferation and inhibition of apoptosis in ER- positive breast cancer
patients [274][75].
Furthermore, hormone replacement therapy (HRT), substituting the hormone estrogen in post-
menopausal women, is associated with a 10% higher breast cancer risk for each five years of
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treatment duration [216]. Overall, great mammography density resulting from the proportions of
epithelial and stromal tissue composing the breast, which can be identified due to high-density
mammography parenchymal patterns, show the greatest impact on the prediction of breast cancer
risk of an individual person when compared to known breast cancer risk factors such as family
history and age at first birth [28].
3.2.2 Development and classification of breast cancer
Breast cancer is a very common but heterogeneous disease. Many malignancies of the breast are
firstly recognized as premalignant lesions. Depending on the cells of origin, premalignant leasions
are either termed atypical ductal hyperplasia (ADH) when originating from epithelial cell lining
the breast ducts, or atypical lobular hyperplasia (ALH) if epithelial cells of the lobules are the
progenitor cells [6]. In many cases premalignant lesions are stable as benign lesions but they
are also known to progress into either a ductal carcinoma in situ (DCIS) or a lobular carcinoma
in situ (LCIS). In situ carcinomas further on might progress into invasive carcinoma such as in-
vasive ductal carcinoma (IDC) [7] or invasive lobular carcinoma (ILC) which then are prone to
form metastasis. Sporadic invasive ductal carcinomas develop from epithelial cells lining the milk
ducts. Normal mammary gland breast ducts are composed of two cell layers - luminal epithelial
cells surrounding the lumen and myoepithelial cells (also termed basal cells) lining the basement
membrane [197]. Basal like breast cancer is characterized by over-expression of genes involved
in fatty acid metabolism and steroid hormone-mediated signaling pathways like estrogen recep-
tor (ER) signaling whereas signature genes of the luminal breast cancer phenotypes are genes
involved in proliferation and differentiation such as G1-S checkpoint of cell cycle proliferation
[239]. Once either myoepithelial cells or luminal epithelial cells experience phenotypically alter-
ations due to the accumulation of pro-oncogenic mutations, one example being mutations in the
phsophatidylinsoitol-3-kinase (P13K) involved in the pro-survival Akt signaling pathway [63], a
ductal carcinoma in situ is established ongoing with a simultaneous loss of myoepithlial cells due
to degradation of the basement membrane [197]. Complete loss of the basement membrane and
myoepithelial cells indicates an invasive carcinoma, which most likely forms metastasis, commonly
spreading to the lung, pleura, liver and bone in breast cancer patients [268].
The three main prognostic determinants for breast cancer patients are lymph node (LN) sta-
tus, tumor size, and histological grade, also known as the Nottingham Grading System (NGS)
which includes the investigation of the percentage of tubule formation, the degree of nuclear
pleomorphism and and accurate mitotic count [66]. Patients with four or more involved lymph
nodes at initial diagnosis have a high risk of experiencing breast cancer metastasis formation orig-
inating from their primary breast tumor [117]. Furthermore, a number of breast cancer metastasis
prognostic markers are established in the clinic and will be discussed in the following. The actual
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tumor size indicates the risk for metastasis formation, tumors < 2 cm in diameter implicate low
risk of metastasis, whereas tumors of 2-5 cm and above hold great potential of metastasis for-
mation. Upon initial diagnosis, axillary lymph nodes are screened for the presence of metastases.
Metastasis free axillary lymph node status indicates a low risk of primary tumor metastasis wheres
presence of lymph node metastasis relates to a high metastasis risk of the primary tumor [268].
Based on comprehensive gene expression profiling, breast cancer subtypes can be classified due
to their hormone receptor status, regarding the expression of hormonal receptors (estrogen receptor
(ER), progesterone receptor (PR)) [5], as well as to over-expression of the ERBB2 gene (epidermal
growth factor receptor 2), also known as HER2. A HER2 positive breast cancer receptor status is
generally associated with a more aggressive cancer phenotype [60] due to HER2 signaling related
activation of pro-survival pathways in the cancer cell. The four major breast cancer subtypes
classified by receptor status are the luminal A (ER+ and/or PR+, HER2-, Ki-67<14%), luminal
B (ER+ and/or PR+, HER2-, Ki-67>14% or ER+ and/or PR+, HER2+), HER2-enriched (ER-,
PR-, HER2+), and triple negative breast cancer (TNBC) (ER-, PR-, HER2-) [188].
As shown in figure 2, the “cell of origin model” proposes the initiation of a specific tumor
subtype due to its parental cell being either a bipotential stem cell which will give rise to basal-
like tumors (ER-, PR-, HER2-), or a luminal progenitor cell which will give rise to either luminal
tumors (ER+, PR+, HER2-) or HER2+ tumors (PR-, ER-) [197]. A second model of breast tumor
subtype-specific transforming events (fig.2) proposes the occurrence of transformations, such as
somatic mutations taking place in the bipotential stem cell leading to the development of the
major breast tumor subtypes mentioned above [197].
Figure 2: Hypothetical models explaining breast tumor subtypes. Cell of origin (A) and tumor subtype-specific transforming
event (B) models. Based on the cell of origin hypothesis, each tumor subtype is initiated in a different cell type (presumably stem or
progenitor cell), whereas according to the model depicted in B, the cell of origin can be the same for different tumor subtypes and the
tumor phenotype is primarily determined by acquired genetic and epigenetic events [197].
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Apart from breast carcinoma cells, genetic profiling has indicated the presence of a variety
of different cell types in human breast tumors, such as endothelial cells, stroma cells, B lympho-
cytes, T lymphocytes and macrophages [193]. Increased lymphocyte infiltration in the tumor and
tumor stoma is generally associated with a good prognosis in ER-/HER2-negative breast cancers
[148]. Fibroblasts, the predominant cells of the breast stroma are known to possibly convert
to cancer associated fibroblasts (CAF) in tumors [232]. Mammary cancer associated fibroblasts
are described to influence tumorigenesis by inducing epithelial-to-mesenchymal transition (ETM),
whereby expression of the metastatic marker vementin is induced in breast tumor cells by the in-
fluence of CAF [238]. Furthermore, breast cancer cells induce CAF to secrete hepatocyte growth
factor, this being one example for the crosstalk between malignant cell and CAFs [158]. Hepa-
tocyte growth factor resembles a ligand of the Met receptor tyrosine kinase whereby aberrantly
activation of Met is associated with high grade tumor invasiveness[84]. Besides CAF, tumor asso-
ciated macrophages reside in the breast cancer microenvironment. The majority of macrophages
within the tumor site are of a polarized M2 phenotype [154]promoting tumor progression by tissue
remodeling, enhanced neo-angiogenesis and suppression of an adaptive immune response due to
secretion of interleukin 10 (IL-10) and activation of regulatory T cells (Tregs) [153].
Besides great diversity among individual breast cancer tumor subtypes, a high grade of het-
erogeneity can also be found within individual mammary tumors. Intratumoral heterogeneity of
breast cancer tumors can be accounted to either breast cancer stem cells acquiring mutations in
a multistep process with their progeny being of limited proliferation capacity or might follow the
competition among different breast cancer tumor cells of distinct phenotypes following the laws of
darwinian evolution [174]. Given the facts of intratumoral heterogeneity which might be altered
during tumor progression, this most likely explains sudden resistance to breast cancer therapies
which will be discussed in the next paragraph.
3.3 Standard therapy of breast cancer
Upon diagnosis of breast cancer, different treatments are available for the patients. Classical breast
cancer treatments such as surgery, radiation therapy and chemotherapy, as well as anti-hormonal
treatment and targeted therapies of breast cancer. Resectable tumors are often treated with
radiation therapy as well as neo-adjuvant chemotherapy to reduce tumor mass prior to surgical
removal of the tumor.
3.3.1 Surgery and radiation therapy
Minimal-invasive core needle biopsies as well as fine needle biopsies are widely used to diagnose
breast cancer due to histological analysis of the retained tumor sample. Vacuum-assisted core
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biopsy instruments remove breast tissue specimens by application of a vacuum at the tumor site,
sucking the sample into a small chamber where it is cut by high-speed rotating knives and can be
suctioned into a chamber outside of the patients body, available for pathological analysis of the
tumor specimens if needed [124].
Due to more advanced diagnostic approaches including diagnostic ultrasound of the breast,
magnetic resonance imaging, sentinel lymph node biopsy and mammography screening, most
tumors are discovered at early stages, thus breast cancer surgery continues to become more
conservative [40]. Breast conserving therapy (BCT) aims on removal of the tumor mass followed
by radiation therapy. Certain selection criteria have to be addressed when considering BCT [202],
namely the overall tumor size and histology of the tumor. Tumors of a size bigger than 4 cm
have to be reduced in size prior to BCT which can be achieved for example by administration of a
neo-adjuvant chemotherapy. Furthermore, the breast tumor needs to be non-invasive phenotype
to achieve disease-free margins upon breast conserving therapy. Moreover, minimally invasive
ablation techniques, such as cryotherapy, radio-frequency ablation or laser interstitial therapy
can be applied for the treatment of breast cancer. Cryotherapy aims on disruption of the cellular
membrane du to sudden temperature drops in the breast tumor tissue from 37°C to -70°C [241]. In
contrast to cryotherapy, radio-frequency ablation (RFA) induced tumor cell death by transmission
of frictional heat generated by intracellular irons moving due to an alternating current [235].
Laser interstitial therapy (LITT) causes cell death due to the delivery of thermal laser energy
through a fiberoptic probe which is inserted in the breast tumor [59]. Some women might still
require palliative radical mastectomy due to chemotherapy-resistant invasive breast tumors as
well as prophylactic mastectomy due to a personal or family history of mammary carcinomas.
Nevertheless, immediate breast reconstruction, remodeling the shape of the removed breast using
the patients own skin, helps to achieve excellent cosmetically results [226]. In addition of primary
breast tumor removal, axillary lymph node dissection (ALND) might be performed, especially
indicated in patients showing an invasive type of primary breast tumor with axillary lymph nodes
already reached by tumor cells originating from the primary breast tumor (node-positive patients)
[16].
Radiation therapy of breast cancer often follows surgical treatment, such as breast conservation
surgery but is also administered as surgical adjuvant radiotherapy to reduce the tumor size prior
to its surgical resection. Surgical adjuvant radiotherapy has been proven to significantly improve
the survival of breast cancer patients with operable tumors [255].
3.3.2 Chemotherapy
The use of systemic cytotoxic chemotherapy still remains first choice in both advanced and early
stage breast cancer. Chemotherapy can be administered as neo-adjuvant chemotherapy (prior
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to any other breast cancer related treatment) or as adjuvant-chemotherapy in combination with
other types of breast cancer treatment. A number of cytotoxic agents which can be classified into
four major groups are available: Alkylating agents, antimetabolites, anthracyclines and taxane.
Alkylating agents (e.g. cyclophosphamide) induce their cytotoxic effect mainly by DNA dam-
aging due to transfer of an alkyl group (CnH2n+1) to the guanine base of DNA which induces
intrastrand and interstrand DNA-crosslinking [184]. Alkylation of nucleotide acid additionally
leads to the activation of DNA repair pathways such as base excision repair (BER) and mismatch
repair (MMR) [79]thus a combinatorial treatment of alkylating agents based chemotherapy and
DNA-repair pathway-blockade should be considered to generate a more effective anti-tumor effect
[128].
Platinum based anti-cancer therapy (e.g. cisplatin) target cells‘ DNA by forming DNA adducts
via cross-linking of the DNA [265]. Accumulation of DNA-damage leads to the induction of
apoptosis in the tumor cell but there is also evidence available that cisplatin induces cellular death
due to necrosis [88].
Antimetabolites (e.g. 5-Fluorouracil, gemcitabine) represent chemicals which mimic natural
cellular metabolites such as purines and pyrimidines required for DNA-synthesis. By incorpora-
tion of the pyrimiden analogue 5-Fluororacil into the DNA during S-phase, cellular replication
is inhibited and cellular apoptosis induced, with damaged DNA being the apoptotic signal [150].
Furthermore, 5-fluorouracil inibits the enzyme thymidylated synthase which is important for pyrim-
idine de novo synthesis, resulting in a depletion of dTTP followed by decreased DNA synthesis
[177].
Anthracyclines (e.g. doxorubicin and daunorubicin) are cytostatic antibiotics commonly used
as adjuvant chemotherapies for the treatment of breast cancer. Activity of anthracyclines is related
to the inhibition of topoisomerase II, inducing growth arrest in the G1 and G2 phase of the cell
cycle due to anthracycline intercalation in the desoxyribonucleic acid (DNA) [105]. Moreover,
Doxorubicin induces cellular apoptosis du to transactivation of the human potent inducer of
apoptosis, the CD95 gene (Fas/APO-1 receptor) by binding of activated p53 [217]. Additionally,
anthracyclines are capable of reducing oxygen to generating reactive oxygen species (ROS) such
as superoxide anion (O2-) and hydrogen peroxide (H2O2) by adding one electron to their chemical
structure, leading to the induction of apoptosis in susceptible tumor cells [162].
The second chemotherapy regimen widely applied is the use of cytostatic active taxanes (e.g
paclitaxel, docetacel, epirubicin), a class of mitotic inhibitors used in breast cancer systemic
chemotherapy. Mitotic cell devision requires the formation of microtubuli structures in the cyto-
plasm of the cell. Microtubuli are composed of polymerized tubulin which consists of a α-subunit
and a β-subunit, assembled into tubulin dimers to form protofilaments lining the microtubuli wall.
To fulfill their function of mitosis, maintenance of cell shape and most important by intracellular
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trafficking, microtubuli require a high grade of dynamic behavior [228]. Paclitaxel blocks micro-
tubuli by binding to the ß-tubulin subunit in microtubuli. Thereby reducing their dynamics thus
impairing cell cycle proliferation by inhibiting the metaphase/anaphase transition of the affected
cell [282].
Resistance to individual chemotherapy regimens accounts for failure of tumorregression upon
systemic chemotherapy in breast cancer treatment. Multiple factors might contribute to inef-
fectiveness of cytotoxic agents such as increased drug eﬄux from the tumor cell, the favoring of
pro-survival pathways and down regulation of cell death pathways or drug deactivation [207]. Thus
treatment schedules for systemic chemotherapy have to be individualized for every breast cancer
patient. Combinatorial treatments approaches composed of different chemo-cytotoxic regimes are
especially indicated in the treatment of metastatic breast cancer. Combination of taxan-based
chemotherapy regimen paclitaxel and anthracycline cytostatic drug doxorubicin with the addition
of a platin regim, generated an objective response rate in stage IV metastatic breast cancer pa-
tients [136]. Comprehensive studies have shown a prolonged survival and improved anti-tumor
response in patients with metastatic breast cancer receiving a combination chemotherapy [33].
3.3.3 Anti-hormonal treatment
Estrogen (17 β-estradiol) belongs to the group of the steroid hormones which is synthesized in the
ovaries in premenopausal women, regulating growth, differentiation and function in many tissues of
the body, examples being the regulation of the normal growth and development of the breast and
maintenance of the menstrual cycle in women. A number of mammary tumors can be classified
as estrogen-positive (ER+) tumors due to expression of the estrogen-receptor in the tumor cells.
Up to now, two isoforms of estrogen receptors are known, ERα and ERβ both members of the
nuclear receptor family, with ERα being the predominant regulator of estrogen-induced target
gene expression in breast caner patients [185, 175]. Binding of estrogen to its receptor leads to
the activation of hormone-responsive genes which promote DNA-synthesis and cell proliferation.
Target genes of estrogen in breast cancer cells are the vascular endothelial growth factor (VEGF)
[8], c-Myc and cyclin D1 [57].
The first approach of anti-hormonal treatments aims on the inhibition of estrogen receptor
signaling by abrogating estrogen binding to its receptor. The anti-estrogen tamoxifen is a selec-
tive estrogen modulator which competitively binds to the estrogen receptor, thus inducing growth
arrest in the breast cancer cells [81]. Treating early breast cancers with tamoxifen was reported
to result in an improvement of 10 year survival rate in women with ER+ mammary carcinomas
[1]. The selective estrogen receptor modulator tamoxifen was approved by the Food and Drug
Administration (FDA) for the treatment of postmenopausal women with metastatic breast cancer.
Toremifen is structurally similar to tamoxifen, differing in only a single chlorine atom thus having
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a similar pharmacological profile. Comparative analysis revealed equal effectiveness of tamoxifen
and toremifen in patients with advanced breast cancer [155]. Similar to the effects of tamoxifen
and toremifen on estrogen-receptor signaling, a third agent, fulvestrant not only inhibits estro-
gen induced signaling by blockade of the estrogen-receptor but also accelerates the receptors
degradation by the ubiquitin-proteasomal pahtway [149].
Instead of blocking the estrogen receptor, aromatase inhibitors inhibit the enzyme aromatase,
a key enzyme in estrogen production. Aromatase is expressed in several tissues such as the
subcutaneous fat, liver, muscle, brain and normal breast tissue [172]. In postmenopausal women
the predominant source of estrogen is the conversion of androstenedione into physiological active
estrogen by the enzyme aromatase [234]. Aromatase inhibitors (e.g. letrozole, anastrozole,
exemestane) lack estrogen-agonist activity, therefore not inhibiting estrogen production in the
ovaries, but being effective in reducing estrogen serum levels in postmenopausal women by ir-
reversibly binding to the aromatase [83].
3.3.4 Targeted therapy
Targeted therapies specifically inhibit cellular signaling pathways associated with carcinogenesis,
such as human epidermal growth factor 2 (HER2), mammalian target of rapamycin (mTor) or
vascular endothelial growth factor (VEGF).
The cell surface receptor of human epidermal growth factor number 2 (HER2) is encoded by
the ERBB2 tyrosine kinase gene and belongs to the greater family of structurally related recep-
tors: HER1 to HER4 [181]. So far, no HER2 specific ligand has been identified, nevertheless,
spontaneous dimerization of the HER2 receptor accelerates the phosphorylation of intrinsic tyro-
sine kinase domains, finally resulting in the activation of the downstream signaling cascades such
as MAPK proliferation pathways or P13K/Akt prosurvival pathways [144]. Activation of MAPK
and P13/Akt associated pathways subsequently lead to a cellular growth promoting effect. HER2
functions as the preferred heterodimerization partner for the other ligand-activated human epider-
mal growth receptors such as EGFR, HER3 and HER4, with the heterodimers being very stable
on the cells surface [278] . Hence, by forming heterodimers with associated human epidermal
growths factors (e.g. EGFR, HER3, HER4), HER2 contributes to an overall signal amplification
of HER-related signaling [126].
The ERBB2 gene is found to be over-expressed in 30% of primary breast tumors in conse-
quence stimulating increased cellular proliferation of these tumor cells [236]. The targeting drug
trastuzumab (herceptin), a humanized, recombinant monoclonal antibody binds to the extracel-
lular domain of HER2 thereby inhibiting dimerization of the HER2 receptor leading to down-
regulation of HER2 related signaling such as pro-survival PI3K pathway [275]. Binding of the
monoclonal antibody trastuzumab to HER2 over-expressing cells additionally engages Fc receptor
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mediated immunity, leading to antibody-dependent cellular cytotoxicity (ADCC) in breast cancer
cells [9].Moreover, antiangiogenic effects were described for trastuzumab, due to inhibition of the
vascular endothelial growth factor pathway [134]. Breast cancer treatment regimens often com-
bine trastuzumab and different chemo-therapeutic approaches, examples being combination of
trastuzumab and paclitaxel leading to overall response rates of 62.5% in patients with metastatic
breast cancer [45]. Combined therapies might help to overcome trastuzumab resistance such as up
regulation of the P13K pathway [17]y or accumulation of p95-HER2, a truncated form of HER2
lacking the trastuzumab binding site [82]. Moreover, trastuzumab-emtansine, a HER2-specific
antibody-drug conjugate combines the monoclonal antibody trastuzumab and the cytotoxic agent
DM1 (deviate of maytansine) via a stable thioether linker [152]. Efficacy of prolonging pro-
gression free survival was proven in HER2 positive advanced breast cancer patients treated with
trastuzumab-emtansine [259].
While trastuzumab inhibits ligand-independent dimerization of HER2, the monoclonal antibody
pertuzumab binds to HER2 at a distinct epitope of the dimerization domain II from trastuzumab,
thereby inhibiting dimerization of HER2-HER3 complexes [13]. In consequence, pertuzumab inter-
feres with ligand dependent HER3-signaling by preventing heterodimers formation of HER2-HER3
[13]. Combined anti-HER2 therapy using both trastuzumab and pertuzumab led to synergistic
effects resulting in improved progression free survival of patients with metastatic breast cancer
[120].
Secondly, HER2 signaling can be targeted by tyrosine kinase inhibitors (e.g. Lapatinib) dis-
rupting e.g. HER2 downstream signaling due to inhibiting phosphorylation of the protein kinase
Akt in the PI3K pathway [262]. Lapatinib, a dual kinase inhibitor of human epidermal growth
factor 2-tyrosine kinase and epidermal growth factor (EGFR)-tyrosine kinase [129] proved to be
efficient in the treatment of HER2-positive patients with a locally advanced or metastatic breast
cancer hence leading to a progression free survival rate of 63% after four months of treatment
[87]. Combined therapies of lapatinib and the chemotherapeutic-agent capecitabine was approved
by the FDA for the treatment of metastatic breast cancer since the combinatorial therapy was
more effective in treating metastatic breast cancer than capecitabine alone [85, 218].
In July 2012, the FDA approved everolimus, a mTor inhibitor for the treatment of advanced
hormone receptor-positive, HER2-negative postmenopausal breast cancer patients in combination
with the aromatase inhibitor exemestane [176]. mTor is a downstream target of phospathidylinositol-
3 kinase (PI3K) signaling initiating cell growth, autophagy and proliferation once activated. The
rapamycin analog everolimus, binds to the serine/threonine kinase mTOR (mammalian target of
rapamycin), thus inhibiting mTor signaling mediated cell proliferation [221].
Apart from interrupting HER2 mediated signaling, the epidermal growth factor receptor (EGFR),
also named human epidermal growth factor 1 (HER1) which is located on the cells´membrane, can
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be selectively blocked in breast cancer therapy. Epidermal growth factor (EGF) is a known ligand
binding specifically to HER1 [24]. Initiated signaling via EGFR activates the intrinsic tyrosine ki-
nase activity of the EGFR which subsequently results in the activation of pro-proliferative pathways
such as the phospathidylinositol-3 kinase (P13K) associated pathway, leading to uncontrolled cell
proliferation of EGFR expressing breast cancer cells [147]. Activated EGFR can also be translo-
cated to the nucleus directed by its nuclear localization sequence (NLS) [107]. In the nucleus,
EGFR functions as a transcriptional co-activator regulating for example the cyclin D1 gene which
is required for highly proliferative activity of the cell [143]. Cetuximab, a chimeric (mouse/human)
monoclonal antibody, selectively binds to the EGFR, thus accelerating internalization of the re-
ceptor and in consequence decrease of EGFR-surface expression [98]. Furthermore, competitive
binding of cetuximab prevents further stimulation of the EGFR by endogenous ligands such as epi-
dermal growth factor (EGF) resulting in the abolishment of pro-proliferation signals in the affected
cell [98]. Moreover, binding of cetuximab to EGFR can induce antibody-dependent cellular cyto-
toxicity in triple negative breast cancer cell lines [210].In combination with the chemotherapeutic
drug cisplatin, cetuximab lead to increased progression free survival in patients with metastatic
triple-negative breast cancer [12].
Targeting of the tumors´ vascularization represents another group of targeted therapy ap-
proaches in breast cancer. The angiogenesis inhibitor bevacizumab (also named Avastin), is a
monoclonal antibody targeting the proangiogenic vascular endothelial growth factor (VEGF). Ele-
vated expression of VEGF has been associated with shorter relapse-free survival in primary breast
cancer patients [129]. Combinatorial therapy of bevacizumab plus paclitaxel leads to prolongation
of progression-free survival in patients with metastatic breast cancer compared to paclitaxel alone
[161].
Therapy resistance is one major hurdle of targeted therapies against breast cancer. Loss of
sensitivity for example by acquired resistance due to mutations, such as activating mutations in the
PI3K gene downstream of HER2, which renders cells to be insensitive for effects of trastuzumab
and lapatinib, are just two examples on how cancer cells acquire a therapy resistance [48]. Further-
more, inhibition of signaling pathways such as the Akt-pathway by application of Akt inhibitors,
might induce compensatory pathways in the cancer cell, one example being the induced expression
and phosphorylation of multiple receptor tyrosine kinases (RTKs) [35].
As discussed above, surgery, chemotherapy, anti-hormonal therapy and targeted therapies
are commonly used for the treatment of breast cancer. Nevertheless, tumor-immunotherapy
approaches are emerging to become more often the choice of treatment for breast cancer patients.
The principles of tumor immunotherapy and current knowledge on immunotherapy in breast cancer
patients will be discussed in the following.
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3.4 Principles of tumor immunology
3.4.1 The immune system
The immune system is a network of various immune cells, and different lymphoid tissues, orches-
trating in protecting the human body against disease. The lymphoid tissues are composed of
primary lymphatic tissues (bone marrow, thymus) and secondary lymphatic tissues (lymph node,
spleen, mucosa associated lymphatic tissue, skin). Whereas generation of immune cells takes place
in the primary lymphatic tissues, mature immune cells migrate to the secondary lymphatic tissues
where adaptive immune responses are initiated. Generally, the immune system can be classified
into innate immunity and adaptive immunity, both mediated by distinct cell populations. A brief
overview on cells of the immune system and their function will be discussed in the following.
Cells of the innate immunity develop in the bone marrow before they migrate to the periph-
ery. Monocytes and macrophages, granulocytes, mast cells, dendritic cells and natural killer cells,
providing immediate immunity without prior exposure to the antigen. Upon antigen encounter,
the innate immunity is the first line response, quickly recognizing antigens in an non-specific way
e.g. via pattern recognition receptors. Toll like receptor 4 (TLR4) is a pattern recognition receptor
recognizing lipopolysaccharide (LPS) originating from gram-negative bacteria whereas the man-
nose receptor binds sugar molecules found on the surface of many bacteria and viruses. Antigen
capture by cells of the innate immune system triggers for example phagocytosis of pathogen de-
rived antigens by macrophages, cellular cytotoxicity mediated by natural killer cells or the release
of toxic granules by granulocytes, overall inducing cellular death. Furthermore, innate immune
cells can be activated by binding of antibodies to their Fc receptor, therefore building a bridge
between innate immunity and the adaptive humoral immune response. Even though antigenic-
response rates are quick, innate immunity fails to establish a long lasting memory response that
provides a pre-existing immune response in case of a secondary infection.
The concept of adaptive immunity is based on the specific recognition of antigens by
antigen-specific receptors present on B lymphocytes and T lymphocytes. In the primary lymphatic
organs, such as bone marrow and thymus, lymphocytes are generated from progenitor cells,
whereas B lymphocytes are generated in the bone marrow and T lymphocytes are generated in
the thymus, respectively. Furthermore, central tolerance of T lymphocytes and B lymphocytes
is established in the primary lymphatic organs. In the thymus, one of the main mechanisms of
T-cell central tolerance is clonal deletion of self-reacting T cells, whereby immature auto reactive
B lymphocytes undergo negative selection and clonal deletion in the bone marrow. Self-reactive B
cells might be rescued from clonal deletion by receptor editing which might replace the self-reactive
receptor with a non auto-reactive B cell receptor.
Positively selected, mature lymphocytes migrate to the secondary lymphatic organs, such as
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the lymph nodes, the spleen and the mucosa-associated lymphoid tissue (MALT). Until encounter
of their specific antigen, mature lymphocyte recirculated between the secondary lymphatic organs
and the blood. Mature lymphocytes activation by antigen recognition takes place in the sec-
ondary lymphatic organs, leading to clonal expansion and maturation of activated lymphocytes.
The adaptive immunity is capable of establishing a durable memory response depending on the
generation of T lymphocyte memory cells and B lymphocyte memory cells. Lymphoid memory
cells are quick in generating an adaptive immune response upon second encounter of an antigen.
B lymphocytes recognize their specific antigen via a B cell receptor (BRC) on the cells sur-
face. Antigen recognition stimulates differentiation of a naive B cell into a plasma cell secreting
antibodies with the same specificity as the cells B cell receptor. Different classes of antibodies are
described such as IgG, IgM, IgA, IgE and IgD, all belonging to the group of immunoglobulins (Igs)
exerting there function via a constant Ig-domain. Pathogens often are opsonized by specific anti-
bodies binding to their surface, accelerating macrophage mediated phagocytosis of the pathogen.
A complete antigenic activation of naive B cells require the costimulatory help of antigen-specific
T lymphocytes. Since T lymphocytes are the major cell type investigated in this scientific work,
they will be analyzed in more detail below.
3.4.2 T cells
T cells develop in the thymus before they migrate into the periphery where they are activated
by MHC-restricted antigen recognition. T lymphocytes are characterized by expression of the
cluster of differentiation 3 (CD3) and an antigen-specific T cell receptor (TCR). Variety of the T
cell receptor repertoire is based on somatic recombination events, the VDJ-recombination. Four
different subtypes of T cells are defined: Cytotoxic T cells (CD8+ T cells), CD4+ T cells, NKT
cells and γδ-T cells.
CD8+ T cells (Cytotoxic T cells) CD8+ T cells recognize on MHC class I presented epi-
topes derived from endogenous protein such as virus or antigens derived from malignant cells.
Recognition of their specific antigen leads to clonal expansion of activated CD8+ T cells which
rapidly clear infected cells by a variety of defense mechanism. Most prominent is the release
of granules by cytotoxic T cells in the immunological synapse being in direct proximity to the
target cell. The secretory cytotoxic granular contain perforines and and serine proteases such as
granzyme A and granzyme B. Upon release, granzymes enter the cytoplasm of the target cell via
membrane-pores in the cells plasma membrane formed by perforines [151]. Granzyme A induces
single-strand DNA damage by activation of the endonuclease (NM23.H1) and the exonuclease
(TREX1) [38]. Moreover, granzyme A disrupts mitochondrial metabolism by cleavage of the
NDUFS3 protein in the electron transport complex 1, leading to the release of reactive oxygen
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species (ROS) and subsequent cell death in the affected target cell [157]. Granzyme B induced
apoptosis of the target cell by activation of pro-caspases e.g. caspase 3, leading to the activation
of caspas-induced apoptotic pathways with final DNA-fragmentation [254]. Cytotoxic T cells are
also capable of inducing cellular death of a target cell by a Fas mediated apoptosis. Upon activa-
tion, CD8+ T cells express the type-II transmembrane protein Fas ligand (FasL, CD95L) on their
cells surface which binds Fas receptor expressed on the target cell. Ligation of the FasL and Fas
receptor induces Fas dependent apoptosis in the target cell [233].
The main cytokine released by CD8+ T cells is IFN-γ resulting in stimulation of MHC class I
antigen presentation pathway by replacement of the constitutive proteasome with the immunopro-
teasome [92]. In the immunoproteasome the catalytic subunits of the vertebrate 20S proteasome
are exchanged for the interferon gamma inducible catalytic subunits LMP2, PMP7 and MECL
[92]. Moreover, IFN-γ released by activated CD8+ T cells induces IFN-γ signaling via the Jak-Stat
pathway which leads to the phosphorylation of the cytoplasmic transcription factor STAT. Phos-
phorylated STAT homodimerizes and translocates to the nucleus where it initiates transcription
of IFN-γ-inducible genes such as major histo compatibility complex genes (MHC) [285][242].
CD4+ T cells In contrast to CD8+ T cells, CD4+ T cells recognize on MHC class II presented
epitopes derived from exogenous protein. MHC-II restricted peptides are recognized by CD4+ T
cells by binding of their T cell receptor (TCR) to the peptide-MHC-II complex. TCR-diversity is
achieved by somatic recombination of the TCR related genes, name V, D, J genes. In theory, 1
X 1015 different TCRs could be composed out of these genes allowing the presence of specific
TCRs for every possible antigen presented on MHC molecules [49]. According to their effector
function, CD4+ T cells either help to sustain an ongoing immune response by the activation of
macrophages and secretion of pro-inflammatory cytokines such as interferon gamma (IFN-γ), or
stimulate antigen-specific B cells to mature into antibody-secreting plasma cells by delivery of co-
stimulatory signals via CD28. Finally, CD4+ regulatory T cells (Tregs) are necessary to impair an
overshooting immune response to maintain homeostasis. Development of the CD4+ T cell linages
into T helper cells 1 (Th1), T helper cells 2 (Th2), T helper cells 17 (Th17) and regulatory T
cells (Tregs), depends on the cytokine milieu present during CD4+ T cell activation [286] whereas
every linage is further on characterized by the specific cytokine profile secreted by these CD4+ T
cells.
T helper 1 cells (Th1) cells differentiate from naive CD4+ T cells if the cytokines IFN-γ
and interleukin 12 (IL-12) are present in the microenvironment. Once differentiated into Th1
cells, the main cytokines secreted of this CD4+ T cell subpopulation upon antigenic stimulation
are IFN-γ, interleukin 2 (IL-2) and tumor necrosis factor β (TNF-β) [215]. Th1 cell can mobilize
the cellular arm of the immune system such as cytotoxic T cells, dendritic cells and macrophages,
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to combat an infection. Macrophages require two signals for optimal activation: IFN-γ and a
sensitizing signal via the CD40 molecule on their cell surface. Th1 cells provide both signals,
hence IFN-γ being the cardinal cytokine secreted as well as expression of the CD40 ligand, both
leading to microbicidal activity of the macrophages such as production of nitric oxide (NO) [108].
IL-2 secreted by activated Th1 cells stimulates clonal expansion of CD8+ cells during the priming
phase and sustains their cytolytic function by upregulated expression of granzyme B [22, 135].
Recruitment of cytotoxic T cells to the site of inflammation is supported CD4+ dependent IFN-γ
secretion, one example being the induction of CD8+ T cell chemoattractants such as CXCL10
on the site of inflammation [22]. Furthermore, IFN-γ secreted by activated Th1 cells promotes
the expression of MHC class I molecules as well as molecules associated with antigen processing
(e.g. TAP) on antigen presenting cells, modulating them indirectly to more effectively prime
cytotoxic T cells [78]. Furthermore, Th1 lymphocytes provide help to CD8+ T cells by activating
of antigen presenting cells (APC) due to interaction of CD40 ligand and CD40 molecule, in
consequence elevating the functional capacity of APCs to confer CD8+ T cell priming. Apart
from stimulating CD8+ T cell proliferation and effector function, CD4+ T cells play a pivotal role
in generating memory cytotoxic CD8+ T cells. Several lines of evidence suggest that CD27-CD70
receptor/ligand engagement is important in CD8+ T cell memory formation. CD70 is induced
on dendritic cells upon CD40-activation and inflammatory stimuli, whereas CD27 is expressed on
cytotoxic T cells. CD27 mediated signal on cytotoxic T cells not only engages their expansion
in a primary immune response but also allows secondary expansion of CTLs due to avoidance of
activation induced cells death by re-encounter with the cognate antigen [71].
T helper 2 cells (Th2), develop in the presence of interleukin 4 (IL-4) and interleukin 2
(IL-2) and later on secrete IL-4 and interleukin 10 (IL-10) as their signature cytokines [215]. Th2
cells are essential for the activation of mature B cells after epitope recognition. Th2 cells mediate
host defense against extracellular pathogens, e.g. parasites by induction of antibody secretion of
mature B cells. IL-4 secreted by Th2 cells is the major accelerator for a IgE-isotype switch in B
cells [227].
Th17 cells expressing a γδ T cell receptor are, contrasting CD8+ T cells and CD4+ T cells
expressing an αβ-TCR, are fare less characterized. Tumor growth factor β (TGF-β) as well as
inerleukin 6 (IL-6), interleukin 21 (IL-21) in the microenvironment favor the differentiation of Th17
cells, mainly secreting IL-17 upon full maturation [132]. Th17 cells produce pro-inflammatory
cytokines such as IL-17, IL-21 and IL-22, their differentiation being initiated by the presence of
tumor growth factor β (TGF-β) and IL-6 plus IL-21 [36]. The function of this T cell subtype
is not fully elucidated, even though IL-17 receptor signaling is described to be important in the
defense of extracellular bacteria and fungi [279]. Increased numbers of γδ T cells in patients´
peripheral blood can be correlated with bacterial and viral infections, the exact function of γδ T
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cells in generating an immune response still under investigation [36].
Regulatory T cells (Tregs) are defined as Foxp3+, CD25+ and CD127- cell population
[74]. Tregs can be divided into two subpopulations, natural Tregs and inducible Tregs (iTregs),
respectively. Whereas natural Tregs develop in the thymus [266], inducible Tregs differentiate in
the periphery upon antigen encounter [139]. Tregs display a great repertoire of immune suppressive
effector functions upon antigen recognition via their T cell receptor. Treg effector mechanisms can
be suppressive either via direct cell-cell contact, via depleting soluble factors such as IL-2 or via
secretion of cytokines associated with suppressive mechanisms, such as IL-10. Regulatory T cells
have been shown to express granzyme B and perforin, important for Treg mediated suppression
through killing of anti-tumor immune cells present in the tumor microenvironment [31]. Soluble
IL-2 is essential for the development and survival of CD4+ T effector cells by binding to the
IL-2 receptor. Regulatory T cells over express the α-subunit of the IL-2 receptor (CD25) thereby
having an increased affinity for IL-2. In consequence, IL-2 is deprived from binding to T effector
cells subsequently leading to cytokine deprivation mediated apoptosis in CD4+ T effector cells
[187]. Furthermore, inhibitory cytokines such as tumor growth factor β (TGF-β), interleukin 35
(IL-35) and interleukin 10 (IL-10) suppress T effector cell functions. Soluble IL-10 suppresses T
cell proliferation both in Th1 and Th2 cells. TGF-β is suggested to play a role in the generation
of Tregs from CD4+ CD25- precursor T cells by triggering Foxp3 expression in naive CD4+ T
cells [80]. Similar to TGF-β, interleukin 35 (IL-35) facilitates the conversion of conventional
CD4+ T cells into regulatory T cells (iT(R)35 cells) [43] secreting the IL-35 which exerts a
suppressive effect on T cell proliferation [44]. Another important suppressive mechanism of Tregs
is the generation of immunosuppressive adenosine [67]. There are several ways of adenosine
generation, firstly it can be generated extracellular from ATP and ADP catalyzed by the enzymes
CD39 and CD73, secondly adenosine can be generated from intracellular ATP, ADP and AMP
via cytoplasmic 5´-nucleotidases. Expression of CD39 and CD73 could be confirmed in human
Tregs [3, 4, 246]. Immunosuppressive functions of adenosine are mediated by reduction of pro-
inflammatory cytokine secreting (e.g. IFN-γ, IL-12, TNF-α) [99, 137] due to binding of adenosine
to the adenosine receptor expressed on antigen presenting cells and Th cell subpopulations. By
the constitutive expression of cytotoxic T lymphocyte antigen-4 (CTLA-4), regulatory T cells can
bind co-stimulatory molecules such as CD80/86 expressed on antigen-presenting cells, thereby
reducing co-stimulatory activity of APCs and subsequently priming of T effector cells, respectively
[219].
Activation of T cells requires the binding of their T cell receptor (TCR) and its cognate epitope
presented on the respective MHC-restriction element, which will be discussed in more detail in
the next paragraph.
29
Introduction
3.4.3 The major histocompatibility complex (MHC)
The MHC class I molecule is a heterodimer, expressed by all nucleated cells and is composed
out of α-chain with three domains: (α1 - α3) and the β2-micorglobulin non-covalently associated
with the α-chains (fig. 3). Up to 800 MHC class I alleles are know in humans [211], encoded by
the heavy chain major histocompatibility genes HLA-A, HLA-B, HLA-C, on chromosome 6. The
β2-micorglobulin is encoded in a different locus on chromosome 15. The antigenic binding site
of the MHC-I molecule is composed of the α1- and α2- domain and preferentially binds peptides
with a length of 8-10 amino acids, which are bound in the closed binding cleft of the MHC class I
molecule by specific anchor residues such as a Leu at position 2 and Val or Leu at position 9 [52].
Figure 3: Structure of the MHC-I and MHC-II molecule. The MHC-I molecule is composed of three domains
(α1 - α3), whereby the α3-domain anchors the MHC-I molecule to the plasma membrane. Furthermore, the β2-
micorglobulin is non-covalently associated with the α-chains. The MHC-II molecule is composed of one α-chain (subunits
α1 and α2) one β-chain (subunits β1 and β2), both chains anchored to the plasma membrane. (picture taken from:
http://www.syncytiabeta.org/~syncyt5/syncytiabeta/index.php?title=Major_Histocompatibility_Complex)
As shown in figure 3, MHC class II molecules are structurally distinct from MHC class I
molecules. Three major groups of MHC class II molecules are know in humans, HLA-DR, HLA-
DP and HLA-DQ also encoded on chromosome 6. In contrast to MHC class I expression, MHC
class II molecules are only expressed on professional antigen presenting cells, such as dendritic
cells, macrophages and B lymphocytes. The MHC class II molecule is a heterodimer composed of
one α-chain (subunits α1 and α2) and one β-chain (subunits β1 and β2), while the open peptide
binding cleft is composed by the α1 and β1 subunits. The morphology of the MHC class II open
peptide binding cleft allows binding a peptides with a length of 12-20 amino acids due to the fact
that residual parts of the antigen can loosely hang over either side of the peptide binding groove
[252].
3.4.4 Antigen-processing and epitope recognition
MHC-class I restricted peptides are derived of endogenous origin and processed via the proteasomal
pathway [223]. The 26S proteasome is composed of a 20S subunit harboring the protease activity
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and two 19S caps, releasing cleaved precursor peptides proteins into the cytoplasm of the cells
[171]. Precursor peptides are transported via the transporter associated with antigen processing
(TAP) in the endoplasmatic reticulum [165]. Newly synthesized α1 domains of the MHC-I molecule
are bound to the chaperon calnexin thus hampering MHC-I α1 domains to leave the endoplasmatic
reticulum. Upon binding of β2-micorglobulin, the MHC-I α1 domains are released from calnexin
building the peptide loading complex including the chaperon calreticulin, tapasin and the ER-
associated amino-peptidase 1/2 (ERAAP) . Peptides longer than 10 amino acids are trimmed by
the ERAAP before loading on the MHC class I molecule, the process being stabilized by tapasin,
calreticulin and ERp57, forming the peptide loading complex (PLC). Upon successful peptide
loading, the MHC class I- peptide complex is released from the PLC and transported in vesicles
derived from the golgi apparatus to the cell surface where it can be recognized by CD8+ T cells.
Even though peptides presented on MHC class I molecules are generally derive form proteins
of endogenous origin, dendritic cells are described to be capable of cross presenting peptides [213].
The process of cross presentation describes the presentation of exogenous peptides on MHC class
I molecules. It is believed, that dendritic cells are capable of cross presenting peptides due to an
adaption of their endocytic and phagocytic pathways [118].
Peptides presented on MHC class II molecules most commonly are derived from exogenous
antigens processed in intracellular vesicles such as lysosomes. MHC class II α- and β-chain
assemble in the endoplasmatic reticulum associated with an invariant chain (Ii) to prevent peptide
binding. Packed into vesicles, the MHC class II-invariant chain complex is transported in the
cytoplasm where it fuses with lysosomes to form the MHC class II-loading compartments (MIICs).
In the MIICs, the invariant chain is cleaved into CLIP (class II-associated Ii peptide) due to low
pH in the lysosome and eventually being exchanged for an antigenic peptide of exogenous origin,
with the help of the dedicated chaperon HLA-DM. Peptide loaded MHC class II molecules are
transported in vesicles to the cell membrane where peptides bound to MHC class II are recognized
by CD4+ T cells [171].
3.4.5 The T cell receptor: Structure and signaling
CD8+ T cells and CD4+ T cells express a T cell receptor (TCR) on their cells surface. The
majority of T cells (95%) express a heterodimic TCR, composed of one α-chain and one β-chain,
whereby every chain harbors a variable region and a constant region. As shown in figure 4, the
variable region is responsible for epitope recognition thus determining epitope-specificity of the
TCR, whereas the constant region anchors the TCR to the cell membrane and is associated with
TCR-signaling. A rather small group of T cells express a TCR composed of a γ-chain and a
δ-chain instead of the α β-TCR.
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Figure 4: Structure of the T cell receptor. The TCR is composed of one α-chain and one β-chain, whereby the variable domains of
the α-chain and β-chain form the TCR-epitope-recognition site. Two CD3 co-receptors are associated with the TCR, harboring ITAM
motifs on their intracellular domains, which are phosphorylated during TCR-signaling. Additional ITAM motifs are located within the
two intracellular ζ-chains, associated with the TCR, mediating the transition of a TCR-dependent signaling into the cytoplasm of the
cell by changing their phosphorylation status. (modified from epidemiologiamolecular.com)
Each TCR is associated with two CD3 transmembrane molecule containing immunorecep-
tor tyrosine-based activation motifs (ITAM) important for TCR-transmitted signaling (fig. 4).
Moreover, two ζ-chains are associated with the TCR, harboring six intracellular ITAM motifs,
important for TCR-signaling. CD4 and CD8 transmembrane molecules function as co-receptors
for the binding of MHC-peptide complexes being the first signal in T cell activation. Only T cells,
which also receive a co-stimulatory signal by engagement of their CD28 molecule, pairing with
CD80/CD86 on antigen presenting cells, are activated and exhibit TCR-mediated signaling. In
the case of absent co-stimulatory signal, the T cell will become anergic and eventually go into
apoptosis. A cascade of downstream signaling is activated upon TCR-MHC-peptide complex and
CD28-CD80/86 ligation. Antigen recognition initiates receptor clustering and activation of the ty-
rosine kinase Lak wich is associated with the cytoplasmic domain of the co-receptors CD4/CD8,
and the kinase Fyn which is associated with the CD3 molecule. Usually, kinases Lak and Fyn
are inhibited in resting cells due to phosphate bound to inhibitory tyrosine residues which are
removed by the leukocyte common antigen CD45 upon antigen encounter. Activated Lak and
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Fyn kinases phosphorylates the ITAMs in the receptors cytoplasmic tails, thereby recruiting the
ζ-chain-associated protein (ZAP-70) which is phosphorylated by Lck. The substrate phosphory-
lated by activated ZAP-70 is the linker of activation in T cells (LAT) and a second linker protein
(SLP-76) in T cells. Transmission of the TCR-mediated signaling from the cell membrane into
the cell requires proteins that either bind to phosphotyrosine residues or function as targets for
protein tyrosine kinases. The enzyme PLC-γ is phosphorylated at the plasma membrane by Tec
kinases which themselves where phosphorylated due to close proximity to the activated TCR upon
binding to adaptor proteins such as LAT, SLP-76. PLC-γ initiates two of the major downstream
signaling pathways in TCR-signaling by cleavage of phosphatidylinositol bisphosphate (PIP2) into
diacylglycerol (DAG) and inositol trisphosphate (IP3). DAG activates the protein kinase C which
resulting in activation of the transcription factor NF-κB whereas IP3 increases the intracellular
Ca2+ concentration by stimulation of calcium release in the endoplasmatic reticulum, thus acti-
vating the calcium-dependent phosphatase calcineurin which activates nuclear factor of activated
T cells (NFAT).
The third major signaling pathway in T cell activation is the MAP kinase pathway, which is
activated due to the recruitment and activation of the G-protein RAS by binding to phosphorylated
tyrosine residues at the cell membrane. Downstream signaling of MAP kinase pathway leads to the
induction of transcription factor AP-1. Genes transcribed by the activated transcription factors
NFkB, NFAT and AP-1 are genes associated with T cell proliferation and differentiation e.g IL-2
and IFN-γ [89]. Moreover, TCR engagement increases the expression of co-stimulatory molecules
on the T cells surface, one examples being the CD40L [115] leading to enhanced T cell proliferation
by interaction the CD40L and the CD40 molecule expressed on dendritic cells [159].
3.4.6 Tumor antigens as targets for the adaptive immune system
One major obstacle in the recognition of cancer cells by the adaptive immune system is self-
tolerance due to autologous origin of cancer tissue. Nevertheless, a number of MHC-restricted
immunogenic epitopes derived of tumor antigens are presented on MHC molecules on malignant
cell, therefore allowing recognition of malignant cells by the adaptive immune system. Tumor
antigens can be classified into two major groups: Tumor- associated antigens (TAA) and tumor-
specific antigens (TSA).
Tumor specific antigens are solely expressed in malignant cells being completely absent in
any healthy tissue, examples being: Mutated antigens, viral antigens and oncofetal antigens.
Mutated tumor antigens are highly immunogenic since they are exclusively expressed in the
given tumor entity such as the breast cancer antigen 1/2 (BRCA 1/2) in mammary carcinomas
[125]. Moreover, commonly mutated in human cancers are the tumor suppressor gene p53 [103]
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and the pro-oncogen Ras [21], thus being possible targets for tumor-immunotherapy approaches.
Mutated tumor antigens can arise from germline mutations (e.g. BRCA 1/2) or might be acquired
spontaneously during life time (e.g. p53 mutations) resulting in cancer initiation and development.
Oncoviral antigens are encoded by oncogenic viruses examples being the human papilloma
virus (HPV) causing cervical carcinoma. The most common HPV-tumor derived antigens are
the HPV oncogenes E6 and E7 which are used as targets in tumor immunotherapy approaches
[37][198].
Oncofetal antigens are typically expressed in fetal tissue but are not expressed in healthy adult
tissue. Nevertheless, expression of oncofetal antigens can be found in malignant adult tissue.
An example of oncofetal antigens being the alpha-fetoprotein (afp) receptor (receive) which is
usually expressed in undifferentiated cells of either fetal or tumor origin [167]. Expression of the
alpha-fetoprotein receptor was found in early stage breast cancer but not in healthy individuals
[167] .
Tumor associated antigens are expressed in healthy tissue as well as in malignant tissue,
therefore called “shared tumor antigens”. Examples being differentiation antigens, overexpressed
antigens and cancer-testis antigens.
Differentiation antigens are largely expressed by a single cancer type, examples being gp100
and MART-1 mainly expressed in malignant melanoma [156] and NY-BR-1 being expressed in
breast cancer [248]. Nevertheless, differentiation antigens are not only expressed in the given
malignancy but also in the healthy tissue the tumor evolved off a fact to keep in mind when
design anti-tumor immunotherapies.
Overexpressed antigens are characterized by expression in both normal and malignant tissue
whereby levels of expression are highly elevated in the cancerogenic tissue compared to normal
tissue. Elevated expression of the human epidermal growth factor 2 (HER2) is found in 30% of
all breast cancers [236] being one example for over expressed antigens.
Cancer-Testis antigens are exclusively expressed by cancer cells and adult reproductive tis-
sues, such as testis and placenta. The cancer testis antigen NY-ESO is expressed in malignant
melanomas and proven to be immunogenic in clinical trials of autologous CD4+ T cell transfer
[108].
3.5 Immunotherapy approaches against breast cancer
Apart from targeted therapies, such as antibody based therapy (refer to part 3.3.4), vaccination
strategies are also applied for the treatment of breast cancer. Two principles of anti-cancer vaccines
have to be distinguished: Passive vaccination strategies and active vaccination strategies.
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3.5.1 Passive vaccination strategies
Passive tumor-immunotherapy relies on the direct anti-tumor effect of the vaccination components.
One example for passive immunotherapy approaches in beast cancer are T-cell receptor mimics
(TCRm), monoclonal antibodies targeting the the HER2 derived E75 protein [114]. TCRm are
monoclonal antibodies with a TCR-like binding domain, recognize HLA-restricted peptides through
the TCR engagement leading to antibody dependent cellular cytotoxicity (ADCC) in human cell
lines [273].
E75 is a 9mer epitope derived from the extracellular domain of the HER2 protein [163].
TCRm specific for E75, recognize their cognate MHC-I-restricted peptide in all tested HER2+
breast cancer cell lines in vitro. Reduction in cell viability was observed possibly due to enhanced
apoptosis since a significant increase of caspase 3 activation was found in the cancer cell lines
treated with the TCRm [114]. HER2 E75 specific TCRm proved to induce apoptosis in all HER2+
cell lines whereby trastuzumab only lead to increased cell death in HER2+ high expressing cell
lines [114], thus TCRm against HER2 seem to be potentially effective in breast tumors with low
HER2 surface expression.
Genetically engineered T cells expressing a chimeric antigen receptor (CAR) represent an-
other example of passive immunotherapy approaches. Artificial chimeric T cell receptors (CARs)
combine specificity of a monoclonal antibody with T cell signaling properties hence being MHC-
independent. Generally, a single chain antibody is coupled to a single lymphocyte activation
domain. First generation CARs transmitted T cell activation signals via ITAM-bearing signaling
chains like CD3ζ whereas second generation CARs include a CD28 domain to achieve better ac-
tivation of engrafted T cells. Superior effector functions were observed in third generation CARs
which include a second co-stimulatory molecule domain such as CD134 or CD137 [34]. First in
vitro studies with dual engineered T cell expressing individual chimeric antigen receptors for both
ERBB2 and MUC1, whereby ERBB2 is associated with a CD3ζ signaling domain providing cyto-
toxic functions and IFNγ-production and the antigen MUC1 is associated with a CD28 signaling
domain, resulted in increased cell proliferation upon MUC1 antigen engagement. Dual-targeted
T cells were found to efficiently kill ERB2+ target cell and to proliferate upon ERBB2 and MUC1
antigen encounter [272]. This study indicates the use of dual-targeted T cells, expressing chimeric
antigen receptors as a possible approach to treat ERBB2+, MUC1+ breast cancers in vivo.
TCR transduced T cells which express a high affinity T cell receptors, are another approach
of passive immunotherapy. The T cell receptor recognizing the HLA-A2-restricted T-cell receptor
γ-chain alternate reading-frame protein (TARP)4-13, was cloned into peripheral blood T cells
using a lentiviral vector. TARP protein is expressed in normal prostate epithelium but also in
adenocarcinomas of the prostate and breast. HLA-A2+ breast cancer cell line MCF-7 which was
transduced with a lentiviral vector encoding TARP, were specifically recognized by TARP-specific
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TCR transduced T cells in vitro [102].
A crucial criterium in therapeutic TCR design is the proper pairing of TCR α-chain and TCR
β-chains, to reduce mispairing events, such as dimerization of novel TCR chains with endogenous
TCR α-chain and TCR β-chain of the target cell. Addition of exogenous disulfide bonds in the
constant domain reduce mispairing events [41].
3.5.2 Active vaccination strategies
Peptide cancer vaccines stimulate the patients own immune response due to the delivery of anti-
genic peptides of a given tumor entity. One example of a therapeutic peptide cancer vaccine is
the HER2-specific peptide vaccine for the treatment of HER2+ breast cancers. Peptides included
in this vaccine are 15-18 amino acids long, derived from the extracellular domain (ECD) or in-
tracellular domain (ICD) of the HER2 protein [55]. Patients with stage III or IV breast cancer
developed immunity against HER2 derived peptides after receiving the HER2 directed peptide vac-
cine [56]. One year after receiving the HER2 peptide vaccine, immunity to the HER2 protein was
still detectable in 38% of the vaccinated patients [56]. An independent clinical trial investigated
the immunogenicity of the HER2 derived peptide E75 in patients with disease-free, node-positive
breast cancers. The peptide E75 is a 9 mer HLA-A2-restricted epitope of the extracellular domain
of HER2-receptor [164], which is mixed with granulocyte-macrophage colony-stimulating factor
prior to vaccination of patients. Overall, the E75 peptide vaccination was reported to elicit a
peptide-specific immune response thus reducing the recurrence rate in disease-free patients with
HER2+, lymph node+ breast cancer [192]. In a cancer peptide vaccine trial, immunogenicity of
the HER2 derived epitopes E75 and GP2 was compared in PBMCs obtained from breast cancer
patients. In contrast to E75 being a peptide derived from the extracellular domain of HER2,
GP2 is a 9 mer, HLA-A2- restricted epitope derived from the transmembrane domain of HER2
[164]. Immunogenicity of the GP2-peptide/ E75-peptide was evaluated in vitro, by stimulation
of pre-vaccination, peripheral blood samples (PBMCs) from HLA-A2+ breast cancer patients
with autologous GP2-peptide pulsed/E75-peptide pulsed dendritic cells and subsequent analysis
of GP2-specific/E75-specific lytic capacity of CD8+ T cells. GP2 stimulated CD8+ T effector
cells lysed 44.2 % of HER2+ target cells versus lysis of 43.8% of HER2+ target cells in case of
E57 stimulated CD8+ T cells. Overall, immunogenicitiy of the peptide GP2 was proven to be
comparable with the immunogenicity of the E57 epitope, thus GP2 vaccine should additionally
be considered for the treatment of HER2+ breast cancer patients [163]. A second tumor antigen
investigated for potential use in anti-tumor peptide vaccines is the transmembrane glycoprotein
MUC1, expressed on glandular epithelium and over-expressed as well as hypo-glycosylated in ade-
nocarcinomas [237]. Vaccination of sixteen metastatic breast cancer patients with a sixteen amino
acid long MUC1 peptide conjugated to the carrier protein keyhole limpet hemocyanin (KLA) plus a
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DTOX adjuvant lead to induction of detectable amounts of class-I-restricted CTLs against MUC1
in the peripheral blood of these patients. Activity of the MUC1-specific CTLs was confirmed on
MHC-I positive adenocarcinoma target cell lines for seven out of eleven vaccinated metastatic
breast cancer patients [206].
cDNA based anti-tumor vaccines for example directed against mammaglobin-A (Mam-A),
an antigen commonly expressed in human breast cancer [267],were recently investigated in a
phase I clinical trial. Breast cancer patients with stage-IV metastatic breast cancer showed an
increase of mammaglobin-A specific, CD4+ICOS(hi) activated T cells which efficiently lyse Mam-
A+ target cells in vitro concluding that anti-Mam-A cDNA based vaccination induces anti-tumor
immunity in breast cancer patients [249]. A pilot clinical trial in patients with metastatic breast
cancer, vaccinated with a plasmid DNA encoding HER2 in combination with low dose granulocyte
macrophage colony-stimulating factor (GM-CSF) and interleukin 2 (IL-2) induced CD4+ T cell
responses agains HER2 and elevated anti-HER2 antibody production in patients receiving the
vaccination [178].
Vaccination viral vectors is another approach in breast cancer immunotherapy. One breast
cancer antigen used in this approach is mucin 1, an oncogene commonly expressed in breast
cancers [46]. A new approach of anti-MUC1 immunotherapy currently investigated in a phase I
clinical trial is based on a recombinant vaccinia ankara virus based vector encoding MUC1 epitopes
and interleukin-2 (IL-2). The vaccinia virus belongs to the group of the poxvirus family, whereby
the modified vaccinia virus Ankara shows a deficiency to grow in human cells [244],thus being
suitable and safe for tumor immunotherapy approaches. Breast cancer patients with advanced
metastatic tumors positive for MUC1, were treated with the viral vector encoding MUC1 epitopes
and showed a transient disease stabilization in four out of 13 enrolled patients [212]. Further
clinical studies are mandatory to certify anti-tumor efficacy of the vaccinia MUC-1-vaccine.
Dendritic cell based vaccines are successfully used in breast cancer therapy. Autologous den-
dritic cells are pulsed with HER2-specific, MHC class II restricted epitopes, if the patient is
HLA-A2+, dendritic cells were additionally pulsed with two HLA-A2-restricted HER2 epitopes.
To induce a pro inflammatory phenotype in HER2-peptide pulsed DCs, the cells were activated
in vitro with IFN-γ and lipopolysaccharide prior to being re-infused in patients with early HER2+
ductal in situ carcinoma (DCIS) or HER2+ DCIS with microinvasion. The vaccine was reported
due induce elevated levels of HER2-specific CD8+ T cells as well as HER2-specific CD4+ T cells
in the peripheral blood of vaccinated patients when compared to healthy donors. Furthermore,
the HER2-dendritic cell based vaccine led to post vaccination increase in lymphocytic infiltration
in the sites of residual DCIS. Most importantly, T cell responses were detectable up to 52 month
post-immunization in the peripheral blood of vaccinated breast cancer patients, suggesting clinical
value of the DC-based vaccine in the treatment of HER2+ DCIS [133].
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The therapeutic effect of a dendritic cell based vaccine specific for the tumor antigen MUC1
was investigated in patients with advanced or metastatic breast cancer. Autologous dendritic
cells were loaded with MUC1 antigens or autologous tumor lysate before being re-infused in the
patients. Clinical response regarding reduction in tumor size and disappearance of malignant
pleural effusion was seen in 7 out of 9 breast cancer patients [131], thus MUC1 derived dendritic
cell vaccine can be considered for immunotherapy of breast cancer. Currently investigated in a
murine breast cancer tumor mode, efficacy of DC based MUC1-specific tumor vaccines might be
increased by fusing recombinant MUC1 protein to a protein transduction domain, e.g. Tat peptide,
derived from human immunodeficiency virus (HIV) [26] leading to increased MUC1 antigen uptake
by dendritic cells in vivo. In a murine MUC1 tumor model, Tat-conjugated MUC1-specific DNA
vaccination induced delayed tumor growth more efficiently than unconjugated MUC1 [276].
3.5.3 Adoptive cellular therapy with TILs
The transfer of natural occurring autologous immune cell populations, such as tumor infiltrating
lymphocytes, which have been expanded ex vivo, is called adoptive cell transfer (ACT). Apart
from tumor infiltrating lymphocytes, genetically engineered T cells discussed in part 3.5.1 can
also be used for adaptive cellular therapy, whereby the following paragraph will be emphasizing
the use of TILs in adoptive cellular therapy.
Many tumors show infiltration of lymphocytes, nevertheless, the tumor persists despite of
the presence of anti-tumor targeted lymphocytes. Current opinion is that the tumor infiltrating
lymphocytes (TILs) experience immune suppression in the tumor microenvironment due to binding
of programmed cell death protein ligand 1 (PDL1) [2] and immunosuppressive cell populations such
as myeloid derived suppressor cells, M2 macrophages and Tregs. In preparation for ACT, TILs are
recovered from a patients tumor specimen such that they are removed from the immunosuppressive
environment and can be expanded in vitro in the presence of interleukin 2 (IL-2). Patients usually
receive a preparative lymphodepletion using chemotherapy or total-body irradiation before ex vivo
expanded TILs are re-infused in the patient [208].
In a clinical phase I study, patients with metastatic breast cancer were treated with ex vivo
expanded tumor-reactive T cells recovered from the bone marrow. Obtained T cells were in vitro
reactivated with autologous dendritic cells loaded with lysates of MCF-7 breast cancer cells as
source of tumor antigen. In seven out of 16 patients (44%), tumor-reactive memory T cells in
the peripheral blood were induced after adoptive cell transfer. Patients with an immunological
response to the adoptive cell transfer showed in increased median survival of 58.6 month compared
to non-responders with a median survival of 13.6 month [58].
On crucial point to consider when applying adaptive cellular therapy is the activation status
of transferred autologous cells, such as tumor specific autologous T cells, since the differentiation
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state of adoptively transferred T cells is crucial to the success of ACT based treatments. One
option might be the use of minimally cultured tumor-infiltrating lymphocytes named “young”
TILs [61]. Whereas standard TIL protocols require a complex procedure of many micro-cultures,
“young” TILs cultures consist of bulk lymphocytes rather than micro-cultures. “Young” TILs are
recovered from the entire resected tumor and minimally expanded in vitro, typically about 10-18
days, without any in vitro testing for tumor recognition. Compared to standard TILs, “young”
TILs have features associated with persistence in vivo, such as expression of high levels of co-
stimulatory molecules and long telomeres [250]. In patients with metastatic melanoma, CD8+
enriched young TILs mediated an objective tumor regression [61].
3.5.4 Targeting of immune checkpoints
Under physiological conditions, inhibitory pathways (also referred to as “immune checkpoints”)
such as the CTLA-4 and the PD1 associated pathways, are crucial for the maintenance of self-
tolerance. Tumors can disregulate the expression of immune checkpoint proteins by manipulating
endogenous anti-tumor immunity.
The cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is expressed on activated CD8+ T
cells and CD4+ T cells but important to note, also on regulatory T cells (Tregs). CTLA-4 shares
identical ligands with the co-stimulatory molecule CD28, the ligands being CD80 and CD86
[76, 256]. Both, CD28 and CTLA-4 are transmembrane protein members of the immunoglobulin
gene superfamily whereby CD28 is highly expressed on resting T cells contrasting rather low
CTLA-4 surface expression in naive T cells [113]. Low surface expression of the CTLA-4 molecule
can be explained by rapid internalization of the CTLA-4 molecule due to interaction of CTLA-
4 with the clathrin-associated protein AP50, directing CTLA-4 to clathrin-coated vesicles [39]
and allowing endocytosis of the CTLA-4 molecule. CTLA-4 surface expression is upregulated in
activated T cells and the CTLA-4 molecule is found to localize in proximity to the TCRs [145].
CTLA-4 engagement dampens the activity of T cells by either competitive binding of the co-
stimulatory molecules CD80/86 or by actively delivering inhibitory signals to the T cells such as
dephosphorylation of the TCR ζ-chain by a CTLA-4 associated tyrosine phosphatase, therefore
abolishing the Lck inducible TCR-signling [140]. Moreover, CTLA-4 is a target gene of the
forkhead transcription factor FOXP3 [104, 74] therefore being constitutively expressed in Tregs.
The exact mechanism of CTLA-4 mediated enhancement of immunosuppressive functions in Tregs
is still unknown. The fully humanized antibodies ipilimumab and tremelimumab are CTLA-4
agonists, their efficacy already being investigated in clinical trials. In a phase 1 clinical study,
26 patients with advanced, hormone-responsive breast cancer were treated with tremelimumab
in combination with the aromatase inhibitor exemestane. The treatment was well tolerated and
induced increased expression of the inducible costimulator (ICOS) in peripheral CD4+ and CD8+
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T cell and an increase in the ratio of ICOS+ T cells to FOXP3+ regulatory T cells [260].
A second immune checkpoint addressed in cancer immunotherapy is the programmed death-1
(PD1) pathway. One function of the PD1 cell surface molecule mediated signaling is to attenu-
ate T cell activation in peripheral tissues by engagement of programmed death-1 ligand (PDL-1)
expressed e.g. on tumor cells and PD1 expressed on tumor specific T cells [20]. Engagement of
PDL-1 of PD1 results in the inhibition of TCR signaling due to colocalization of PD1 and CD3ζ-
chain and subsequent inhibition of TCR-mediated phosphorylation of ZAP70 by the recruitment
of SHP-2 (Src homology 2 domain-containing tyrosine phosphatase 2) which induces the dephos-
phorylation of the proximal TCR signaling molecules [281]. Efficacy of an anti-PDL1 antibody
was also investigated in a multicenter phase 1 study. A total of 207 patients with advanced cancer
of different entities such as breast cancer (4), non-small-cell lung cancer (75), melanoma (55),
colorectal cancer (18), renal-cell cancer (17), ovarian cancer (17), pancreatic cancer (14) and
gastric cancer (7). Induced durable tumor regression was observed in 9/25 melanoma patients,
2/17 renal-cell cancer patients, 5/49 non-small-cell lung cancer patients and 1/17 ovarian cancer
patients [23].
Currently, at least three active clinical trials are running, evaluating immune checkpoint mod-
ulation in breast cancer. Ipilimumab is tested in combination with or without cryoablation in
early-stage breast cancer scheduled for mastectomy (clinical trial identification: NCT01502592).
Furthermore, anti-PD-L1 monoclonal antibodies are investigated in two clinical trials in a variety of
advanced and recurrent solid tumors, including breast cancer (NCT00729664 and NCT01375842).
3.6 The breast cancer associated antigen NY-BR-1
Serological analysis of recombinant tumor cDNA, expression libraries (SEREX), originating from a
metastasis of a 60 year old female patient with metastatic ductal carcinoma of the breast, identified
the antigen (TAA) NY-BR-1 as a breast cancer-associated tumor antigen [111]. Sequence analysis
of NY-BR-1 cDNA, mapped a NY-BR-1 sequence of 4125 base pairs with a continuous open
reading frame (ORF) on chromosome 10p11-12 (37 exons).
NY-BR-1 mRNA expression is restricted to the mammary gland (strong expression), testis
(strong expression) and placenta (faint expression) [111] but is found to be strongly over expressed
in 84% of tested breast tumors. A homologous gene, NY-BR-1.1 was identified on chromosome
9 and is described to display 54% DNA-sequence homology to the NY-BR1 antigen. NY-BR-
1.1 mRNA is described to be weakly expressed in breast tissue, testis and brain but so far no
expression of the NY-BR-1.1 protein has been described in brain tissue. Analysis of NY-BR-1
and NY-BR-1.1 mRNA expression in breast cancer tumors revealed some tumors to express either
antigen exclusively, whereas the majority of tested breast cancer tumors express mRNA for both
antigens [111].
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The protein sequence for NY-BR-1 (1341aa) includes a predicted DNA-binding site, a bispecific
nuclear localization signal, five ankyrin repeats (a unique motif which mediates protein-protein
interactions [141] ) and a leucin zipper motif. Presence of a nuclear localization signal indicates a
preferred nuclear accumulation of the NY-BR-1 protein [111]. In contrast to this finding, NY-BR-1
protein is also described to co-localize with the plasma membrane, implying a possible function as
a trans-membrane protein and being attractive for antibody based therapies [225].This finding is
supported by the identification of two cis-acting cell membrane targeting domains in the NY-BR-1
amino acid sequence. Ambivalent NY-BR-1 protein localization is confirmed by the findings of
Varga et. al who describe a nuclear as well as a cytoplasmatic localization of the NY-BR-1 protein
[257].
Among normal tissue, NY-BR-1 protein is solely expressed in the ductal epithelium of the breast
but strongly over expressed in breast cancer tumors whereas all other normal tissues are found
to be negative for NY-B-1 protein expression. Moreover, NY-BR-1 protein expression can not be
confirmed in any other carcinomas apart from breast cancer [257]. In fact, 100% of all noninvasive
carcinoma lesions, ductal carcinomas in situ and lobular neoplasia were described to be NY-BR-
1 positive. Moreover, 63.5 % of all invasive breast cancer tumor lesions are NY-BR-1 positive
including 80.7 % of combined ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)
[248]. NY-BR-1 protein expression can be found in 77% of grade 1 primary breast carcinomas, in
63% of grade 2 primary breast carcinomas, and in 50% of grade 3 primary breast carcinomas, thus
NY-BR-1 protein expression negatively correlates with tumor progression [257]. NY-BR-1 protein
expression was found in all samples of ductal carcinoma in situ and lobular neoplasia, adjacent
to invasive breast carcinoma, immunohistochemically stained for NY-BR-1 protein expression. In
invasive carcinoma lesions, NY-BR-1 protein was expressed in 60% of investigated tumors whereby
60% being invasive ductal carcinoma and 59% subtypes of other invasive carcinomas (papillary,
tubular, lobular, and mucinous) [257]. Moreover, concordance of NY-BR-1 protein expression
in the primary tumor and its metastasis is 88% in grade 2 breast tumors and 91% in grade 3
breast carcinomas [257]. Progression in breast carcinoma grading (grade 1 to grade 3) directly
correlates with heterogeneity of NY-BR-1 protein expression[257]. Two splice variants of the NY-
BR-1 protein, one shorter variant lacking the 5´-prime sequence compared to the longer splice
variant, are described. Equal immunohistochemical staining intensity for both splice variants was
observed in primary spermatocytes and in the testis. On the contrary, only weak expression of
the shorter splice variant was described in normal breast tissue and invasive breast cancer cells
contrasting a very strong expression of the longer splice variant in these tissues [247].
A strong correlation of estrogen receptor (ER) expression and NY-BR-1 expression was de-
scribed in 66% of tested NY-BR-1 positive tumors [257]. Estrogen-response element (ERE)-like
sequences located in proximity to the NY-BR-1 promotor region could be identified, suggesting a
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ERα depended regulation of NY-BR-1 protein expression. Studies obtained from patients receiving
tamoxifen for treatment of ERα positive breast carcinomas reveal a sustained decrease in NY-
BR-1 protein expression under tamoxifen treatment thus suggesting a dose dependent inhibition
of NY-BR-1 protein expression by this anti-hormonal therapy [247]. No correlation of NY-BR-1
protein and mRNA expression and menopausal status of women could be detected [247]. Further-
more, an inverse correlation of NY-BR-1 protein expression and both HER2/neu amplification and
epidermal growth factor receptor (EGFR) expression was described, thereby identifying NY-BR-1
as a potential therapeutic target for patients with HER2/neu and EGFR negative status [248].
Despite the above described inverse correlation of NY-BR-1 protein expression and HER2/neu
amplification, co-expression of these proteins was described in 50% of HER2/neu-amplified and
EGFR positive breast cancer tumors [247]. In consequence, combinational therapy options of
immunotherapy and HER2-/EGFR-targeted therapies should be considered for future treatment
of NY-BR-1+ breast cancers.
Even though the NY-BR-1 protein is found to be expressed in the ductal epithelium of the
breast and in metastasis of primary breast cancer tumors as mentioned above, so far no cell line
stably expressing NY-BR-1 protein endogenously is available in vitro, most likely due to loss of
NY-BR-1 protein expression in vitro, with the underlying mechanism not yet described.
3.7 Aim of the study
The aim of this project is the identification of novel HLA-restricted NY-BR-1-specific CD4+ and
CD8+ T cell epitopes using three different HLA-transgenic mouse strains (HHDtg-, DR3tg- and
DR4tg-mice). HLA-restricted NY-BR-1-specific T cell epitopes might be used for: vaccination
strategies, immunomonitoring, expansion of T cells for adoptive T cell transfer and the generation
of TCR transduced T cells. So far, only a limited number of NY-BR-1 specific epitopes identified
by reverse immunology has been described. With the global approach of identifying NY-BR-1
specific epitopes applied in this thesis, further NY-BR-1 specific epitopes, not covered by reverse
immunology, were expected to be identified. Furthermore, no CD4+ T cell epitopes had been
described so far, thus the aim of this study is to identify novel NY-BR-1 specific T cell epitopes
applying the following strategy:
1. Identification of further HLA-A*02 in HHDtg mice
2. Identification of NY-BR-1-specific HLA-DR-restricted candidate epitopes in DR3tg mice
and DR4tg mice
3. Verification of natural processing of novel NY-BR-1-specific epitopes in human cells
Finally we would like to investigate the presence of MHC-restricted, NY-BR-1-specific T cells in
peripheral blood obtained from breast cancer patients and healthy donors.
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4 Materials and Methods
4.1 Materials
4.1.1 General instrumentation
Table 4: General instrumentation
Equipment Manufacturer
Biofuge Fresco Centrifuge Heraeus, Hanau, Germany
Biological Safety Cabint Heraeus, Hanau, Germany
BioPhotometer Eppendorf, Hamburg, Germany
BioRad Mini-gel apparatus Bio-Rad, Richmond, CA
CO2 incubator Binder, Tuttlingen, Germany
Innova 4230 Incubator Shaker New Brunswick Scientific, Edison, NJ
Leica DM1L Microscope Leica, Wetzlar, Germany
Microbiological Incubator Heraeus, Hanau, Germany
MP220 pH Meter Mettler Toledo, Columbus, OH
Multichannel Pipette Eppendorf, Hamburg, Germany
Multifuge x3 FR centrifuge Heraeus, Hanau, Germany
Pipetboy Brand, Wertheim, Germany
Piepette (P2, P10, P100, P200, P1000) Gilson, Bad Camberg, Germany
Power PAC 300 power supplier Bio-Rad, Richmond, Germany
Refrigerator Liebherr, Ochsenhausen, Germany
Sorvall RT7 Centrifuge Sorvall, Newton, CT
Thermomixer Eppendorf, Hamburg, Germany
Verti 96-Well Thermal Cycler Applied Biosystems, Froster City, CA
AID Elispot plate reader Autoimmune Diagnostika GmbH, Strassberg,
Germany
FACS Calibur Flow Cytometer Becton Dickinson, Heidelberg, Germany
FACS Canto Becton Dickinson, Heidelberg, Germany
4.1.2 General disposables
Table 5: General disposables
Material Manufacturer
Falcon tubes 15ml, 50ml Greiner, Frickenhausen, Germany
Pipette filter tips (10, 20, 100, 200, 1000µl) Starlab, Milton Keynes, United Kingdom
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Pipette tips (10, 20, 100, 200, 1000µl) Greiner, Frickenhausen, Germany
Combitips (2.5, 5ml) Eppendorf, Hamburg, Germany
Sterile serological pipettes (5, 10, 25ml) Greiner, Frickenhausen, Germany
Safe-Lock tubes (0.5, 1.5, 2ml) Eppendorf, Hamburg, Germany
Tissue culture flasks (25, 75, 150cm2) TPP, Trasadingen, Switzerland
Cell culture test plates, flat bottom (6, 12, 24
wells)
TPP, Trasadingen, Switzerland
Round bottom 96-well plates TPP, Trasadingen, Switzerland
Petri Dishes Greiner, Frickenhausen, Germany
Cryotubes Greiner, Frickenhausen, Germany
Nitrocellulose membrane Whatmann, Dassel, Germany
Needles (18G, 27G) Becton Dickinson, Heidelberg, Germany
Inject-F, Syringes Braun, Melsungen, Germany
EliSpot plates Merc Miliore, Darmstadt, Germany
Liquid reservoirs Carl Roth GmbH, Karlsruhe, Germany
FACS tubes Becton Dickinson, Heidelberg, Germany
Cell strainers Becton Dickinson, Heidelberg, Germany
4.1.3 General chemicals and reagents
Table 6: General chemicals
Equipment Manufacturer
Trypsin/EDTA 10x PAA Laboratories GmbH, Pasching, Austria
Phosphate Buffered Saline (PBS) Biochrom AG, Berlin, Germany
Dimethyl sulfoxide (DMSO) Applichem, Darmstadt, Germany
Agarose Sigma, Saint Louis, MO
Tris Base Sigma, Saint Louis, MO
Ammonium Persulfate (APS) Sigma, Saint Louis, MO
Tetramethylethylendiamine (TMED) Bio-Rad, Saint Louis, MO
Sodium dodecyl sulfate (SDS) Sigma, Saint Louis, MO
Glycine GERBU Biotechnik, Gaiberg, Germany
Tween20 GERBU Biotechnik, Gaiberg, Germany
Non-fat milk powder Carl Roth GmbH, Karlsruhe, Germany
Bovine Serum Albumin (BSA) Sigma, Saint Louis, MO
Methanol Sigma, Saint Louis, MO
Ethanol Sigma, Saint Louis, MO
Ethidium Bromide Carl Roth GmbH, Karlsruhe, Germany
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β-Mercaptoethanol Sigma, Saint Louis, MO
Paraformaldehyde Sigma, Saint Louis, MO
Tryptone Sigma, Saint Louis, MO
Yest extract GERBU Biotechnik, Gaiberg, Germany
Sodium Chloride (NaCl) Sigma, Saint Louis, MO
Agar Sigma, Saint Louis, MO
Leukosept Greiner, Frickenhausen, Germany
Table 7: General reagents
Material Manufacturer
Gene Ruler 100bp DNA Ladder Fermantas, St. Leon-Rot, Germany
O´Gene Ruler 1kb DNA Ladder Fermantas, St. Leon-Rot, Germany
6x Orange Loading Dye Fermantas, St. Leon-Rot, Germany
Precision Plus Protein Standard Bio-Rad, Richmond, CA
Cell Lysis Buffer Cell Signaling Technology, Beverly, MA
Bio-Rad Protein Assay Reagent Bio-Rad, Richmond, CA
Restriction enzymes (PvuI, KpnI, NotI, XbaI) Fermantas, St. Leon-Rot, Germany
FastAP Thermosensitive Alkaline Phosphatase ThermoFisher Scientific, Schwerte, Germany
BCIP/NBP Liquid Substrate System Sigma, Saint Louis, MO
4.1.4 Plasmids
Table 8: Plasmids used for cloning of the NY-BR-1 breast cancer antigen
Plasmid Manufacturer
pcDNA3.1(-) Invitrogen, Carlsbad, CA
pcDNA3.1(-)zeo Invitrogen, Carlsbad, CA
4.1.5 Kits
Table 9: Kits
Material Manufacturer
RNeasy Plus Mini kit Qiagen, Hilden, Germany
Transcriptor First Strand cDNA Synthesis Kit Roche, Applied Science, Mannheim, Germany
Rapid DNA ligation Roche, Applied Science, Mannheim, Germany
QIAquick Gel extraction Kit Qiagen, Hilden, Germany
QIAGEN Plasmid Maxi Kit Qiagen, Hilden, Germany
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DNA isolation kit Qiagen, Hilden, Germany
Effectine Transfection Reagent Kit Qiagen, Hilden, Germany
ECL Plus Western blotting Detection System GE Healthcare, Buckinghamshire
CD4 (L3T4) MicroBeads mouse Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany
IFN-γ Secretion Assay - Cell Enrichment and
Detection kit (PE), mouse
Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany
IFN-γ Secretion Assay - Cell Enrichment and
Detection kit (PE), human
Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany
panT cells MicroBeads human Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany
X-tream Gene HP DNA transfection reagent Roche, Applied Science, Mannheim, Germany
4.1.6 Antibodies
Table 10: Antibodies used for Western blot analysis
Material Manufacturer
mouse anti-NY-BR-1 monoclonal antibody
clone#2
group of Prof. Jäger, NCT, Heidelberg
mouse anti-β-actin monoclonal (#691001) MP Biomedicals, Solon, OH
Goat-anti-mouse IgG-HRP (#sc2005) Santa Cruz Biotechnology, Santa Bruz, CA
Table 11: Antibodies used for flow cytometry
Material Manufacturer
Mouse anti-human HLA-DR FITC (#347363) Becton Dickinson, Heidelberg, Germany
Anti-mouse CD4 FITC (#11-0041-81) eBioscience, San Diego, CA
Anti-human CD4 FITC (#300506) BioLegend, San Diego, CA
Rat anti-mouse CD8a APC (#553035) Becton Dickinson, Heidelberg, Germany
Anti-human CD8 APC (#17-0087-42) eBioscience, San Diego, CA
Mouse anti-human HLA-A2 (hybridoma
BB7.2)
Prof. G.J. Hämmerling, DKFZ, Heidelberg,
Germany
Goat anti-mouse PE Dianova, GmbH, Hamburg Germany
Mouse anti-human HLA-A2 PE (#558570) Becton Dickinson, Heidelberg, Germany
Anti-human CD80 PE (#12-0809-42) eBioscience, San Diego, CA
Anti-human CD86 PerCp (#46-0869-41) eBioscience, San Diego, CA
Anti-HLA-DR APC (#559866) Becton Dickinson, Heidelberg, Germany
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Anti-human CD4 PE (BLD-344605) BioLegend, San Diego, CA
Mouse anti-murine Kb (E3-25) Prof. G.J. Hämmerling, DKFZ, Heidelberg,
Germany
Mouse anti-murine Db (B22.249) Prof. G.J. Hämmerling, DKFZ, Heidelberg,
Germany
anti-human CD3 PE-Vio770 Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany
anti-human CD4 PerCPCy5.5 Becton Dickinson, Heidelberg, Germany
anti-human CD8 APC-H7 Becton Dickinson, Heidelberg, Germany
anti-human CD25 V450 Becton Dickinson, Heidelberg, Germany
anti-human CD127 FITC Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany
anti-human FoxP3 APC eBioscience, San Diego, CA
anti-human IFN-γ PE Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany
anti-mouse IFN-γ PE Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany
pacific orange Lifescience, Carlsbad, CA
Milli-MarkTM Anti-CAR-PE, clone RmcB
(#FCMAB418PE)
Millipore, Schalbach, Germany
Anti-CAR, clone RmcB (#05-644) Millipore, Schalbach, Germany
Table 12: Antibodies used for EliSpot assays
Material Manufacturer
Rat anti-mouse IFN-γ (#551216) Becton Dickinson, Heidelberg, Germany
Biotinylated rat anti-mouse IFN-γ (#554410) Becton Dickinson, Heidelberg, Germany
Streptavidin-alkaline phosphatase (#554065) Becton Dickinson, Heidelberg, Germany
Anti-human IFN-γ mAb (#3420-3-1000) Mabtech, Nacka Strand, Sweden
Biotinylated anti-human IFN-γ mAb
(#3420-6-1000)
Mabtech, Nacka Strand, Sweden
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4.1.7 Cytokines
Table 13: Cytokines
Material Manufacturer
Human IFN-γ recombinant carrier free
(#34-8319-82)
eBioscience, San Diego, CA
Recombinant human IL-4 (#204 IL) R&D Systems, Minneapolis, MN
GM-CSF (Leukine, Sargromastim) Sanofi, Paris, France
Recombinant TNF-α (#210-TA/CF) R&D Systems, Minneapolis, MN
Recombinant IL-1β (#210-LB/CF) R&D Systems, Minneapolis, MN
Prostaglandin E2 (PGE2) (#PG532-1MG) Sigma, Saint Louis, MO
Recombinant human IL-6 (#206-IL/CF) R&D Systems, Minneapolis, MN
Recombinant human IL-12 (#219-IL/CF) R&D Systems, Minneapolis, MN
Recombinant human IL-7 (#C-61712) Promokine, Heidelberg, Germany
Recombinant human IL-2 (#C61240) Promokine, Heidelberg, Germany
Recombinant human IL-15 (#247-IL/CF) R&D Systems, Minneapolis, MN
4.1.8 Cell culture
Table 14: Cell culture medium and supplements
Material Manufacturer
RPMI 1640 PAA Laboratories, Pasching, Austria
αMinimum Essential Medium Eagle (MEM) Sigma, Saint Louis, MO
Fetal Calf Serum (FCS) PAA Laboratories, Pasching, Austria
Penicillin/Streptomycin (Pen/Strep) PAA Laboratories, Pasching, Austria
Zeocin Invitrogen, Carlsbad, CA
G418(=Neomycin) Gibco-Invitrogen, Karlsruhe, Germany
α-methylmannopyranoside Sigma, Saint Louis, MO
DMEM PAA Laboratories, Pasching, Austria
Lipopolysacharides (LPS) Sigma, Saint Louis, MO
Glutamine Gibco-Invitrogen, Karlsruhe, Germany
McCoy´s 5A Promocell, Heidelberg, Germany
x-Vivo Medium Lonza, Basel, Switzerland
Human Serum, type AB, off the clot Biochrome AG, Berlin, Germany
AIM-V Medium Invitorgen, Carlsbad, CA
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Table 15: Murine tumor cell lines
Cell line Source MHC background Cell line type
[Ref]
EL4 German Cancer Research Center,
Heidelberg, Germany
H-2b, C57BL/6 derived T lymphoma
[230]
EL4-Rob/HHD German Cancer Research Center,
Heidelberg, Germany
H-2b/β2mb-/b-,
HLA-A*0201
lymphoma
[190]
B16 German Cancer Research Center,
Heidelberg, Germany
H-2b, C57BL/6 derived melanoma [73]
GL261 German Cancer Research Center,
Heidelberg, Germany
H-2b, C57BL/6 derived glioblastoma
[245]
Table 16: Human cell lines
Cell line Source MHC background
of interest
Cell line type
[Ref]
Hek293T ATCC, Rockville, MD unknown human
embryonic
kidney cells
[191][91]
HBL-100 German Cancer Research Center,
Heidelberg
HLA-DRB1*301 human breast
epithelial cells
[32]
Ma-Mel 21 Skin Cancer Unit, DKFZ,
Heidelberg, Germany
HLA-DR negative
Ma-Mel 36 Skin Cancer Unit, DKFZ,
Heidelberg, Germany
HLA-DRB1*0301
HLA-DRB1*0401
Ma-Mel 51 Skin Cancer Unit, DKFZ,
Heidelberg, Germany
HLA-DRB1*0301
Ma-Mel 73a Skin Cancer Unit, DKFZ,
Heidelberg, Germany
HLA-DRB1*0401
MCF-7 ATCC, Rockville, MD HLA-DRB1*0301 breast epithelial
cell line,
derived from
metastatic site
[240]
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SK-BR-3 ATCC, Rockville, MD HLA-DRB1* mammary
gland/breast,
derived from
metastatic site
[251]
T2 T2 (ATCC®CRL-1992TM) HLA-A*0201 174xCEM.Z2;
fusion of
B-LCL 721 and
T lymphoma
[220]
T2/DR3 German Cancer Research Center,
Heidelberg
HLA-DRB1*0301,
HLA-A*02
transfectant
provided by F.
Momburg,
DkFz
T2/DR4 German Cancer Research Center,
Heidelberg
HLA-DRB1*0401,
HLA-A*02
transfectant,
provided by
Harald
Kropshofer ,
Ulm
Table 17: Other cells
Material Source
TOP10 E.coli competent cells Invitrogen, Carlsbad, CA
4.1.9 Software
Table 18: Software
Software Source
Microsoft office 2010 Microsoft, Redmont, USA
GraphPad Prism 5 GraphPad Software, Inc., San Diego, USA
Cell Quest Becton Dickinson, Heidelberg, Germany
FlowJo Becton Dickinson, Heidelberg, Germany
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4.1.10 Database
Table 19: Database
Database Source
SYFPEITHI www.syfpeithi.de
4.2 Methods
4.2.1 Preparation of buffers and medium
Table 20: TBS-T
Component Amount
1 x TBS, with 0.1% (v/v) Tween 20
Table 21: 50 x Tris-acetate-EDTA (TAE) buffer, pH 8.0, 1L
Component Amount
Tris base 242 g
Acetic acid 57.1 ml
500mM EDTA solution 100 ml
H2O Adjust final volume to 1L
Table 22: 1 x PBS, pH 7.4, 1L
Component Amount
PBS Dulbecco w/o CA2+, Mg2+ 9.55 g
H2O Adjust final volume to 1L
Table 23: 10 x SDS-PAGE running buffer, IL
Component Amount
Tris base 30 g
10% SDS solution 100 ml
Glycin 144 g
H2O Adjust final volume to 1L
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Table 24: 1x Tris-buffered saline (TBS), pH 7.6, 1L
Component Amount
Tris base 2.24 g
Acetic acid 57.1 ml
500mM EDTA solution 100 ml
H2O Adjust final volume to 1L
Table 25: Transfer buffer, pH 8.5, 1L
Component Amount
Tris base 3 g
Glycin 17.5 g
Methanol 200 ml
H2O Adjust final volume to 1L
Table 26: Stripping buffer, pH 6.8, 100 ml
Component Amount
0.5M Tris-HCL (pH 6.8) 6.25 ml
10% (v/v) SDS solution 20 ml
β-Mercaptoethanol 700 µl
H2O Adjust final volume to 1L
Table 27: Cell freezing medium
Component Amount
FCS 90% (v/v)
DMSO 10% (v/v)
Table 28: LB medium, pH 7.5, 1L
Component Amount
Tryptone 10 g
Yeast extract 5 g
NaCl 10 g
H2O Adjust final volume to 1L
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Table 29: FACS buffer
Component Amount
FCS 3% (v/v)
2% NaN3 5 ml
PBS Adjust final volume to 500 ml
Table 30: MACS buffer
Component Amount
0.5M EDTA 4 ml
BSA 5 g
PBS Adjust final volume to 1L
Table 31: Cell culture medium
Component supplements
culture medium (RPMI 1640) 10% FCS, 100 U/ml penicillin, 100 µg/ml
streptomycin
complete α MEM 10% FCS, 2 mmol/l glutamine , 100 U/ml
penicillin, 100 µg/ml streptomycin, 25 ml
ConA sup, 25 ml, 50 µmol/l
2-mercaptoethanol
T cell medium (complete α MEM) 5% (v/v) culture supernatant from concavalin
A stimulated rat spleen cells, 5% (v/v) Methyl
α-D-mannopyranoside (αMM)
Dendritic cell culture medium (RPMI 1640) 200U/ml interleukin (IL)-4, 560 U/ml
granulocytes-macrophage growth factor
GM-CSF, 10% FCS, 100 U/ml penicillin, 100
µg/ml streptomycin
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4.2.2 Cell culture
Melanoma cell lines Ma-Mel21, Ma-Mel36b, Ma-Mel79b, Ma-Mel73a, EL4 cells and T2 cells
were cultured in complete RPMI 1640 medium (culture medium). T2/DR3, T2/DR4, EL4-
NY-BR-1 transfectants and EL4-Rob/HHD cells were cultured in complete RPMI 1640 medium
supplemented with 0.4 mg/ml G418 (Gibco-Invitrogen, Karlsruhe). The breast cancer cell line
MCF-7 was cultured in complete DMEM medium. SK-BR-2 and HBL-100 breast cancer cell
lines were cultured in McCoys Medium (PAA-Laboratories) supplemented with 10% FCS (PAA
Laboratories) and 100 U/ml penicillin, 100 µg/ml streptomycin (PAA Laboratories).
All cell lines were cultured at 37°C in a humidified atmosphere with 5.0 % CO2.
4.2.3 Protein detection by Western blot analysis
Cell lysates were generated using appropriated amounts of the Cell Lysis Buffer (Cell Signaling)
and incubated for 15 min on ice followed by 25 min centrifugation at 13,000 rpm, 4°C. Protein
concentration was determined by Bio-Rad Protein Assay reagent on a BioPhotometer. Cell lysates
were stored at -20°C.
Heat denatured whole cell protein samples (15 µg- 50 µg) were mixed with 5 x loading dye
and separated on a 10% polyacrylamid gel, and electro-transferred onto nitrocellulose membranes.
Successful protein transfer was confirmed by Ponceau S staining of the nitrocellulose membrane.
Before blocking of the membrane with 5% of non-fat milk in TBS-T, Ponceau S was washed away
with TBS-T buffer. After blocking, the membranes were incubated with the respective primary
antibody diluted in 0.5% non-fat milk in TBS-T buffer and left rotating at 4°C over night. Next,
membranes were washed in intervals of 1 x 10 min and 2 x 5 min with TBS-T before incubated
with the respective horseradish peroxidase conjugated secondary antibody diluted in 0.5% non-fat
milk in TBST for 1h at RT. Following another interval of washing with TBS-T buffer, protein
signals were detected using the enhanced chemiluminescence (ECL) system by exposing blots to
an x-ray film.
4.2.4 Flow cytometry
If not otherwise indicated, 1 x 106 cells were resuspended in 100 µl FACS buffer and stained in a
1:100 dilution with the respective antibodies for 30 min at 4°C in the dark.
Next, cells were washed two times with FACS buffer and finally resuspended in 200 µl FACS
buffer. Data were acquired on a FACS Calibur if not indicated otherwise.
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4.2.5 Molecular cloning
NY-BR-1 full length DNA was isolated from pcDNA3.1-NY-BR-1 by Kpn1 and Not1 digestion
over night. The resulting interest was separated on a 1% agarose gel by gel-electrophoresis and
extracted using the QIAquick Gel Extraction Kit (Qiagen). Prior to ligation into the multiple
cloning site, the target vector was dephosphorylated by using FAST alkaline phosphatase (Ther-
moFisher Scientific), according to the manufacture´s protocol. Successful cloning was verified
by digestion of the pcDNA3.1(-)zeo construct with the restriction enzymes Not1 and Kpn1 over
night and subsequent gel-electrophoresis.
4.2.6 Transformation and amplification of cloned plasmid
Amplification of the construct was achieve by transformation of Top10 bacteria and subsequent
growing of colonies on LB agar with ampicillin. Colonies were picked and used to inoculated 3 ml
of LB-medium containing 100 µg/ml ampicillin. Positive clones were further expanded by using
the Maxi-Prep Kit (Qiagen) accordingly to the manufacturers instructions. DNA concentration
was determined by a BioPhotometer.
4.2.7 NY-BR-1 specific peptide library and synthetic candidate peptides
A NY-BR-1 specific peptide library consisting of 174 peptides (20mers), overlapping by 12 amino
acids was purchased. To perform a combinatorial peptide library screening, NY-BR-1 library
peptides were organized in 26 pools (K1-K13 and L1-L13), each pool consisting of 13 NY-BR-1
specific library peptides (fig. 44). The final concentration of each library peptide in the respective
pool used in IFN-γ Elispot assay was 1.5 µg/ml.
Calculation: Peptide library stock of 200 µg/ml => 13 peptides in each library peptide pool,
which leads to a dilution of each single library peptide of 1:13 in the peptide library pool, thus
each peptide has a final concentration of 15.4 µg/ml in the peptide pools. Library peptide pools
are 1:5 diluted with medium before used in an IFN-γ Elispot assay and further diluted 1:2 on the
IFN-γ Elispot assay plate, thus the final concentration of each peptide in the IFN-γ Elispot assay
is 1.5 µg/ml.
The second level matrix screened with splenocytes of immunized DR4tg mice was composed
of 16 library peptide pools (A1-A8, B1-B8), each one consisting out of eight NY-BR-1-specific
library peptides, except for the peptide pools A5, A6, A7, A8 which only harbors seven NY-BR-1-
specific library peptides and the peptide pool B8 which only consists out of four NY-BR-1-specific
library peptides. The final concentration of each library peptide in the respective pool used in the
IFN-γ Elispot assay was 2.1 µg/ml.
Calculation: Peptide library stock of 200 µg/ml => 8 peptides in each library peptide pool,
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which leads to a dilution of each single library peptide of 1:8 in the peptide library pool, thus each
peptide has a final concentration of 25 µg/ml in the peptide pools. Library peptide pools are 1:6
diluted with medium before used in an IFN-γ Elispot assay and further diluted 1:2 on the IFN-γ
Elispot assay plate, thus the final concentration of each peptide in the IFN-γ Elispot assay is 2.1
µg/ml.
Peptide pools C1-C19 were composed out of two individual library peptides and the final
concentration of each peptide used in IFN-γ Elispot assay was 2 µg/ml.
Calculation: Library peptide stock of 200 µg/ml => 100 µl of two single library peptides
were mixed with 800 µl PBS (1:10 dilution) to generate the peptide pools C1-C19, thus the final
concentration of each library peptide in the C pools is 20 µg/ml. Prior to the IFN-γ Elispot assay,
peptide pools C1-C19 were diluted 1:5 with medium before used in an IFN-γ Elispot assay and
further diluted 1:2 on the IFN-γ Elispot assay plate, thus the final concentration of each peptide
in the IFN-γ Elispot assay is 2 µg/ml.
Individual NY-BR-1 specific library peptides were applied as single peptides in the assays at
a final concentration of 2 µg/ml in the case of DR3tg mice and DR4tg mice and at a final
concentration of 100 ng/ml performing experiments with splenocytes of HHDtg mice. All library
peptides were dissolved in DMSO at a concentration of 50 mg/ml and stored at -20°C until use.
Individual candidate peptides selected by the library screen were synthesized and HPLC-purified
at the peptide synthesis core facility of the German Cancer Research Center, Heidelberg. All
peptides were dissolved in DMSO at a concentration of 50 µg/ml and stored at -20°C until use.
4.2.8 HLA-transgenic mice
Animal experiments were approved by the internal ethics committee of the German Cancer Re-
search center and by the District Government in Karlsruhe. All mice were housed and bred in
individual ventilated cages under SFP conditions within the German Cancer Research Center,
Heidelberg animal facility.
HLA-DRB1*0301-transgenic mice (HLA-DR3tg) HLA-DRB1*0301-transgenic (HLA-
DR3tg) mice express the HLA-DRB1*0301 molecule on a IA0/0 H2 background, thus expression
of murine MHC-I molecules H2-Kb / H2-Db is still given [130]. HLA-DRB1*0301 transgene
expression was confirmed by analysis of peripheral blood lymphocytes (PBMCs) obtained from
the submandibular vein of HLA-DR3tg mice. PBMCs obtained from HLA-DRB1*0301 transgenic
mice were stained for 30 min, 4°C with an anti-HLA-DR-FITC antibody (Becton Dickinson,
Heidelberg) and analyzed by flow cytometry on a FACS-Calibur.
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HLA-DRB1*0401-transgenic mice (HLA-DR4tg) Murine MHC-II deficient, HLA-DRB1*
0401-transgenic (HLA-DR4tg) mice express a chimeric version of the HLA-DRB1*0401 molecule
(HLA-DRB1*0401:IEd) on a IA0/0 H2 background [110]. More precisely, the HLA-DRB1*0401
chimeric gene contains the human HLA-DRB1*0401 peptide binding α1 and β1 domains fused
to the murine IEd-α2 and IEd-β2 domains. Furthermore, HLA-DR4tg mice also express murine
MHC-I, H2-Kb / H2-Dbmolecules.
HLA-A*0201-transgenic mice (HHD-tg) HHDtg mice express the α1 and α2 domain of
the human HLA-A*0201 molecule and the murine α3 domain of the murine Db molecule, linked
to the human β2-microglobulin. In consequence, only HLA-A*0201 restricted CD8+ T cells are
generated in HHD-tg mice. In addition, HHDtg mice express IAb molecules.
4.2.9 Isolation of murine PBMCs
Mouse blood (5-10 drops) drawn from the submandibular veins, were mixed with 100 µl of
PBS/Heparin (5U/ml Heparin Natrium 25 000 (Ratiopharm), 2% FCS (PAA Laboratories), 0.1%
NaN3) and incubated on ice. Mouse blood was diluted with 200 µl PBS. Then 200 µl were
added on top of 300 µl Bicoll solution (Biochrom, density 1.007mg/ml) without disrupting the
Bicoll layer. Samples were centrifuged at 3400 rpm, 15 min. Emerging interphase representing all
mononuclear cells was carefully transferred into a fresh eppendorf tube and resuspended in 1 ml
PBS. Following another centrifugation step at 2700 rpm, 10 min, cell pellets were resuspended
in 200 µl FACS buffer and transferred on a 96 well plate to proceed with anti-HLA-DR staining
for 30 min in the dark at 4°C, using the mouse anti-HLA-DR FITC-conjugated antibody 1:100 in
FACS buffer. Samples were washed twice with FACS buffer and subsequently analyzed on a FACS
Calibur.
4.2.10 Analysis of a NY-BR-1-specific T cell response for HLA-DRB1*0301-/*0401-
transgenic mice
DR3tg mice and DR4tg mice were immunized twice (day 0, day 7) by intramuscular (i.m.) injection
of 100 µg DNA of the NY-BR-1 encoding expression vector (pcDNA3.1(-)NY-BR-1). To exclude
immunogenic effects generated by the expression vector itself, mice immunized with pcDNA3.1(-)
served as a control group. On day 14, mice were sacrificed and splenocytes were tested for NY-
BR-1 specific T cell responses in vitro by recognition of NY-BR-1 specific peptide library pools,
individual library peptides (20mers) and candidate epitopes (15mers) in IFN-γ EliSpot assays using
the culture medium.
Individual library peptides were tested with a final concentration of 2 µg/ml for DR3tg mice
and DR4tg mice and at a final concentration of 100 ng/ml for HHDtg mice. IFN-γ EliSpot assays
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were performed using 96 well Multiscreen EliSpot plates (Millipore, Schalbach, Germany) coated
with 1 µg/ml rat anti-mouse IFN-γ capture antibody for 1h at 37°C or overnight at 4°C. After
blocking the EliSpot plates with culture medium for 1 h, 106 – 1.5 x 106 splenocytes were co-
incubated with the respective library peptide pools or individual library peptides for 18 h in culture
medium in a total volume of 200 µl per well. Cells were discarded and plates were washed with
PBS Tween20 0.05% twice and PBS three times before adding 1µg/ml biotinylated secondary
antibody in 100 µl per well and incubation of plates for 1h at 4°C. Following another washing
step with PBS, cells were incubated with streptavidin-conjugated alkaline phosphatase for 30 min
and signals were developed by adding 100 µl BCTP/NBT (Sigma, Saint Louis, MO) to the again
washed wells. The enzymatic reaction was stopped after 1 min by distilled water to all wells.
IFN-γ spots numbers were analyzed on the AID EliSpot Reader classic (Autoimmune Diagnostika
GmbH, Strassberg, Germany).
4.2.11 IFN-γ Secretion Assay with murine spleen cells
To analyze CD4+, NY-BR-1 specific T cell responses, splenocytes obtained from immunized mice
were stained for CD4+/IFN-γ+ T cells by mouse IFN-γ Secretion Assay–Cell Enrichment and De-
tection Kit (PE) (Miltenyi Biotec, Bergisch Gladbach) according to the optimized manufacturer´s
protocol in combination with an additional staining for murine CD8+ cells using the CD8-APC
antibody (eBioscience, San Diego). Briefly, 2 x 107murine spleen cells were seeded in 6 well plates
in 2 ml culture medium and over night stimulated with 5 µg/ml of the respective peptide. Cells
were transferred to a 96 well plate formate for the IFN-γ-catch period lasting 2 1/2 hours at 37°C,
5% CO2. Subsequently, cells were additionally stained with mouse-CD4-FITC (eBioscience, San
Diego, CA), anti-mouse CD8 APC (eBioscience) and anti-IFN-γ PE (Miltenyi Biotec) were per-
formed. IFN-γ positive cells were enriched according to the manufactures protocol by application
of anti-PE microbeads.
All experiments were also performed without the enrichment for IFN-γ positive cells. Data
was acquired on a FACS-Calibur and analyzed with FlowJo software.
4.2.12 Generation of murine HLA-DRB1*0301- and HLA-DRB1*0401- restricted
CD4+ T cell lines
DR3tg mice were immunized subcutaneously (s.c.) with 100 µg of the 15mer peptides BR1-88,
BR1-1238, BR1-1347 and DR4tg mice with the 15 mer peptides BR1-537, BR1-656/-775, BR1-
1242. After 13 days, mice were sacrificed and T cell lines were generated from splenocytes upon
incubation of 6 x 106 splenocytes with 0.2 µg/ml of the respective peptide in 24 well plates in 2 ml
complete α-MEM (Sigma-Aldrich, Saint Louis, MO). Every 5 to 7 days, half of the supernatant
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was exchanged by the above mentioned medium containing 5% (v/v) of culture supernatant from
ConA stimulated rat-spleen cells (= T cell medium), as a source of interleukin (IL)-2. Spleen cell
cultures were restimulated every four weeks by addition of 6 X 106 irradiated syngeneic feeder
cells together with antigenic peptide (0.2 µg/ml).
4.2.13 Determination of HLA-restriction of established murine T cell lines
HLA-DRB1*0301- and HLA-DRB1*0401- restriction of the established murine T cell lines was
confirmed in IFN-γ EliSpot assays by co-incubating 105 T cells and 5 X 104 human T2/DR3
and T2/DR4 cells, respectively in the presence of 1 µg/ml of the cognate peptide. After 18 hrs
NY-BR-1 peptide specific signals were detected.
4.2.14 Generation of human dendritic cells
PBMCs were obtained from HLA-DRB1*0301+ and HLA-DRB1*0401+ healthy donors. Adherent
PBMCs were cultured in dendritic cell culture medium (RPMI 1640) to induce DC maturation.
Five to seven days later, surface expression of DC markers was determined by FACS using anti-
CD80-PE(eBioscience, San Diego, CA), anti-CD86-PerCp(eBioscience, San Diego, CA), anti-
CD11c-FITC (Becton Dickinson, Heidelberg, Germany), anti-HLA-DR-APC (Becton Dickinson,
Heidelberg, Germany) antibodies. Data were acquired on a FACS-Calibur.
4.2.15 Recombinant adenovirus (Ad5-NY-BR-1) used for infection of human target
cells
E1-deleted replication deficient recombinant adenoviral vectors, one encoding the NY-BR-1 pro-
tein (Ad5-NY-BR-1), the second one being the empty viral vector (Ad5), were purchased at
GeneCust (Dudelange, Luxembourg). GenCust provided the recombinant adenoviral vectors at
a concentration of 1012pfu/ml which were dissolved in PBS to a final concentration of 5 X
108pfu/ml. Optimal multiplicity of infection (MOI) and time point for infection of melanoma cell
lines Ma-Mel21, Ma-Mel36b, Ma-Mel79b, MaMel73a and breast cancer cell line SK-BR-2 cell was
determined by analysis of NY-BR-1 protein expression, detected by Western blot analysis using the
anti-NY-BR-1 antibody (NY-BR-1 monoclonal antibody clone #2). Infections were performed in
a final volume of 2 ml of the respective cell culture medium in 6 well plates.
In addition, human PBMCs from healthy donors, depleted of CD3+ cell, and HLA-matched
human in vitro generated dendritic cells were infected with either Ad5-NY-BR-1 or Ad5 and NY-
BR-1 protein expression was analyzed by Western blot 48 hrs after infection. 1 X 105 PBMCs
depleted of were infected with Ad5-NY-BR-1 at an MOI=100 in a final volume of 2 ml. Infections
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of 1 X 105 in vitro generated dendritic cells were performed with an MOI=1000 in a 96 well
formate and in a total volume of 100 µl.
4.2.16 Generation of human dendritic cells (DCs) as antigen presenting cells for
murine NY-BR-1-specific HLA-DR restricted T cell lines
Mature HLA-matched dendritic cells were loaded with whole cell lysate obtaind from melanoma
cell line (Ma-Mel73a) which was infected with an recombinant adenoviral vector encoding the NY-
BR-1 protein (Ad5-NY-BR-1), MOI=100. Infected Ma-Mel73a cells were cultured in six well plates
in a volume of 2 ml culture medium and cells were harvested 48hrs after infection and resuspended
in PBS. Whole cell protein lysates were generated by repeated thaw-freeze cycles under sterile
conditions. Protein concentration was determined by Bradford analysis. Furthermore, NY-BR-
1 expression was confirmed by Western blot analysis using the primary NY-BR-1 monoclonal
antibody clone #2 (1:1000) and a secondary anti-mouse antibody (SantaCruz Biotechnology,
Santa Cruz, CA).
To test for natural processing of the identified epitope, mature DCs ( 2x104) were seeded into
each well of an EliSpot plated coated with IFN-γ specific antibody followed by incubation with
20 µg of whole cellular protein derived from Ma-Mel73a cells infected with recombinant Ad5-NY-
BR-1 (MOI=100) in 100µl x-Vivo medium (Lonza). Furthermore, mature DCs were pulsed with
1 µg/ml NY-BR-1-specific peptide. After 18 hrs 1 X 105 murine T cells were added per well and
incubation was continued for another 18 hrs.
4.2.17 Histological staining of breast cancer biopsies
120 tumor biopsies of breast cancer patients were collected by Prof. Schneeweiss at the Heidelberg
University Hospital and screened by immunohistology for NY-BR-1 expression (using the NY-BR-1
monoclonal antibody clone #2 ) at the Pathology Department, University Hospital Heidelberg.
4.2.18 HLA-typing of patients and healthy donors
The HLA genotype of healthy donors and breast cancer patients was determined by high-resolution
PCR by an external collaboration partner (Institute for Immunologie and Genetik (Kaiserslautern,
Germany). DNA submitted for HLA genotyping was isolated from PBMCs using the DNA-isolation
kit (Qiagen) according to the manufactures instructions , kindly done by Elke Dickes, German
Cancer Research Center, Heidelberg. Twenty-four patients with positive expression in the tumor
specimen were selected due to their HLA genotype (supplement fig. 36).
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4.2.19 Detection of NY-BR-1 specific T cells among PBMCs of breast cancer pa-
tients and healthy donors
PBMCs of breast cancer patient and healthy donors were thawn and cultured overnight in 50
ml flasks in culture medium. 2 X 106 PBMCs/ml were seeded on a 24 well plate in medium
supplemented with 20 IU/ml interleukin (IL)-2 (PromoKine, Heidelberg, Germany) and 10 ng/ml
interleukin (IL)-7 (PromoKine). Every four days half of the supernatant was exchanged for fresh
medium supplemented with (IL)-2 and (IL)-7.
After 17 and 24 days PBMCs were harvested and IFN-γ secretion was analyzed in IFN-γ
EliSpot assay. Briefly, IFN- γ EliSpot plates were coated for 2 hrs at 37°C with 10 µg/ml per well
with capture IFN-γ mAb. After blocking with culture medium, 105 PBMCs/well were incubated
with 5 µg/ml of cognate peptide for 16-18 hrs. Plates were washed with PBS and 100 µl/well
secondary biotinylated anti-human INF-γ mAb was added at 1 µg/ml per well and incubated for
2 hrs at 37°C. Avidin-conjugated alkaline phosphatase antibody was added after ELISpot plates
were washed again with PBS an incubated at room temperature for 30 min. IFN-γ secretion
was detected by adding 100 µl BCTP/NBT (Sigma, Saint Louis, MO) to the again washed wells
stopping the enzymatic reaction after 1 min by addition of distilled water to the wells. EliSpot
results were analyzed using the AID Elispot reader.
4.2.20 Immunofluorescent staining of PBMCs of breast cancer patients and healthy
donors
Furthermore, immunofluorescent staining (FACS) was performed on PBMCs obtained from pa-
tients and healthy donors after 24 days of in vitro stimulation. In more detail, after an in vitro
stimulation period of 24 days PBMCs were harvested and resuspended at 1 X 107 c/ml in x-Vivo
medium (Lonza). 1 X 106 PBMCs in 200 µl/well x-Vivo medium (Lonza) were plated on a 96
well round bottom plate and incubated over night at 37°C, 5%CO2 in the presence of 5 µg/ml
of antigenic peptide. After 18 hrs, IFN-γ secretion assay was performed according to the manu-
factures instructions using the IFN-γ secretion Assay - Cell Enrichment and Detection Kit (PE),
(Miltenyi). In more detail, after being washed once with MACS-buffer, cells were incubated with
the IFN-γ-Catch reagent and incubated for 45 min at 37°C. To distinguish live and dead cells,
samples were firstly washed with FACS buffer and then stained with Pac Orange (Lifesciences) in
a dilution of 1:1000 in FACS-buffer and incubated on ice for 20 min. Following another washing
step with 200 µl FACS-buffer, samples were incubated with IFN-γ-(PE) detection antibody for 10
min on ice in the dark. Next, surface staining for CD3-PE-Vio770 (Miltenyi), CD4-PerCPCy5.5
(Becton Dickinson), CD8-APC-H7 (Becton Dickinson), CD25-V450 (Becton Dickinson), CD127-
FITC (Miltenyi) was performed by incubating the samples for 20 min on ice in the dark with the
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respective antibodies. Samples were permeabilized by resuspension in 200 µl FIx/PERM Solution
(1x) (Becton Dickinson) and incubated for 30 min on ice in the dark. Samples were washed with
Perm Buffer (1x) (Becton Dickinson) and incubated for 10 min on ice in the dark. In the last
step, intracellular staining for FoxP3 was conducted by incubating the permeabilized samples with
FoxP3-APC antibody (eBiosciences) in FACS Perm Buffer (Becton Dickinson) for 30 min on ice in
the dark. Finally, samples were washed with FACS-Perm buffer and resuspended in FACS buffer.
Cells were measured on a FACS-Canto and date were analyzed with FlowJo software.
4.2.21 Transfection of breast cancer cell lines SK-BR-2, HBL-100 with NY-BR-1-
GFP using the X-treame Gene HP DNA Transfection Reagent
Breast cancer cell lines SK-BR-2 (HLA-DRB1*0401) and HBL-100 (HLA-DRB1*0301) were trans-
fected with pcDNA3.1(-)-NY-BR-1-GFP (kindly provided by the group of Prof. Dirk Jäger) using
x-treame Gene HP DNA transfection reagent according to the manufactures instructions. Briefly,
3 x 105 cells were cultured in 12 well plates in 1ml McCoys medium (PAA laboratories), 100 U/ml
penicillin, 100 µg/ml streptomycin (PAA laboratories), until they reached 80% confluence before
being transfected with 2 µg NY-BR-1-GFP DNA. Plasmid DNA was set to a concentration of
0.01 µg per 100 µl of diluent (Optimen medium) and mixed with the transfection reagent in a 1:3
ratio. 200 µl of plasmid DNA-diluent mix were added to the cells and cells were harvested 24 hrs
and 48 hrs after transfection. In addition, cells were treated with 250 U/ml IFN-γ 24 hrs prior to
transfection.
4.2.22 Transient transfection of human and murine cells with NY-BR-1
1 X 105 Hek293T cells and MCF-7 cells per well were seeded in a 6 well plated and grown until
cells reached 70% confluence. Cells were transfected with the 0.2 µg DNA of the expression
vector pcDNA3.1(-)NY-BR-1 whereas EL4 / EL4-Rob/HHD cell lines were transfected with 0.2
µg DNA of the linearized construct pcDNA(3.1)zeo-NY-BR-1 using the Effectine Transfection
reagent Kit (Qiagen), according to the manufactures instructions. Linearization of pcDNA3.1(-)
was achieved by digesting the plasmid overnight using the restriction enzyme Xba1. Transfections
were performed in 6 well plates in a total volume of 2 ml of the respective culture medium.
4.2.23 Generation of stable NY-BR-1 expressing transfectants
1 X 105 EL4 or EL4-Rob/HHD cells per well were seeded in a 6 well plate and grown until cells
reached 70% confluence. Cells were transfected with 0.2 µg DNA of linearized pcDNA3.1-NY-BR-
1(zeo) vector. Limiting dilutions were performed on transfected EL4-NY-BR-1 and EL4-Rob/HHD
bulk cultures. To select for stable transfected cell clones, single EL4-NY-BR-1 clones were cultured
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in medium containing 0,8 mg/ml G418 (=neomycin) and single EL4-Rob/HHD-NY-BR-1 clones
were cultured in medium supplemented with G418 0,4 mg/ml and zeocin 200 µg/ml, respectively.
4.2.24 Isolation of human PBMCs
Human blood samples of NY-BR-1+ breast cancer patients were kindly provided by Prof. Schneeweiss,
University Hospital, Heidelberg. EDTA-supplemented patients blood was diluted 1:1 with PBS
and and human peripheral mononuclear cells were isolated by using Bicoll solution (Biochrom,
density 1.077 g/ml). More precisely, 50 ml falcon tubes were filled with 13 ml of Bicoll solution
and diluted EDTA-blood was carefully added on top of the bicoll layer. Samples were centrifuged
at 1800 rpm without break and resuspended in 20 ml PBS. After centrifugation, interphase of
mononuclear cells collected, transferred to a fresh 50 ml falcon tube and washed 2 times with
PBS (1400 rpm, 15 min with brake). Finally, cells were resuspended either in culture medium for
in vitro culturing or in freezing medium for long term preservation in liquid nitrogen. PBMCs of
healthy donors were isolated following the same protocol.
4.2.25 IFN-γ -treatment of human cell lines
HLA-DR expression requires IFN-γ treatment of certain human cell lines. Melanoma cell lines
(Ma-Mel79b) and breast cancer cell lines HBL-100, SK-BR-2, were seeded at 5 X 105 cells/well
on a 6 well plate in a 2 ml RPMI 1640, 10%FCS, 1% PenStrep. The next day, 250 U/ml of
human IFN-γ was added to each well. HLA-DR expression was verified 48 hrs later by staining
cells with a pan-specific anti-HLA-DR APC antibody (1:100).
4.2.26 MHC surface expression of EL4-NY-BR-1 clones
MHC surface expression of newly generated EL4-NY-BR-1 clones was analyzed by staining of these
cell lines with 100 µl of Db hybridoma (B22.249) supernatant or 100 µl of a Kb hybridoma (E3-25)
supernatant, kindly provided by G.J. Hämmerling, Dkfz, for 30 min, 4°C. Cells were washed two
times with FACS buffer before staining cells with a secondary goat anti-mouse-IgG FITC antibody
(1:100), 30 min, 4°C in the dark. Following another washing step, cells were resuspended in 200
µl FACS buffer and data were acquired on a FACS Calibur. Additionally EL4-NY-BR-1 clonal cell
lines were stained for anti-IAb using a directly coupled anti-mouse IAb- FITC antibody in a 1:100
dilution.
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5 Results
The full length NY-BR-1 breast cancer associated antigen was previously cloned into the mam-
malian expression vector pcDNA3.1(-) and the construct was obtained from Inka Zörnig. Firstly,
functionality of the expression vector was tested in mammalian cell lines in vitro. Moreover,
subcloning of the full length NY-BR-1 DNA into pcDNA3.1-NY-BR-1(-)zeo was required for the
establishment of NY-BR-1 expressing target cell lines.
5.1 Generation of a NY-BR-1 encoding expression vector suitable
for the generation of NY-BR-1 expressing target cells
In order to test functionality of the expression vector pcDNA3.1(-)NY-BR-1, human embryonic
kidney cell line HEK293T and human breast cancer cell lines MCF-7 were transiently transfected
with the mammalian expression vector pcDNA3.1(-)NY-BR-1. Untransfected HEK293T cells (fig.
5 A, lanes 1,2) and MCF-7 cells (fig. 5 B, lanes 5,8) cells were used as control groups in this
experiment.
NY-BR-1 protein expression was detectable in HEK293T cells 24 hrs after transfection with
pcDNA3.1(-)NY-BR-1 (fig. 5 A, lanes 5,6) using 50 µg of cellular protein, in a volume of 20 µl
for Western blotting. Signals of the NY-BR-1 protein expression were absent in untransfected
HEK293T cells ( fig. 5 A, lanes 1,2) as well as in cells transfected with the empty pcDNA3.1(-)
vector (fig. 5 A lanes 3,4), indicating that NY-BR-1 protein expression is absent in HEK293T
cells and that transfection of the pcDNA3.1(-) vector itself does not lead to any false positive
NY-BR-1 expression signals.
In MCF-7 cells, expression of NY-BR-1 protein was analyzed 24 hrs and 48 hrs after transfection
of the cells, using 50 µg of cellular protein in a volume of 20 µl for Western blot analysis. NY-BR-1
protein expression was detectable after transfection of MCF-7 cells with pcDNA3.1(-)NY-BR-1(fig.
5 B, lanes 3,6). Intensity of NY-BR-1 protein expression in transfected MCF-7 cells did not differ
regarding the investigated time points of 24 hrs and 48 hrs after transfection thus, already 24hrs
post transfection was identified as the optimal time point for reaching maximal protein expression
in MCF-7 cells transfected with pcDNA3.1(-)NY-BR-1. NY-BR-1 protein expression was neither
detectable in untransfected MCF-7 cells (fig. 5 B, lanes 5,8) nor in MCF-7 cells transfected with
the empty pcDNA3.1(-) (fig. 5 B, lanes 4,7). Therefore, similar to our findings in HEK293T cells,
NY-BR-1 false positive experssion signals of the empty pcDNA3.1(-) expression vector itself, as
well a a potential endogenous NY-BR-1 protein expression in MCF-7 cells, could be excluded.
HEK293T cells, transfected with pcDNA3.1(-)NY-BR-1 were included as positive control in this
experiment (fig. 5 B, lane 1).
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Figure 5: Verification of NY-BR-1 protein expression in transiently transfected human HEK293T cells and MCF-7 cells. A:
HEK293T cells, lane 1,2: untransfected cells, lane 2, 3: cells transfected with pcDNA3.1(-), lane 4, 5: cells transfected with
pcDNA3.1(-)NY-BR-1. B: MCF-7 cells, lane 1: HEK2937-NY-BR-1 cells, lane 2, 5: cells transfected with pcDNA3.1(-), lane 4, 8:
cells transfected with pcDNA3.1(-)NY-BR-1.
It is important to note that in addition to the NY-BR-1-specific protein band at 160 kDa
further protein bands were detected in all NY-BR-1 positive samples.
5.2 Generation of stable EL4-Rob/HHD-NY-BR-1 double transfec-
tants
In order to generate syngeneic cell lines with endogenous NY-BR-1 expression that could be
used as stimulator cells for the expansion of HLA-A2-restricted CD8+ T cell lines as well as for
investigating HLA-A2-restricted, NY-BR-1-specific CTL responses, we used the murine lymphoma
cell line EL4-Rob/HHD which expresses a chimeric HLA-A2Db molecule as the parental cell lines.
However, since EL4-Rob/HHD cells already hold a resistance for neomycin (G418), re-cloning
of the NY-BR-1 DNA-sequence from the pcDNA3.1(-)NY-BR-1 constuct, encoding a neomycin
resistance, into the pcDNA3.1(-)zeo mammalian expression vector, encoding a zeocin resistance,
was performed.
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Figure 6: NY-BR-1 protein expression in stable EL4-Rob/HHD transfectants. Stable transfection of EL4-Rob/HHD with
pcDNA3.1(-)NY-BR-1zeo, 50 µg of cellular protein in a volume of 20 µl was analyzed for three selected clones. Lane 1: EL4
cells, lane 2: clone A9B3, lane 3: clone B8D9, lane 4: clone B10C4
Transfectants with stable NY-BR-1 protein expression were established by limiting dilutions of
EL4-Rob/HHD bulk cultures under the selective pressure of 200 µg/ml zeocin. Individual clones
obtained by limiting dilutions were screened for NY-BR-1 protein expression. Clones A9B3, B8D9
and clone B10C4 shown as representative results in figure 6. NY-BR-1 protein expression could be
detected in clone B10C4 (fig. 6, lane 4) and clone A9B3 (fig. 6, lane 2) whereas it was only to a
very low extend detectable in clone B8D9 (fig. 6, lane 3) and not detectable in EL4 cells (fig. 6,
lane 1). EL4-Rob/HHD-NY-BR1 clone B10C4 was selected, in vitro expanded and cryopreserved
for further use, providing a syngeneic murine NY-BR-1-expressing target cell line.
5.3 Generation of stable EL4-NY-BR-1 single transfectants
In vivo tumor models are important to evaluate a translational impact of newly developed T
cell lines. The murine lymphoma-blast cell line EL4 was selected as target cell line due to its
syngeneic H2 background, thus being suitable for either tumor challenge or tumor protection
experiments in C57BL/6 mice. EL4 cells lack murine MHC-II (IAb) expression on the contrary
murine MHC-I molecules (H2-Db, H2-Kb) are highly expressed on their cell surface. Implantation
of EL4-NY-BR-1 transfectants in HLA-tg mice of C57BL/6 background, will allow an evaluation
on the contribution of CD4+ HLA-DRB1*0301- /HLA-DRB1*0401-restricted T cells to a CD8+
T cell mediated tumor regression, as well as first insights into the composition of the tumor-
miroenvironment regarding a NY-BR-1 positive tumor.
EL4 cells were transfected with a linearized version of the pcDNA3.1(-)zeo to increase transfec-
tion efficacy. Next, EL4-NY-BR-1 bulk cultures were further used for the generation of individual
El4-NY-BR-1 clones by the process of limiting dilutions. After approximately two weeks, single
clones grew out and were expanded in vitro. Once enough material was available, NY-BR-1
protein expression was evaluated among the different EL4-NY-BR-1 clones.
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Figure 7: NY-BR-1 protein expression in EL4-NY-BR-1 stable transfectants. NY-BR-1 protein expression was analyzed in indicated
individual EL4-NY-BR-1 clones. 15 µg of cellular protein in a volume of 20 µl was analyzed for each sample by Western blot analysis.
Western blot analysis revealed different NY-BR-1 protein expression levels comparing the in-
dividual EL4-NY-BR-1 clones (fig. 7). Finally, clone D8P3 was selected as a NY-BR-1high(fig.
7, lane 1) , clone D1P4 was selected as NY-BR-1intermediate (fig.7, lane 3) and clone F7P4 was
selected as a NY-BR-1low expressing clone (fig. 7, lane 17) and further expanded in vitro. All
remaining clones were cryopreserved and stored in liquid nitrogen. NY-BR-1 protein expression
was absent in parental EL4 cells (fig. 7, lane 23). As positive control, NY-BR-1 transfected
MCF-7 cells were included in this experiment (fig. 7, lane 13), since NY-BR-1 protein expression
was detected previously in MCF-7 cells transfected with pcDNA3.1(-)NY-BR-1 (fig. 5 B).
5.3.1 Expression of MHC molecules on stable EL4-NY-BR-1 transfectant clones
Regarding our attempt to prove the contribution of CD4+ T cells among a CD8+ T cell mediated
anti-tumor response, the MHC-phenotype (H2-Db/Kb IAb-/-) of EL4-NY-BR-1 transfectants, was
analyzed by immunoflourescent surface molecule staining. Individual EL4-NY-BR-1 clones (D8P3,
D1P4, F7P4) were stained with either a murine anti-Kb-specific monoclonal antibody (E3-25),
a murine anti-Db-specific monoclonal antibody (B22.249) or with a IAb-specific monoclonal an-
tibody. Analysis of acquired flow cytometry data confirmed strong expression of murine H2-Kb,
H2-Db molecules in the tested EL4-NY-BR-1 clones D8P3, D1P4 and F7P4 (fig. 8). However,
when comparing the H2-Kb molecule expression levels among the parental EL4 cell line (MFI=786)
and the established clones D8P3 (MFI=345), D1P4 (MFI=460) and F7P4 (MFI=399), a reduc-
tion of H2-Kb molecule expression levels was observed. Similar tendencies were observed regard-
ing a reduction on expression levels of the H2-Db molecule, hereby the parental cell line EL4
(MFI=600) and the established clone D8P3 (MFI=533) showed similar expression levels of the
H2-Db molecule. In contrast, H2-Db molecule expression levels were reduced in clones D1P4
(MFI=375) and F7P4 (MFI=305) compared to the parental El4 (MFI=600) cell line (fig. 8).
67
Results
Reduced expression levels of the surface molecules H2-Kb and H2-Db among the established EL4-
NY-BR-1 transfectants should be considered when using these clones for in vivo tumor challenge
experiments in mice.
Figure 8: Expression of MHC molecules on stable EL4-NY-BR-1 transfectant clones. EL4-NY-BR-1 transfectants were stained
for H2-Kb/Db expression using the monoclonal antibodies (anti-Kb: E3-25)/(anti-Db: B22.249) detected by an anti-mouse-IgG FITC
antibody, and expression of IAb (anti-IAb-FITC). Cells were treated with 500 U/ml of murine IFN-γ for 48 hrs when indicated.
To test for IAb molecule expression under the influence of murine IFN-γ, which might be
secreted in the tumor microenvironment in vivo, EL4-NY-BR-1 clones were treated with murine
IFN-γ prior to flow cytometry staining. Even after IFN-γ treatment, expression of the murine IAb
molecule remained negative for clonal cell line D8P3, D1P4 and F7P4 (fig. 8B) but induced IAb
expression in the murine melanoma cell line B16, which was included as a positive control cell line
for IFN-γ induced IAb expression (fig.8B).
To sum up, selected EL4-NY-BR-1 clonal cell lines D8P3, D1P4 and F7P4 express
murine H2-Kb / H2-Db but no IAb molecules on the cell surface even upon IFN-γ
treatment.
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5.4 Identification of NY-BR-1-specific T cell candidate epitopes by
using various HLA-transgenic mouse strains
In order to identify novel NY-BR-1-specific HLA-restricted T cell epitopes, three different trans-
genic mouse strains including HHDtg mice (transgenic for HLA-A*0201), DR3tg mice (transgenic
for HLA-DRB1*0301) and DR4tg mice (transgenic for HLA-DRB1*0401) were immunized with
global NY-BR-1 antigen, followed by a combinatorial screening of a NY-BR-1-specific peptide
library.
The NY-BR-1-specific peptide library was composed of 174 20mers overlapping by 12 aa
covering the full length NY-BR-1 protein sequence. Individual library peptides were organized
in 26 pools (K1-K13, L1-L13), each pool harboring 13 single library peptides (supplement fig.
44), five library peptides (#24, #146, #166, #171, #173) were not included in the 26 peptide
pools (K1-K13, L1-13), but included as single library peptides in the screening process. Upon
combinatorial analysis (“matrix screening”), library peptides containing potential NY-BR-1-specific
T cell epitopes were determined and further tested as individual library peptides.
Four milestones for the identification of NY-BR-1-specific epitopes in HLAtg mice
were defined:
I. Identification of positive NY-BR-1-specific library peptides (Milestone I)
II. Identification of NY-BR-1-specific T cell candidate epitopes in
HLA-DR3tg mice and HLA-DR4tg mice
(Milestone II)
III. Verification of HLA-restriction of NY-BR-1-specific T cell
candidate epitopes
(Milestone III)
IV. Verification of processing of NY-BR-1-specific epitopes in human
cells
(Milestone IV)
Figure 9 shows the workflow on identifying novel NY-BR-1-specific HLA-restricted T cell
epitopes using three HLA-tg mouse strains.
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Figure 9: Workflow, identification of NY-BR-1-specific, HLA-restricted T cell epitopes in HLA-transgenic mice. Indicated in
blue are the milestones I-III defined for the identification of NY-BR-1-derived CD4+ T cell epitopes in HLA-tg mice.
5.4.1 Identification of positive NY-BR-1-specific library peptides in HHDtg mice
HHDtg mice were immunized either with the pcDNA3.1(-)NY-BR-1 expression vector (recipient
mice) or were designated as control group, injected with the empty pcDNA3.1(-) vector. Ten days
after immunization, mice were sacrificed and splenocytes, isolated from the immunized mice, could
be analyzed for NY-BR-1-specific T cell responses in IFN-γ EliSpot assays. Screening of the NY-
BR-1 peptide library resulted in detectable IFN-γ-secretion in 1-2 out of 4 mice, upon stimulation
of splenocytes with peptide-pools L1, L3, L5, L7, L10, K2, K6, K10, K11 and K12 (fig.10). Tested
peptide library pools showed different immunogenicity when tested with splenocytes obtained from
immunized HHDtg mice, since IFN-γ spot numbers varied between 30-40 spots (peptide pools
K10, K11, K12 and L7) and were below 30 spots (peptide pools K6, L1, L2 and L10) (fig.
10). Additionally, the already published NY-BR-1-specific, HLA-A*0201 restricted T cell epitopes
p158-167 and p960-968 [112] were included in this experiment, however, they did not elicit IFN-
γ-secretion among splenocytes obtained from vaccinated HHDtg mice. IFN-γ-secretion was not
detectable in any mice of the control group, thus potential immunogenicity of the empty vector
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can be considered to be irrelevant in this context (fig. 10).
Figure 10: NY-BR-1 peptide library screening with splenocytes of HHDtg mice. IFN-γ EliSpot assay results performed with
indicated numbers of splenocytes isolated from DNA vaccinated HHDtg mice. Splenocytes were either incubated for 18 hrs with library
peptide pools K1-K13 and L1-L13 or with the known HLA-A*0201, NY-BR-1-specific epitopes #p158-167 and #p160-169. Each
column represents one individual mouse; bars, standard error of the mean upon duplicate determination.
As shown in figure 11, following combinatorial analysis, a total of 30 library peptides (25
library peptides identified by combinatorial analysis of the matrix screen and five additional library
peptides: #24, #146, #166, #171, #173 which were not included in the first matrix screen)
were selected to be tested as individual library peptides in subsequent experiments (fig. 11).
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Figure 11: Combinatorial analysis of NY-BR-1 peptide library screening (first matrix) with splenocytes of HHDtg mice. NY-
BR-1 library pools which were selected as positive pools due to results obtained in IFN-γ EliSpot assay are depicted in yellow and
possible immunogenic NY-BR-1-derived library peptides are depicted in orange.
Due to a limited number of available HHDtg mice for further experiments, no individual tests
of active library peptides identified in the first matrix screen (fig. 11), was performed. Instead the
potentially activated library peptides determined in the matrix screen were directly submitted to
in silico analysis, using the SYFPEITHI database (33). According to their SYFPEITHI prediction
score, the eighteen first top-scoring predicted HAL-A*0201-restricted, NY-BR-1-specific candidate
epitopes were screened as individual library peptides (fig. 12).
Table 33: In silico prediction of HLA-A*0201-restricted candidate epitopes. HLA-A*0201-restricted 9mer candidate epitopes were
predicted, by using the SYFPEITHI database, for selected NY-BR-1 library peptides as determined by combinatorial matrix screening.
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The remaining candidate library peptides #94, #163, #118, #70, #59 as well as the single
library peptides not included in the first matrix screening (#24, #146, #166, #171, #173) could
not be further investigated due to the limited number of HHDtg mice available.
Nevertheless, first screening of individual library peptides #107, #131, #141 and #120 iden-
tified library peptide #107 eliciting a positive IFN-γ response (mean of 25 IFN-γ-spots ) (fig.12
A) in one out of three tested mice, NY-BR-1 peptide library pools K10 and L10 were included as
technical positive controls in this experiment, since activity of peptide library pools K10 and L10
was observed in the first matrix screening (fig. 10).
Figure 12: IFN-γ EliSpot results with splenocytes of HHDtg mice employing single NY-BR-1 library peptides. Splenocytes from
HHDtg mice immunized with pcDNA3.1(-)NY-BR-1 were isolated and incubated with 2 µg/ml individual library peptides in an IFN-γ
EliSpot for 18 hrs. Each column represents one individual mouse; bars, standard error of the mean upon duplicate determination.
Figure 12 A, B, C represent three individual experiments.
No IFN-γ response could be detected for any of the three mice immunized with the empty
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vector pcDNA3.1(-), excluding NY-BR-1-specific immunogenicity of the empty vector itself.
As depicted in figure 12 B, a second screening of individual library peptides with splenocytes
obtained from immunized HHDtg mice was conducted, testing individual library peptides #107,
#144, #75, #159, #72 and #66. After all, no positive signal could be detected for any of the
tested library peptides in this IFN-γ EliSpot assay (fig.12 B). In a third experiment we investigated
NY-BR-1 library peptides #107, #42, #36, #10, #23, #127, #111, #96, #83, #18, #14 and
#120. IFN-γ secretion was detectable for library peptide #111 and library peptide #96 but
not for any other of the remaining NY-BR-1 library peptides (fig.12 C). In conclusion, NY-BR-1
library peptides #111 and #96 should be included in further investigations for the identification of
NY-BR-1-specific HLA-A*0201-restricted T cell epitopes. Due to restricted numbers of offsprings
resulting in shortage of HHDtg mice, we were not able to carry out further experiments in this
mouse strain in the moment, but experiments will continue as soon as suitable numbers of HHDtg
mice are available.
Overall, milestone I on identifying probably active NY-BR-1-specific library peptides
#96 and #111, was approached by screening a NY-BR-1-specific library in HHDtg
mice. However, low response rates in performed IFN-γ EliSpot assays and the lack
of reproducibility due to HHDtg mice being not available for further experiments,
activity of NY-BR-1-specific library peptides #96 and #111 has to be confirmed in
future experiments.
5.4.2 Identification of positive NY-BR-1-specific library peptides in DR3tg mice
In the next step, immunogenicity of the NY-BR-1 antigen was investigated in DR3tg mice. Firstly,
DR3tg mice were immunized with the pcDNA3.1(-)NY-BR-1 DNA construct(recipient mice).
After 14 days, transgenic mice were sacrificed and IFN-γ EliSpot assay was performed, testing the
complete NY-BR-1 peptide library on isolated splenocytes of individual mice. Mice immunized
with the empty vector pcDNA3.1(-) served as the control group (control mice). Peptides #24,
#146, #166, #171 and #173 were not included in the combinatorial matrix screen but tested
as individual peptides later on directly. Out of 26 tested peptide library pools, peptide pools K2,
K10, K11, K12, L5, L9, L11, L12 and L13 elicited IFN-γ responses in at least two out of four mice
immunized with the pcDNA3.1(-)NY-BR-1 vector but did not induce IFN-γ response in control
mice immunized with the pcDNA3.1(-) vector. Remaining peptide library pools K1, K3, K4, K5,
K6, K7, K8, K9, L1, L2, L3, L4, L6, L7, L8 and L10 did only induce a marginal IFN-γ response,
hence not considered as positive peptide pools (fig.13).
74
Results
Figure 13: NY-BR-1 peptide library screening with splenocytes of DR3tg mice. IFN-γ EliSpot results on DR3tg splenocytes
isolated from DNA vaccinated mice were incubated for 18 hrs with the NY-BR-1 peptide library pools (K1-K13, L1-L13). Each column
represents one individual mouse; bars, standard error of the mean upon duplicate determination.
Nine positive pools, namely K2, K10, K11, K12, L5, L9, L11, L12 and L13 were selected and
according to the combinatorial peptide matrix system, 20 single potentially immunogenic peptides
could be determined (fig. 14)
75
Results
Figure 14: Combinatorial analysis of NY-BR-1 peptide library screening (first matrix) performed with splenocytes of DR3tg
mice. NY-BR-1 peptide library pools which were selected as positive pools due to results obtained in IFN-γ EliSpot assay are depicted
in yellow, potential immunogenic individual library peptides are marked in orange.
In the following experiment, 20 library peptides selected upon combinatorial matrix screening
in DR3tg mice, namely #11, #12, #22, #35, #39, #48, #51, #63, #70, #83, #87, #96,
#135, #143, #155, # 156, #167, #168, #169, #172, and additional five individual library
peptides which were not included in the first matrix screened, namely #24, #146, #166, #171
and library peptide #173 were analyzed for recognition by splenocytes of DNA-immunized DR3tg
mice. Library peptide #166 was described by others to harbor a published NY-BR-1-specific
HLA-DRB1*0301 restricted T cell epitope-sequence [271]. It turned out that peptides #12 and
#168 could stimulate an IFN-γ secretion as detected by EliSpot assay in at least 2/4 immunized
mice with a range of observed IFN-γ spot numbers between 118 and 161 spots (fig. 15). Mean
spot numbers observed were 82-248 IFN-γ-spots upon stimulation of splenocytes originating form
DR3tg mice with library peptides #155, #156, #169 and #172 in at least 3/4 immunized DR3tg
mice (fig. 15).
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Figure 15: IFN-γ EliSpot results with splenocytes of DR3tg mice employing single NY-BR1 library peptides. 1.5 X 106
splenocytes of DNA-vaccinated DR3tg mice were incubated with the respective library peptide for 18 hrs on an IFN-γ EliSpot assay.
Each column represents one individual mouse; bars standard error of the mean upon duplicate determination.
In conclusion, library peptides #12, #155, #156, #168, #169 and #172 were considered
for further analysis since they represented potential candidates of harboring NY-BR-1-specific,
HLA-DRB1*0301-restricted CD4+ T cell epitopes.
Overall, milestone I for DR3tg mice on identifying positive NY-BR-1-specific library
peptides was completed by determination of library peptides #12, #155, #156,
#168, #169 and #172 as potentially epitope containing NY-BR-1-specific library in
DR3tg mice.
5.4.3 Identification of positive NY-BR-1-specific library peptides in DR4tg mice
Similar to the strategy followed for DR3tg mice, DNA-immunized DR4tg mice were divided in
two experimental groups: mice immunized with pcDNA3.1(-)NY-BR-1 expression vector (recipient
mice) and mice immunized with the empty pcDNA3.1(-) expression vector (control mice). After
14 days, mice were sacrificed and splenocytes of DNA-immunized DR4tg mice were used to screen
the NY-BR-1-specific peptide library. As shown in figure 16, peptide pools K3, K4, K8, K10, K11,
K13, L2, L3, L4, L5, L6, L7, L8, L9, L10 and L13 were considered positive in stimulating IFN-γ
secretion within splenocytes of DNA-immunized DR4tg mice determined by IFN-γ EliSpot assay
in at least 1/4 mice. Peptide pools K13 and L3 elicited the greatest IFN-γ response reaching an
average of 95-144 IFN-γ-spots in at least 1/4 immunized mice (fig. 16). Overall, splenocytes
obtained from recipient mouse two (Recipient 2), elicited greatest IFN-γ-secretion upon incubation
with the positive peptide library pools ( K3, K4, K8, K10, K11, K13, L2, L3, L4, L5, L6, L7, L8,
L9, L10 and L13), when compared to IFN-γ responses obtained with splenocytes originating from
the other DR4tg recipient mice. In contrast, IFN-γ secretion was not detected in any member of
the control group mice (fig 16).
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Figure 16: NY-BR-1 peptide library screening with splenocytes of DR4tg mice. IFN-γ EliSpot results on splenocytes isolated
from DNA-vaccinated DR4tg mice were incubated for 18 hrs with NY-BR-1 peptide library pools (K1-K13, L1-L13). Each column
represents one individual mouse; bars, standard error of the mean upon duplicate determination.
Combinatorial analysis of the results obtained in the first matrix screening with splenocytes
of DNA-vaccinated DR4tg mice resulted in a total number of 65 individual library peptides to be
screened (60 library peptides resulting from combinatorial analysis of the conducted matrix screen
and five additional peptides not included in the initial first matrix screen),(fig. 17).
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Figure 17: Combinatorial analysis of NY-BR-1 peptide library screening (first matrix) performed with splenocytes of DR4tg
mice. NY-BR-1 library pools which were selected as positive pools due to results obtained in IFN-γ EliSpot assay are depicted in
color.
To facilitate screening of the selected 65 candidate library peptides, a second matrix was
applied, composed out of 16 pools (A1-A8, B1-B8). Each pool harbored eight individual library
peptides, except pools A5-A8 which only contained seven individual library peptides and pool B8
only containing four individual library peptides (fig. 18).
Figure 18: Arrangement of the NY-BR-1-specific second matrix. 65 single NY-BR-1 library peptides were organized in 16 pools
(A1-A8, B1-B8). Individual library peptides resulted from the combinatorial analysis of the first matrix screening with splenocytes of
DNA-immunized DR4tg mice (fig. 16).
As shown in figure 19, screening of the second matrix by IFN-γ EliSpot assay, identified
peptide pools A2, A7, B1 and B6 as truly negative NY-BR-1 peptide pools which were excluded
since no IFN-γ-response was observed in any of the recipient mice above an average of 40 IFN-
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γ-spots, whereas the remaining peptide pools elicited an average of IFN-γ secretion ranging from
75-316 IFN-γ-spots, in at least 1/4 immunized DR4tg mice (fig. 19). In this particular case,
truly negative pools were excluded since data on positive NY-BR-1 peptide pools could only be
partially reproduced (supplement figure 45).
Figure 19: Screening of a second level NY-BR-1-specific library in DR4tg mice. IFN-γ EliSpot assay results on an experiment
conducted with splenocytes of DNA vaccinated DR4tg mice. Splenocytes obtained from immunized DR4tg mice were incubated with
peptide pools (A1-A7, B1-B8) for 18 hrs. Each column represents one individual mouse; bars, standard error of the mean upon
duplicate determination.
As depicted in figure 20, 38 NY-BR-1 library peptides (33 library peptides resulting from
combinatorial analysis of the second level matrix screen plus five individual library peptides not
included so far in the matrix screen) were selected for further analysis, were identified by com-
binatorial analysis of the results obtained by screening the second matrix (peptide pools A1-A8,
B1-B8) with splenocytes of DNA-immunized DR4tg mice.
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Figure 20: Combinatorial analysis of NY-BR-1 peptide library screening (second matrix) performed with splenocytes of DR4tg
mice. NY-BR-1 peptide library pools which were selected as positive pools due to results obtained in IFN-γ EliSpot assay (fig. 19)
are depicted in yellow, potential immunogenic library peptides are marked in orange.
Given the fact, that the high number of 38 individual library peptides was selected for further
screening, these individual NY-BR-1-specific library peptides were organized in a third matrix.
More precisely, the remaining 38 library peptides were organized in pairs of two, composing
peptide pools C1-C19 (fig. 34) and subjected to subsequent analysis by IFN-γ EliSpot assay.
Table 34: Arrangement of the NY-BR-1-specific third matrix. 38 single NY-BR-1 library peptides were organized in 16 pools
(C1-C16). Individual library peptides resulted from screening of the second matrix (fig. 19) with splenocytes of DNA-immunized
DR4tg mice.
As depicted in figure 21 A, stimulation of IFN-γ secretion in splenocytes of DR4tg immunized
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mice (recipients) was detected for third matrix pools C1, C5, C7, C11, C12 in 4/4 mice with
average IFN-γ spot numbers ranging between 40 and 244 spots. Peptide pools C13 and C16
elicited a positive IFN-γ response in at least 1/4 recipient mice, as shown in figure 21 B. However,
mean IFN-γ spot numbers determined by EliSpot assay, were low in regard to peptide pool
C13 (average 24 IFN-γ-spots). Additionaly, only splenocytes obtained from recipient mouse one
(Recipient 1) did elicit a specific IFN-γ response, thus this experiment might not detect all active
library peptides containing potential NY-BR-1-specific epitopes due to very low IFN-γ-signals
(below an average of 10 IFN-γ-spots) detected among splenocytes obtained from DNA-immunized
DR4tg mice.
Figure 21: Screening of pools C1-C19 in DR4tg mice. Splenocytes were isolated from DNA vaccinated DR4tg mice and incubated
with the respective library pool for 18 hrs on an IFN-γ EliSpot assay. Pools C1-19 were screened in two individual experiments A:
Screening of pools C1-15, B: Screening of pools C16-19. Each column represents one individual mouse; bars, standard error of the
mean upon duplicate determination.
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Then, we set out to analyze individual library peptides #3, #68, #82, #95, #148, #44,
#58, # 71, #97, #35, #112, #8, #117, #156 included in selected positive pools C1, C5, C7,
C11, C12, C13 and C16. The results shown in figure 22 indicate immunogenicity of individual
library peptides #58, #68, #82 and #97 in 2/4 immunized DR4tg mice with mean IFN-γ
spot numbers ranging from 10-57 IFN-γ spots (fig. 22 A, B). Upon stimulation of splenocytes
obtained from immunized DR4tg mice, with library peptide #112, a positive IFN-γ response
between 172-252 IFN-γ-spots was observed (fig. 22 C). Library peptide #156 elicited a positive
IFN-γ response with a mean spot number of 91 IFN-γ-spots in 1/4 immunized DR4tg mice, when
incubated with splenocytes obtained from these mice (fig. 22 D). Furthermore, we could detecte
a positive IFN-γ-response upon incubation of splenocytes obtained from immunized DR4tg mice,
with library peptide #112. Subsequently, the five library peptides #68, #82, #97, #112 and
#156 were considered as candidate library peptides potentially containing a NY-BR-1-specific,
HLA-DRB1*0401-restricted CD4+ T cell epitopes. Library peptide #58 was so far not further
investigated due to technical difficulties but will be included in future experiments.
Figure 22: IFN-γ EliSpot results with splenocytes of DR4tg mice employing single NY-BR1 library peptides. IFN-γ EliSpot assay
was performed with splenocytes obtained from DNA-immunized DR4tg mice, which were incubated with the indicated library peptides
for 18 hrs (A-D). Each column represents one individual mouse; bars, standard error of the mean upon duplicate determination.
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We identifying positive NY-BR-1-specific library peptides #58, #68, #82, #97,
#112 and #156 which potential harbor NY-BR-1-specific epitopes, by screening a
NY-BR-1-specific library in DR4tg mice, thus milestone I was reached.
5.4.4 In silico prediction of HLA-DRB1*0301 and HLA-DRB1*0401-restricted NY-
BR-1-specific CD4+ T cell candidate epitopes
Potential HLA-DRB1*0301- and HLA-DRB1*0401- restricted CD4+ T cell epitopes contained in
NY-BR-1-specific library peptides determined by screening a NY-BR-1-specific peptide library with
splenocytes of DNA-immunized DR3tg mice (5.4.2) and DNA-immunized DR4tg mice (5.4.3),
were predicted in silico by the SYFPEITHI database (fig.35).
The SYFPEITHI algorithm scoring system evaluates the likelihood of binding of a epitope
motive to a given anchor position within the MHC-molecule. Among described natural T cell
epitopes, the MHC-I-restricted epitope GILGFVFTL, which is derived rom the influenza A matrix
protein scores 30 which can be considered as a reference value for “high” SYFPEITHI algorithm
scores for HLA-A*02-restricted CTL epitopes. The natural processed MHC-II-restricted epitope
Trp2149-163 [183] which is derived from the melanoma differentiation antigen Trp2, scores 21 when
submitted to the SYFPEITHI epitope prediction algorithm.
As depicted in table 35 A, analyzing the in silico prediction-results of the SYFPEITHI algo-
rithm regarding HLA-DRB1*0301-restricted T cell epitopes contained in the selected NY-BR-1-
derived library peptides #12, #169, #155 and #156, poteintial HLA-DRB1*0301-restricted T
cell candidate epitopes could be identified. In the case of library peptide #12, prediction of a HLA-
DRB1*0301-restricted epitope BR1-88 (prediction score 34) requires an additional vain-residue
at aa position 88 to the original library peptide sequence. Library peptide #169 contains the
predicted HLA-DRB1*0301-restricted candidate epitope BR1-1347 (prediction score 22). Library
peptides #155 and #156 are predicted to contain a H2-Db restricted CTL epitope, which could
be considered as internal control peptide in HLA-transgenic mice with a H2b background. With
a SYFPEITHI algorithm score of 15 in case of library peptide #155 and a SYFPEITHI algorithm
score of 13 for library peptide #156, both NY-BR-1-derived library peptides are predicted by the
SYFPEITHI algorithm with low probability to contain HLA-DRB1*0301-restricted, NY-BR-1 spe-
cific T cell epitopes. Even though SYFPEITHI algorithm scores are rather low for NY-BR-1-derived
library peptides #155 and #156, the corresponding library peptides were recognized after global
NY-BR-1-specific DNA-vaccination in DR3tg mice (fig. 15). Hence, the possible contribution
of HLA-DRB1*0301-restricted epitopes BR1-1238 and BR1-1245, contained in library peptides
#155 and #156, to positive IFN-γ response determined by EliSpot assay was further investigated.
Library peptide #168 was predicted to comprise candidate epitope BR1-1339 (prediction score
18) whereas candidate epitope BR1-1370 (prediction score 17) is located in the aa sequence of
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library peptide #172. Both NY-BR-1-derived epitopes were not further investigated in this work
due to limited financial resources but will be included into future experiments.
Table 35: In silico prediction of NY-BR-1-specific T cell epitopes among previously identified NY-BR-1-derived library peptides.
Predicted HLA-DRB1*0301 (A) and HLA-DRB1*0401 (B) restricted, NY-BR-1-specific epitopes are typed in bold; N-terminal and
C-terminal amino acid positions are typed in superscript; Db-restricted CD8+ T cell epitopes are underlined (Vormehr, unpublished);
*synthetic candidate epitopes with identical aa sequences derived from repetitive stretches within primary sequence of the NY-BR-1
protein; amino acid residues added to the original library peptide sequence are shown in brackets.
As shown in table 35 B, high scoring HLA-DRB1*0401-restricted epitopes were predicted in
library peptide #68, #82, #97 and #112. Library peptide #68 harbors the predicted HLA-
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DRB1*0401-restricted candidate epitope BR1-537 (prediction score 26). Notably, peptides #82
and #97 are located in a repetitive sequences of the NY-BR-1 protein, thus the predicted can-
didate epitope BR1-656/-775 (prediction score 26) is identical for these two library peptides.
Furthermore, the HLA-DRB1*0401-restricted NY-BR-1-derived epitope BR1-1242 was predicted
to be located in the amino acid sequence of library peptide #155 (prediction score 20). NY-BR-
1-derived CD4+ T cell epitopes BR1-894, harbored in library peptide #112, so far could not be
investigated due to limited financial resources, but will be investigated more thoroughly in future
experiments.
To sum up, predicted 15mer NY-BR-1-specific, HLA-DRB1*0301-restricted can-
didate epitopes BR1-88, BR1-1238, BR1-1347 and HLA-DRB1*0401-restricted can-
didate epitopes BR1-537, BR1-656/-775, BR1-1242 were synthesized and used for
further analysis (fig. 35).
5.4.5 Detection of CD4+ T cells specific for the NY-BR-1-specific candidate epi-
topes in HLA-DRB1*0301- and HLA-DRB1*0401-transgenic mice
Splenocytes originating from DR3tg mice which were DNA-vaccinated with global NY-BR-1 anti-
gen, elicited a positive IFN-γ response in at least 1/4 mice upon stimulation with 15mer candidate
epitopes BR1-88, BR1-1238 and BR1-1347, whereby intensity of induced IFN-γ response, indi-
cated by columns (mean of duplicate determination; bars, standard error of the mean) differed
regarding individual mice as well as regarding the three tested candidate epitopes. Mean spot
numbers observed were 50-100 spots in 1/3 mice for candidate epitope BR1-88, 180-250 spots in
2/4 mice for candidate epitope BR1-1238 and 100-280 spots in 3/4 mice for candidate epitope
BR1-1347. No NY-BR-1-specific IFN-γ response was induced in splenocytes of control mice im-
munized with the empty pcDNA3.1(-) vector, upon stimulation with candidate epitopes BR1-88,
BR1-1238 and BR1-1347 (fig. 23 A).
As shown in figure 23 B, splenocytes originating from DR4tg mice, DNA vaccinated with
global NY-BR-1 antigen, were tested for eliciting an IFN-γ response upon stimulation with candi-
date epitopes BR1-537, BR1-656/-775 and BR1-1242. IFN-γ responses was detectable following
stimulation of splenocytes with candidate epitopes BR1-537, BR1-656/-775 and BR1-1242. Can-
didate epitope BR1-656/-775 elicited an IFN-γ responses ranging from 100-250 spots in 3/4 mice
responding, spot numbers observed for candidate epitope BR1-1242 showed a greater diversity re-
garding immunized mice showing 50-150 spots in 3/4 mice. The range of spot numbers observed
for candidate epitope BR1-537 was 100-200 spots with 3/4 mice responding (fig. 23 B).
True for both, experiments performed, as shown in figure 23 A, B, candidate epitopes investi-
gated in this experiment, did not generate a significant NY-BR-1-Specific IFN-γ signal in any of
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the control mice immunized with the pcDNA3.1(-) construct (fig. 23 A, B).
Experiments were performed at least three times for each transgenic mouse strain and repeat-
edly revealed similar results, indicating a NY-BR-1-specific IFN-γ secretion upon stimulation of
murine splenocytes with the candidate epitopes BR1-88, BR1-1238 and BR1-1347 in DR3tg mice
and candidate epitopes BR1-537, BR1-656/-775 and BR1-1242 in DR4tg mice. Peptides BR1-
1245, BR1-1339 and BR1-1370 were not included in IFN-γ EliSpot assays and will be investigated
in future experiments.
Figure 23: Recognition of NY-BR-1-specific candidate epitopes by splenocytes originating from DR3tg and DR4tg mice.
Splenocytes of DR3tg mice (A) and DR4tg mice (B) DNA-immunized with global NY-BR-1 antigen, were isolated and incubated
with the indicated 15mer NY-BR-1-specific candidate epitope for 18 hrs. Each column represents one individual mouse; bars, standard
error of the mean upon duplicate determination.
To determine the CD4+ phenotype of the IFN-γ secreting splenocytes upon stimulation with
the indicated candidate epitope in vitro, IFN-γ secretion assays together with (FACS) immunoflu-
orescence staining of the IFN-γ secreting cells, were performed. CD4+IFN-γ+ splenocytes were
detectable in DNA-immunized DR3tg mice following stimulation of splenocytes with candidate
epitopes BR1-1347 and BR1-1238 with frequencies of CD4+IFN-γ+ cells rangeing from 0.15% to
2.75%. Whereas in control mice immunized with the empty vector, frequencies of CD4+IFN-γ+
cell were maximum 0.18% (fig. 24 A). Splenocytes of only one immunized DR3tg mouse, which
were stimulated with candidate epitope BR1-88, did show a distinct population of CD4+IFN-γ+
splenocytes with a frequency of 0.17%. However, the epitope BR1-88 was still considered in
further experiments, since frequencies of CD4+IFN-γ+ splenocytes upon stimulation with peptide
BR1-88 were higher in recipient mice than among splenocytes isolated from mice immunized with
pcDNA3.1(-), (fig. 24 A).
In DR4tg mice, stimulation of HLA-DRB1*0401-transgenic splenocytes with candidate epi-
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topes BR1-537 and BR1-656/-775 but not with candidate epitope BR1-1242 resulted in the
stimulation of CD4+IFN-γ+ T cells, detectable by immunoflourescent staining (fig. 24 B). Maxi-
mum frequency of CD4+IFN-γ+ T cells of 0.25% was detected among splenocytes, obtained from
an immunized DR4tg mice upont stimulation of the splenocytes with peptide BR1-656/-775.
Detected amounts of CD4+IFN-γ+ T cells were always lower in control mice immunized with
pcDNA3.1(-) when compared to amounts of CD4+IFN-γ+ T cells detected in immunized DR4tg
mice (fig. 24 B).
Figure 24: Detection of NY-BR-1-specific CD4+IFN-γ+ T cells in splenocytes of HLA-DRtg mice. IFN-γ secretion assay
results upon stimulation of splenocytes originating from DR3tg mice (A, C) and DR4tg mice (B, D), immunized with global NY-
BR-1 antigen. Splenocytes were stimulated during the assay with the indicated NY-BR-1-specifc candidate epitopes. Samples were
enriched for IFN-γ positive cells in DR3tg mice (C) and DR4tg mice (D) by magnetic sorting. Results are presented as percentag of
CD4+IFN-γ+cell popultions among all viable cells. (Statistic analysis: unpaired t test, significant (*) if P < 0.05)
Furthermore, CD4+IFN-γ+ T cell responses were investigated by a modified IFN-γ secretion
assay which includes an enrichment step for IFN-γ-secreting cells. Results obtained from this assay
showed that NY-BR-1-specific CD4+IFN-γ+ T cell among splenocytes of vaccinated DR3tg mice
could be enriched up to 53.68% for CD4+ T cells specific for the candidate epitope BR1-1347
and up to 33.48% for CD4+ T cells specific for candidate epitope BR1-1238 (fig. 24 C). In line
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with with our findings obtained in the classical IFN-γ secretion assay, amounts of CD4+IFN-γ+
T cells specific for the promiscuous epitope BR1-88 were very low, thus even after enrichment,
the amount of detected CD4+IFN-γ+ T cells specific for peptide BR1-88 was at maximum 8.74%
among total CD4+ T cells (fig. 24 C).
As shown in figure 24 D, NY-BR-1-specific CD4+IFN-γ+ T cell among splenocytes of vacci-
nated DR4tg mice, could be enriched for CD4+ T cells specific for candidate epitope BR1-537 up
to 25.96% and for candidate epitope BR1-656/-775 up to 29.72% (fig. 24D). Regarding peptide,
BR1-1242, peptide-specific CD4+IFN-γ+ T cells among splenocytes of vaccinated DR4tg mice,
could be enriched up to 19.15%.
To sum up, antigen-specific CD4+IFN-γ+ T cells among splenocytes of vaccinated HLA-DRtg
mice could be enriched by the modified IFN-γ secretion assay (fig. 24 C, D), which includes an
enrichment step for IFN-γ-secreting cells, thus overall confirming our results obtained with the
classical IFN-γ-secretion assay (fig. 24 A, B).
In conclusion, CD4+IFN-γ+ T cells specific for candidate epitopes BR1-88, BR1-
1238 and BR1-1347 could be identified in vaccinated DR3tg mice, whereas CD4+IFN-
γ+ T cells specific for candidate epitopes BR1-537, BR1-656/-775 and BR1-1242
could be identified in vaccinated DR4tg mice. Overall, Milestone II, regarding the
identification of NY-BR-1-specific candidate epitopes in DR3tg mice and DR4tg mice
was accomplished. Furthermore, we confirmed, that the newly identified NY-BR-1-
derived candidate epitopes elicit a CD4+ T cell dependent immune response among
splenocytes of DNA-vaccinated, DR3tg mice and DR4tg mice.
5.4.6 Detection of CD8+ T cells specific for NY-BR-1 in DR3tg mice and DR4tg
mice
Interestingly, we also observed a NY-BR-1-specific CD8+ T cell response upon stimulation of
splenocytes, obtained from DR3tg mice, DNA-vaccinated with global NY-BR-1 antigen, with
candidate epitopes BR1-1347 and BR1-1238 (fig. 25A). In splenocytes obtained from DR4tg
mice vaccinated with global NY-BR-1 antigen, a NY-BR-1-specific, CD8+ T cell response was
observed following stimulation of these splenocytes with candidate epitope BR1-656/-775 in one
mouse of four mice (fig. 25B). When stimulating HLA-DRB1*0401-transgenic splenocytes with
candidate epitopes BR1-537 and BR1-1242, no NY-BR-1-specific, CD8+ T cell dependent IFN-γ
response was observed.
Given the foregoing results on detecting NY-BR-1-specific, CD8+ T cell responses in DR3tg
mice, upon stimulation of splenocytes with the 15mer candidate epitope, we investigated the
presence of H2-Kb/Db-restricted NY-BR-1-specific epitopes within the amino acid sequence of
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the tested candidate epitopes. In fact, one NY-BR-1 specific, Db-restricted CTL epitope (amino
acid position: NY-BR-1p1242-1249) contained in the amino acid sequence of candidate epitope
BR1-1238 (Vormehr unpublished data) was described. We postulate, that the newly identified
NY-BR-1 specific, Db-restricted CTL epitope is processed out of the 15mer candidate epitope
therefore stimulating a NY-BR-1-specific CD8+ T cell response in vivo. Interestingly, we so far
could not identify a H2b-restricted CTL epitope harbored in the amino acid sequence of the 15mer
library peptide BR1-1347. Even though, as shown in figure 25 A, CD8+ T cells were detected upon
stimulation of splenocytes obtained from immunized DR3tg mice with library peptide BR1-1347.
Hence, we assume the presence of a H2b-restricted CTL epitope in the amino acid sequence of
library peptide BR1-1347 which will have to be further investigated in future experiments. Overall,
further experiments, investigating immunogenicity of the newly identified NY-BR-1 specific, H2b-
restricted CTL epitope are currently performed in the group of Prof. Eichmueller.
Figure 25: Detection of NY-BR-1-specific, CD8+IFN-γ+ T cells in splenocytes of HLA-DRB1*0301-/DRB1*0401-transgenic
mice. IFN-γ secretion assay results on stimulation of splenocytes originating from DR3tg mice (A) and DR4tg mice (B), vaccinated
with global NY-BR-1 antigen, with the indicated NY-BR-1-derived peptide. Results are presented as percentage of CD8+IFN-γ+ cell
populations. (Statistic analysis: unpaired t test, significant (*) if P < 0.05)
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5.5 Verification of HLA-DRB1*0301-restriction / HLA-DRB1*0401-
restriction of identified NY-BR-1-specific candidate epitopes
5.5.1 Establishment of NY-BR-1-specific, HLA-DRB1*0301- and HLA-DRB1*0401-
restricted murine CD4+ T cell lines
In order to establish murine CD4+ T cell lines, DR3tg mice were immunized once with 100 µg
peptide of candidate epitopes BR1-88, BR1-1238 or BR1-1347. Individual DR4tg mice were
injected with 100 µg peptide of candidate epitopes BR1-537, BR1-656/-775 or BR1-1242. After
13 days splenocytes isolated of immunized DR3tg-/ DR4tg- mice were pooled and cultured in
T cell medium supplemented with 0.2 µg/ml of the respective peptide together with irradiated
syngeneic feeder cells. After repeatedly restimulation, CD4+ T cell lines specific for candidate
epitopes BR1-88, BR1-1347, BR1-537, BR1-656/-775 and BR1-1242 were successfully expanded
in vitro. Unfortunately, no CD4+ T cell line specific for the candidate epitope BR1-1238 could be
established due to poor proliferation capacity of cells and subsequent loss of viable cells in culture.
Flow cytometry analysis was performed to prove a CD4+ phenotype of the newly generated T
cell lines BR1-88, BR1-1347, BR1-537, BR1-656/-775 and BR1-1242. Immunoflourescent staining
of CD4+ T cell lines was performed by staining the cells using flourochrome-coupled antibodies
directed against the surface molecules CD4 and CD8, signals were detected by flow cytometry. T
cell lines BR1-88, BR1-1347, BR1-537 and BR1-1242 show a single CD4+ cell population with
frequencies of 99%, 98.9%, 96.7%, 97.8 when gated on the lymphocyte population (fig. 26).
As shown in figure 26, T cell line BR1-656/775 not only consists out of a CD4 positive
population with a frequency of 64.5%, but also appears to have a CD4-CD8- cell population
within the lymphocyte gate. The specific phenotype of the CD4 negative cell population among
the T cell line BR1-656/-775 needs to be further investigated.
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Figure 26: Phenotypic characterization NY-BR-1-specific T cell lines. 1 X 106 T cells were stained for anti-CD4-FITC and
anti-CD8-FITC. Cells were gated on the lymphocyte population.
Overall, the immunoflourescent staining confirms the established murine T cell
lines being dominated by a CD4+ phenotype compared to the amount of cells display-
ing a CD8+ phenotype, detected by flow cytometry using a FACS-Calibur cytometer.
(fig. 26).
5.5.2 Verification of HLA-DRB1*0301-/*0401-restriction of NY-BR-1-specific can-
didate epitopes
Next, we wanted to prove the HLA-DRB1*0301-/*0401-restriction of the NY-BR-1-specific candi-
date epitopes BR1-88, BR1-1347, BR1-537, BR1-656/-775 and BR1-1242, by usage of T2/DR3,
T2/DR4 transfectants. Those transfectants exclusively express the relevant restriction element
on their surface on a MHC-II negative background.
Candidate epitope BR1-88 was clearly recognized by T cell line BR1-88 only if presented on
T2/DR3 cells, indicated by detectable IFN-γ-spots in an IFN-γ EliSpot assay (55 IFN-γ-spots)
(fig. 27 A). On the contrary, IFN-γ secretion was absent in the case of presenting candidate
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epitope BR1-88 on T2/DR4 or T2 cells (IFN-γ-spots < 10), showing that T cell line BR1-88
truly is HLA-DRB1*0301-restricted for recognizing its cognate peptide BR1-88. To prove peptide
specificity of the T cell line BR1-88, an irrelevant HLA-DRB1*0301-restricted T cell epitope,
derived from the melanoma associated tumor antigen Trp-2, was included in the IFN-γ EliSpot
assay. When loaded on T2/DR3 cell, no IFN-γ secretion higher than the negative control was
observed, confirming antigen specificity of T cell line BR1-88. T cell line BR1-1347 proved
HLA-DRB1*0301 restriction by exclusive recognition of the cognate epitope BR1-1347 loaded on
T2/DR3 cells, indicated by 87 IFN-γ-spots in average, but not when loaded onto T2 or T2/DR4
cells indicated by IFN-γ spot numbers below 10 spots. Furthermore, peptide specificity of T
cell line BR1-1347 was demonstrated by loading T2/DR3 cells with the irrelevant Trp-2-specific
epitope mentioned above which did not result in IFN-γ secretion of T cell line BR1-1347 above
the background level of 10 IFN-γ-spots. Unloaded T2, T2/DR3, T2/DR4 cells did not stimulate
any IFN-γ secretion in T cell line BR1-1347 (fig. 27 A).
HLA-DRB1*0401-restriction of T cell lines BR1-537, BR1-656/-775 and BR1-1242 was demon-
strated by recognition of T2/DR4 target cells loaded with the cognate peptide. True for all three
T cell lines, IFN-γ secretion was most prominent when the cognate peptide was loaded on T2/DR4
cells in comparison to T2, T2/DR3 cells loaded with the respective peptide (fig. 27 B).
No IFN-γ secretion was induced in T cell line BR1-537 upon recognition of unloaded T2,
T2/DR3, T2/DR4 cells as well upon recognition of T2/DR4 cells loaded with the irrelevant
candidate epitope BR1-1242, hereby demonstrating peptide specificity of T cell line BR1-537.
But it also has to be taken into consideration, that T cell line BR1-537 apparently also elicits
IFN-γ secretion upon encounter of its cognate antigen loaded on T2/DR3 and T2 cells, indicated
by 56 IFN-γ-spots and 33 IFN-γ-spots, respectively. This signal has to be considered as being
unspecific background activity of T cell line BR1-537.
As shown in figure 27 B, similar results were obtained for T cell line BR1-1242, since the the
cognate peptide was only recognized when loaded on T2/DR4 cells, indicated by 67 IFN-γ-spots
detected in IFN-γ EliSpot assay, whereby no IFN-γ-spots greater than 10 spots were reached
by co-incubation of T cell line BR1-1242 with peptide loaded T2/DR3 and T2 cells or by co-
incubation with unloaded T2, T2/DR3 or T2/DR4 cells. Additionally, peptide specificity of T cell
line BR1-1242 was demonstrated by loading T2/DR4 cells with the irrelevant candidate epitope
BR1-537 which did not induce any IFN-γ secretion of T cell line BR1-1242 (fig. 27 B).
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Figure 27: Recognition of peptide loaded T2, T2/DR3, T2/DR4 cells by HLA-DRB1*0301 and HLA-DRB1*0401restricted T
cell lines; A: HLA-DRB1*0301-restricted T cell lines, B: HLA-DRB1*0401-restricted T cell lines. T2, T2/DR3 or T2/DR4 cells were
externally loaded with the relevant peptides: BR1-1347, BR1-88 (A); BR1-537, BR1-1242, BR1-656/-775 (B) or with the control
peptide Trp-2 when incubated with T cell line BR1-1347 and T cell line BR1-88. Peptide BR1-1242 was used as a control peptide for T
cell line BR1-537 and peptide BR1-537 was used as a control peptide for T cell line BR1-1242 . 1 X 105 T cells were co-incubated with
peptide loaded T2, T2/DR3 or T2/DR4 cells in an IFN-γ EliSpot assay for 18 hrs. Columns represent reconition of the transfectants
by the indicated murine CD4+ T cell line ; bars, standard error of the mean upon duplicate determination; in case of T cell line
BR1-1242: bars, standard error of the mean upon triplicate determination.
In the case of T cell line BR1-656/-775, the relevant peptide was recognized when loaded on
T2/DR4 cells, indicated by 51 IFN-γ-spots whereby the numbers of IFN-γ-spots detected upon
recognition of unloaded T2/DR4, T2/DR3 or T2 cells, were below 10 spots (fig. 27 B). Peptide
specificity could so far not be investigated for T cell line BR1-656/-775 due to poor proliferation
capacity of this T cell line, but will be analyzed in future experiments.
Importantly, recognition of peptide BR1-537 loaded T2/DR4 cells by T cell line BR1-537
elicited an almost two times higher IFN-γ-response, indicated by 251 IFN-γ-spots in the IFN-γ
EliSpot assay, as recognition of peptides BR1-656/-775 and BR1-1242 by their corresponding
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T cell lines.
To sum up, NY-BR-1-specific candidate epitopes BR1-88 and BR1-1347 are HLA-
DRB1*0301-restricted and NY-BR-1-specific candidate epitopes BR1-537, BR1-656/-
775 and BR1-1242 were shown to be HLA-DBRB1*0401-restricted. Overall, reach-
ing milestone III regarding the verification of HLA-DRB1*0301-/*0401-restriction of
NY-BR-1-specific candidate epitopes, was accomplished.
5.5.3 Peptide affinity differs among established NY-BR-1-specific, murine HLA-
DRB1*0301-/*0401-restricted T cell lines
In the following experiment we aimed to evaluate the peptide affinity of all five generated T
cell lines by titration of the cognate peptide starting from 1000 ng/ml followed by 1:2 dilution
steps with reaching a final concentration of 62.5 ng/ml. Peptide affinity of HLA-DRB1*0301-
restricted T cell lines BR1-88 and BR1-1347 was tested on peptide loaded T2/DR3 cells. As a
negative control, unloaded T2/DR3 cells were included in the IFN-γ EliSpot assay. 1000 ng/ml
of candidate epitope BR1-1347 loaded on T2/DR3 cells was needed to elicit recognition by T
cell line BR1-1347 indicated by IFN-γ secretion, infact none of the lower peptide concentrations
resulted in specific recognition of the peptide loaded target cells by this T cell line (fig. 28).
T cell line BR1-88 showed a higher affinity for its relevant peptide BR1-88 compared to T cell
line BR1-1347 recognizing peptide BR1-1347, since not only at a concentration of 1000 ng/ml
but also with 500 ng/ml of cognate peptide loaded on T2/DR3 cells, specific recognition of the
cognate peptide BR1-1347 could be detected. It has to be mentioned that in the case of T2/DR3
cells loaded with 500 ng/ml peptide, the average of IFN-γ secretion by T cell line BR1-88 declines
to less than 50% of the IFN-γ response observed with a peptide concentration of 1000 ng/ml.
Unspecific recognition of T2/DR3 cells was excluded since unloaded T2/DR3 cells did not result
in significant IFN-γ secretion in T cell lines BR1-88 and BR1-1347 (fig. 28).
HLA-DRB1*0401-restricted T cell line BR1-656/-775 specifically recognized its cognate pep-
tide BR1-656/-775 at a concentration ranging from 1000 ng/ml to 125 ng/ml, even though it
needs to be clarified that overall detected IFN-γ secretion was low for this T cell line compared
to the two remaining HLA-DRB1*0401-restricted T cell lines. T cell line BR1-537 elicited a very
strong IFN-γ response with any applied concentration of the peptide BR1-537 loaded on T2/DR4
cells which even led to an over saturated signal in case of the two highest peptide concentrations
of 1000 ng/ml and 500 ng/ml, applied. Similar findings were obtained with T cell line BR1-1242,
here over saturated signals were detected with peptide concentrations ranging from 1000 ng/ml -
250 ng/ml of peptide BR1-1242 loaded on T2/DR4 cells. Strong IFN-γ signals are still detectable
for T cell line BR1-1242 recognizing 125 ng/ml and 62.5 ng/ml of peptide BR1-1242 loaded on
T2/DR4 cells (fig. 28).
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Figure 28: Peptide affinity of different NY-BR-1-specific CD4+ murine T cell lines. 5 X 104 T2/DR3, T2/DR4 or T2 target
cells/well were externally loaded with 1 µg/ml - 0.0625 µg/ml of indicated candidate epitopes. IFN-γ-secretion was investigated upon
recognition of peptide loaded T2/DR3, T2/DR4 cells by indicated peptide-specific T cell lines.
The T cell lines BR1-1242 and BR1-537 represent the highest affinity for their relevant peptide,
indicated by specifically recognizing the relevant peptides at a concentration of as little as 62.5
ng/ml. However, the amount of secreted IFN-γ varies between these T cell lines, with the T cell
line BR1-1242 eliciting the stronger IFN-γ signal (average of 163 IFN-γ spots) compared to the
signal obtained with T cell line BR1-537 (average of 150 IFN-γ spots) . On the other hand, T cell
lines BR1-88 and BR1-1347 recognized their peptides BR1-88 and BR1-1347 with a much lower
affinity, since the minimum peptide concentrations required to elicit a positive IFN-γ response are
500 ng/ml and 1000 ng/ml, respectively (fig. 28).
In summary, peptide affinity varies among the five newly generated, HLA-DR
restricted murine T cell lines as confirmed by specific recognition of peptide loaded
T2/DR3, T2/DR4 target cells.
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Figure 29 summarizes the NY-BR-1-specific peptide library peptides identified in HHDtg mice,
DR3tg mice and DR4tg mice and indicates the potential NY-BR-1-specific candidate 15mer epi-
topes harbored in identified NY-BR-1-specific library peptides, which were further used to establish
murine HLA-DRB1*0301-/ *0401-restricted CD4+ T cell lines.
Figure 29: Identification of NY-BR-1-specific, HLA-restricted T cell epitopes in HLA-transgenic mice. Indicated in red are
the identified NY-BR-1-specific library peptides and NY-BR-1-specific candidate epitopes as well as the established murine HLA-DR-
restricted, NY-BR-1-specific CD4+ T cell lines. Indicated in blue are the milestones I-III reached for the identification of NY-BR-1-
derived CD4+ T cell epitopes in HLA-tg mice.
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5.6 NY-BR-1-derived, HLA-DRB1*0301-/*0401-restricted CD4+ T
cell epitopes are endogenously processed in human cells
Given the fact that only NY-BR-1-specific epitopes naturally processed in human cells are of future
clinical relevance, we investigated endogenous processing of the newly identified HLA-restricted,
NY-BR-1-specific candidate epitopes in human cells. Various approaches were conducted to con-
firm natural processing of NY-BR-1-specific, HLA-DR-restricted CD4+ T cell epitopes in human
cells.
Finally, NY-BR-1 containing cell lysates were generated from Ad5-NY-BR-1 infected melanoma
cell line Ma-Mel73a and used to peptide pulse HLA-matched in vitro generated human dendritic
cells for recognition by the murine HLA-DR-restricted T cell lines.
5.6.1 Generation of NY-BR-1 expressing target cells
Since no NY-BR-1 expressing human target cell lines were available, we firstly tried to establish a
NY-BR-1 expressing target cell by transfection of HLA-matched cell lines with NY-BR-1 encoding
expression vector or by using a NY-BR-1 encoding adenoviral construct for the infection of target
cells. Apart from HLA-matched human cell lines, HLA-matched CD3-depleted PBMCs and in
vitro generated HLA-matched dendritic cells were infected with a recombinant adenovirus type 5
(Ad5) to generate NY-BR-1 expressing target cells which could be used to confirm endogenous
processing of NY-BR-1-derived candidate epitopes in human cells.
a) Transfection of human breast cancer cell lines SK-BR-2 and HBL-100 with
pcDNA3.1(-)NY-BR-1-GFP
To generate HLA-matched, NY-BR-1 expressing breast cancer cell lines, the breast cancer derived
cell lines SK-BR-2 (HLA-DRB1*0401 positive) and HBL-100 (HLA-DRB1*0301 positive) were
transiently transfected with the pcDNA3.1(-)NY-BR-1-GFP construct. Untransfected cells were
included as a control group in this experiment. Expression of the NY-BR-1/-GFP fusion protein
in transfected HBL-100 (fig. 30 A) and SK-BR-2 (fig. 30 B) cells was detected by flow cytometry
on a FACS-Calibur. GFP-positive cell populations could be detected in both, SK-BR-2 transfected
and HBL-100 transfected cell lines, even though percentages of transfected cells were below 10%
for both cell lines (3.01% HBL-100-GFP+ cells, 17.18% SK-BR-2-GFP+cells) (fig. 30). Gated
on the GFP+ cell population, 37.13% of HLB-100-GFP+ cells also express the surface molecule
HLA-DR whereas only 1.73% of all SK-BR-2-GFP+ cells express the HLA-DR surface molecule
(fig.30).
Due to the fact, that HLA-DR-expression is naturally low on HBL-100 cells and SK-BR-2 cells,
both cell lines were treated with human 500 U/ml of human IFN-γ 24 hrs prior to transfection,
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to enhance HLA-DR surface expression.
Given the low frequencies of cells transfected with pcDNA3.1(-)NY-BR-1-GFP, we suggest
that the transfection efficacy might be reduced due to the large size of the pcDNA3.1(-)NY-BR-
1-GFP vector (10.2 kb) used for transfection leading to a difficulties of the construct entering into
the cells´ cytoplasm. Overall, amounts of NY-BR-1/-GFP fusion protein expressing SK-BR-2 and
HBl-100 cells generated by this transfection approach were too low for using these cells reliably
as NY-BR-1-specific target cell lines.
Figure 30: Transfection of breast cancer cell line HBL-100 and SK-BR-2 with pcDNA3.1(-)-NY-BR-1-GFP. Breast cancer cell
line HBL-100 (A) and SK-BR-2 (B) were transfected with a NY-BR-1-GFP DNA construct. NY-BR-1/-GFP fusion protein expression
and HLA-DR-expression were analyzed 48 hrs after transfection and IFN-γ treatment (500 U/ml) of cell lines by flow cytometry.
Concluding the results, transient transfection of SK-BR-2 and HBL-100 cell lines
with pcDNA3.1(-)NY-BR-1-GFP leads to detectable NY-BR-1/-GFP fusion protein
expression in these cell lines. Nevertheless, detection of double positive cells, express-
ing the NY-BR-1/-GFP fusion protein and the HLA-DR surface molecule was low
37.1% HBL-100 double positive cells and 1.73% double positive SK-BR-2 cells, thus
the total amount of double positive cells remains to little to consider this approach as
sufficient for the generation of a NY-BR-1-expressing, HLA-matched human target
cell line.
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b) Infection of a HLA-DR-expressing breast cancer cell lines and a melanoma cell
lines with Ad5-NY-BR-1
Infection of target cells by recombinant adenovirus type 5 (Ad5), can be mediated by the coxsackie
virus and adenovirus receptor (CAR-receptor), a type 1 transmembrane receptor which has two
Ig-like extracellular domains, a transmembrane domain and a cytoplasmic domain [77]. Initially,
surface expression of the CAR-receptor was verified on different human breast cancer cell lines
and human melanoma cell lines. Furthermore, the surface expression of the HLA-DR molecule
was tested on these cell lines, since presentation of relevant epitopes was proven to be restricted
to this specific isotype as demonstrated in paragraph 5.5.2.
Breast cancer cell lines HBL-100 (DR3+), SK-BR-2 (DR4+) and melanoma cell lines Ma-
Mel21(DR-) and Ma-Mel79b(DR3+) were analyzed for HLA-DR surface expression by staining of
the cells with an anti-HLA-DR-FITC antibody.
As shown in figure 31 A, results obtained revealed expression of HLA-DR molecules on the
surface of melanoma cell line Ma-Mel79b but only marginal or absent surface expression of HLA-
DR molecules in the breast cancer cell lines HBL100 and SK-BR-2. The HLA-DR negative
melanoma cell line Ma-Mel21 was included as a negative control in this experiment (fig. 31 A).
To induce HLA-DR molecule surface expression, cell lines SK-BR-2, HBL-100 and Ma-Mel79b
were treated for 48 hrs with 500 U/ml of human IFN-γ. IFN-γ treatment, induced HLA-DR-
surface expression in SK-BR-2 cells and HBL-100 cells (fig. 31 A). Surface expression of the
HLA-DR molecule was already present in Ma-Mel79b cells prior to IFN-γ-treatment but could be
further increased by treating the cells with human IFN-γ (fig. 31A).
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Figure 31: Surface expression of HLA-DR-molecules and CAR-receptor in tested breast cancer and melanoma cell lines. (FACS)
immunofluorescence staining including anti-HLA-DR FITC antibody (A) and anti-CAR-PE, (in the case of cell line Ma-Mel79b: anti-
CAR-IgG antibody detected by a goat-anti-mouse-FITC antibody) (B) was performed on breast cancer cell lines HBL-100, SK-BR-2
and melanoma cell lines Ma-Mel21, Ma-Mel79b.
In the next experiment we set out to screen the same panel of melanoma and breast cancer
cell lines for surface expression of the CAR-receptor. Data analysis revealed expression of CAR-
receptor in cell lines HBL-100, SK-BR-2, Ma-Mel21 and Ma-Mel79b (fig. 31B).
Based on the results obtained by CAR-receptor expression analysis, cell lines SK-BR-2, Ma-
Mel21 and Ma-Mel79b were selected to further investigate the optimal time point for maximal
NY-BR-1 protein expression after infection of cells with Ad5-NY-BR-1 (fig. 32). In addition, cell
lines Ma-Mel21 and Ma-Mel79b were used to determine the optimal viral dose (multiplicity of
infection=MOI) needed for successful infection of these cell lines with Ad5-NY-BR-1 (fig. 33).
Firstly, SK-BR-2 cell line was infected with Ad5-NY-BR-1 at an MOI=100. NY-BR-1 protein
expression was analyzed at 24 hrs, 48 hrs and 72 hrs after infection of cells. After 24 hrs NY-BR-1
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protein expression was detectable (fig. 32 A, lane 1) but signal intensity still increased after 48
hrs (fig. 32 A, lane 3). Interestingly, detectable NY-BR-1 protein expression after 72hrs ( fig. 32
A, lane 5) was lower than signals detected after 48 hrs. Uninfected SK-BR-2 cells served as a
negative control in this experiment (fig. 32 A, lane 7).
Similar results were obtained for infection of Ma-Mel21 cells and Ma-Mel79b cells with Ad5-
NY-BR-1. Detectable NY-BR-1 protein expression was most pronounced 48 hrs after infection of
cells with Ad5-NY-BR-1 (fig. 32 B, lane 3, 10) and declined 72 hrs after infection of cells (fig.
32 B, lane 6, 12). Overall, intensity of NY-BR-1 protein expression was higher in Ma-Mel21 cells
compared to Ma-Mel79b cells infected with Ad5-NY-BR-1.
Figure 32: NY-BR-1 protein expression in human cell lines after Ad5-NY-BR-1 infection. SK-BR-1 (A), Ma-Mel21, Ma-Mel79b
(B) were infected with Ad5-NY-BR-1 (MOI=100) and NY-BR-1 protein expression was investigated in 15 µg of cellular protein,
extracted 24 hrs, 48 hrs and 72 hrs after initial infection of cells, by Western blot analysis.
Since we determined 48 hrs after infection of cell lines with Ad5-NY-BR-1 as the time point
of optimal NY-BR-1 protein expression, we wanted to investigate in the next set of experiment
the optimal virus dose to achieve maximal protein expression in cell lines infected with Ad5-NY-
BR-1 at this time point. Selected target cells Ma-Mel21 and Ma-Mel79b were infected with a
series of different multiplicities of infection (MOI), MOI=1, MOI=10, MOI=50 and MOI=100,
respectively. Western blot analysis revealed highest amounts of NY-BR-1 protein expression 48
hrs after infection of cell lines Ma-Mel79b and Ma-Mel-21 at an MOI=100 (fig.33 A, B: lane
8). NY-BR-1 protein expression was absent after infection of cells with Ad5-NY-BR-1 (MOI=10)
but detectable at an MOI=50 (fig.33 A, B: lane 6) and rapidly declined to almost undetectable
levels at MOI=10 (fig.33 A, B: lane 4) before being undetectable at an MOI=1 (fig.33 A, B:
lane 2). NY-BR-1 protein expression was not detectable in samples of uninfected Ma-Mel21 and
Ma-Mel79b cells (fig. 33 A, B: lane 9).
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Figure 33: Identification of optimal infection dose (=MOI) of Ad5-NY-BR-1 on various human melanoma cell lines. Melanoma
cell lines Ma-Mel21 (A), Ma-Mel79b (B) were infected with Ad5 or Ad5-NY-BR-1 at different MOIs; MOI= 1: lane 1, 2 ; MOI=10:
lane 3, 4; MOI=50: lane 5, 6; MOI=100: lane 7, 8. 15 µg of cellular protein in a volume of 20 µl lysate was analyzed for each
sample by Western blotting, 48 hrs post infection.
Infection of cells with Ad5-Control virus did not result in any detectable protein signal at any
time point or any of the tested MOIs.
Summing up, we have evidence that 48 hrs after infection of target cells with
an MOI=100 is the optimal time point for detection of maximal NY-BR-1 protein
expression in the melanoma cell lines tested.
c) Incubation of human PBMCs with Ad5-NY-BR-1
As it was described that human PBMCs depleted of CD3+ cells can be used as target cells after
being incubated with an antigen-encoding Ad5 virus [183], we depleted PBMCs obtained from
healthy donors of CD3+ T cells, due to the fact that cells of lymphoid origin are considered to be
relatively resistant to be infected by adenovirus [199]. The remaining cells, were incubated either
with Ad5 or Ad5-NY-BR-1 constructs (MOI=100). Cell lysates obtained from CD3-depleted,
PBMCs which were incubated with Ad5-NY-BR-1/Ad5, were tested for NY-BR-1 protein ex-
pression by Western blot analysis. As shown in figure 34, NY-BR-1 protein expression was not
detectable in CD3-depleted PBMCs incubated with Ad5-NY-BR-1 (lane 3, 6). Cell lysates ex-
tracted from Ma-Mel73 cells infected with Ad5-NY-BR-1 were included as a positive control for
the detection of NY-BR-1 protein in this experiment (fig 34). Reasons for not detecting NY-BR-1
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protein expression after incubation of PBMCs depleted for CD3+ T cells might either be an unsuc-
cessful infection due to the absence of CAR expression, or lack of expression of the Ad5-NY-BR-1
construct in human PBMCs. This question could be answered by investigating surface expression
of CAR on PBMCs, and by incubating the western blot membrane with an antibody detecting
adenovirus-derived protein. Based on the results obtained, incubatuion of PBMCs depleted for
CD3+ T cells with Ad5-NY-BR-1 was not further considered for the verification of endogenous
processing of NY-BR-1-specific candidate epitopes in PBMCs of healthy donors.
Figure 34: NY-BR-1 protein expression in PBMCs of healthy donors after infection with Ad5-NY-BR-1. NY-BR-1 protein
expression in PBMCs depleted for CD3+ T cells, infected at a MOI=100 with Ad5-NY-BR-1, was analyzed by Western blot, 15 µg of
cellular protein were analyzed for each sample.
d) Infection of human in vitro generate dendritic cells (DCs) with Ad5-NY-BR-1
Since HLA-matched human dendritic cells represent optimal antigen presenting capacity, we
wanted to investigate endogenous processing of the NY-BR-1-specific candidate epitopes BR1-88,
BR1-1347, BR1-537, and BR1-1242 by recognition of Ad5-NY-BR-1 infected HLA-matched, in
vitro generated human dendritic cells by established murine HLA-DR-restricted T cell lines.
In vitro generation and phenotypic characterization of human dendritic cells (DCs)
from HLA-matched healthy donors Human dendritic cells were generated in vitro from
PBMCs of HLA-matched healthy donors. In vitro generated mature dendritic cells were phenotyp-
ically characterized by flow cytometry prior to IFN-γ EliSpot assay experiments. Comprehensive
immunoflourescent-staining for the human surface markers CD11c, CD80, CD86 and anti-HLA-
DR were performed. Dendritic cells stained for the panel of surface markers, were analyzed by flow
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cytometry. As shown in figure 35, 82.53% of in vitro generated dendritic cells displayed a double
positive phenotype regarding expression of the surface molecules CD11c and HLA-DR. Further-
more, prominent surface expression of the co-stimulatory molecule CD86 was detected among the
dendritic cell population expressing both, CD11d and HLA-DR surface molecules (fig.35).
In general it can be testified that these in vitro generated dendritic cells show surface molecule
expression such as CD11c, HLA-DR and CD86 which are described to be characteristic for mature
in vitro generated, monocyte derived dendritic cell [194].
Figure 35: Phenotypic characterization of in vitro generated human dendritic cells. Human DCs were generated form PBMCs
of healthy donors over a time period of 7 days, receiving IL-4 and GM-CSF every other day. Immunofluorescent staining of differentiated
DCs was performed with anti-CD11c FITC, anti-CD80 PE, anti-CD86-PerCp and anti HLA-DR APC antibodies and analyzed by using
a FACS-Calibur.
Next, we tried to infected differentiated human DCs with Ad5-NY-BR-1 (MOI=1000) which
potentailly could be recognized by the established murine CD4+ T cell lines BR1-88, BR1-1347,
BR1-537 and BR1-1242 in an antigen specific manner. Therefore, we firstly investigated the
surface expression of the CAR-molecule on the differentiated dendritic cells (fig. 36 A). Im-
munoflourescent staining for the adenoviral receptor CAR did reveal absence of receptor surface
expression in human dendritic cells (fig. 36 A). However, dendritic cells were incubated with
Ad5-NY-BR-1 to possibly generate dendritic cells which express the NY-BR-1 protein after in-
fection with Ad5-NY-BR-1. Incubation of in vitro generated dendritic cells with Ad5-NY-BR-1
at a MOI=1000 did not affect viability of the dendritic cells as evaluated by visual inspection of
the cells. As shown in figure 36 B, NY-BR-1 protein expression could not be detected in cellu-
lar protein samples extracted from DCs which had been incubated with Ad5-NY-BR-1 (lane 1)
but was detectable in Ma-Mel73a-Ad5-NY-BR-1 cell lysates included as a positive control in this
experiment (lane 4) .
In line with these findings, Ad5-NY-BR-1 infected dendritic cells were not specifically recog-
nized by any of the four tested murine HLA-DR-restricted T cell lines (fig.36 C).
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Figure 36: Incubation of human dendritic cells with AdV-NY-BR-1. Surface expression of the CAR-receptor in human dendritic
cells, DCs were stained with an anti-CAR PE antibody, data were acquired by flow cytometry (A). Western blot analysis of AdV-NY-
BR-1 infected dendritic cells, 15 µg of cellular lysate were analyzed per sample (B). HLA-matched in vitro generated DCs were either
incubated with Ad5-NY-BR-1 (MOI=1000) or with Ad5 (MOI=1000). After 24 hrs indicated murine HLA-DR-restricted T cell lines
were co-incubated with human DCs in an IFN-γ EliSpot assay for 18 hrs. Columns, mean of duplicate determination; bars standard
error of the mean (C).
Overall, infection of in vitro generated dendritic cells with Ad5-NY-BR-1 was not
successful thus these cells were not further considered as target cells for investigation
of endogenous processing of NY-BR-1-specific candidate epitopes in human target
cells.
5.6.2 Experiments using Ad5-NY-BR-1 infected melanoma and breast cancer cells
as target cells
With the following experiment we aimed to investigate endogenous processing of the NY-BR-1-
specific candidate epitopes BR1-88, BR1-1347, BR1-537, BR1-656/-775 and BR1-1242 in human
cell lines. Therefore, HLA-matched melanoma cell line Ma-Mel79b (DR3+), Ma-Mel21 (DR3-)
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and breast cancer cell line SK-BR-2 (DR4+) were infected with Ad5-NY-BR-1 and tested for
recognition by NY-BR-1 specific, HLA-DR-restricted murine T cell lines.
HLA-DRB1*0301 positive cell line Ma-Mel79b was infected with Ad5-NY-BR-1 or Ad5 at a
MOI=100 and tested for recognition by T cell line BR1-88 and BR1-1347. Ma-Mel21 (DR-)
cells infected with Ad5-NY-BR1 were used as negative control. Additionally, BR1-88/BR1-1347
peptide loaded Ma-Mel79b cells and Ma-Mel21 cells, as well as T2/DR3 cells, loaded with BR1-
88/BR1-1347 peptides, were included in the IFN-γ EliSpot assay. HLA-DRB1*0301-restricted
T cell lines BR1-88 and BR1-1347 did not recognize Ma-Mel79b and Ma-Mel21 cells infected
with Ad5-NY-BR-1, as it was expected for cell line Ma-Mel21(DR-) but not for cell line Ma-
Mel79b (DR3+). However, Ma-Mel79b cells and T2/DR3 cells externally loaded with the cognate
peptide were recognized by both T cell lines BR1-88 and BR1-1347. Nevertheless, as shown for
T cell line BR1-1347 in figure 37 A, recognition of externally peptide loaded Ma-Mel79b cells
(mean of 22 IFN-γ-spots) and peptide loaded T2/DR3 cells (mean of 11 IFN-γ-spots) was low,
probably indicating “exhaustion” of the T cell line BR1-1347 on the day of the IFN-γ EliSpot assay.
Peptide loaded T2 cells similar to unloaded T2 and T2/DR3 cells, were not recognized by T cell
line BR1-1347 (fig.37 A). T cell line BR1-88 recognized peptide loaded Ma-Mel79b cells (71 IFN-
γ-spots) to a much greater extent than peptide loaded T2/DR3 cells (mean of 6 IFN-γ-spots).
To exclude failure of Ad5-NY-BR-1 infection of the selected target cells, as a potential reason for
poor recognition of these target cells by the tested CD4+ T cell lines, NY-BR-1 expression was
confirmed for Ad5-NY-BR-1 infected Ma-Mel21 and Ma-Mel79b cells used as target cells in the
IFN-γ EliSpot assay by Western blot analysis (fig.38).
HLA-DRB1*0401-restricted T cell lines BR1-537, BR1-565/-775 and BR1-1242 did not specif-
ically recognize Ad5-NY-BR-1 infected SK-BR-2 (DR4+) cells and Ad5-NY-BR-1 infected Ma-
Mel21 cells, as expected for HLA-DRB1*0401 negative Ma-Mel-21 cells (fig. 37 C,D,E). Exter-
nally loaded target cell lines Ma-Mel-21, SK-BR-1 and T2/DR4 cells with the relevant peptides
BR1-537, BR1-565/-775, BR1-1242, were also investigated for recognition by the matching T cell
lines. As shown in figure 37 D, only T cell line BR1-1242 induced IFN-γ secretion upon recog-
nition of BR1-1242 peptide loaded target cell line SK-BR-2 (mean of 42 IFN-γ-spots), whereas
peptide loaded T2/DR4 cells were specifically recognized by T cell line BR1-537 (mean of 50
IFN-γ-spots) (fig. 37 C) and by T cell line BR1-1242 (IFN-γ-spots not measurable due to signal
over-saturation in the well) (fig. 37 D). Important to notice, T cell line BR1-1242 also reacts with
IFN-γ secretion upon encounter of peptide loaded T2 cells (mean of 90 IFN-γ spots), this signal
has to be considered as background signal of T cell line BR1-1242. Peptide loaded Ma-Mel21
(DR-) cells were not specifically recognized by any of the HLA-DRB1*0401-restricted murine T
cell lines (fig.37 C, D, E).
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Figure 37: IFN-γ EliSpot results on recognition of Ad5-NY-BR-1 infected target cells by novel murine HLA-DR-restricted T
cell lines. Target cell lines SK-BR-2, Ma-Mel79b and Ma-Mel21 were infected with Ad5-NY-BR-1 (MOI=100) and used in IFN-γ
EliSpot assay. 5 X 104 target cells/ well were incubated with 1 X 105 T cells (A: T cell line BR1-1347, B: T cell line BR1- 88, C: T
cell line BR1-537, D: T cell line BR1-1242, E: T cell line BR1-656/775) for 18 hrs. Target cells were peptide loaded with 1 µg of the
relevant peptide, when indicated. Columns, mean of duplicate determination; bars standard error of the mean.
108
Results
However, NY-BR1 protein expression after infection of target cell line SK-BR-2 and Ma-Mel21,
with Ad5-NY-BR-1, was confirmed by Western blot analysis (fig. 38). Therefore, lack of specific
recognition of HLA-DRB1*0401+ target cells by murine HLA-DRB1*0401-restricted CD4+ T cell
lines, is more likely due to insufficient stimulation of the relevant CD4+ T cell line tested, than
to a lack of NY-BR-1 antigen expression within the analyzed target cells after infecteion with
Ad5-NY-BR-1.
Figure 38: Western blot analysis of NY-BR-1 protein expression in Ad5-NY-BR-1 infected target cell lines Ma-Mel79b, Ma-
Mel21 and SK-BR-2. Target cell lines were infected with Ad5-NY-BR-1 (MOI=100). 15 µg of cellular protein was analyzed for each
sample by Wester blot analysis.
Collectively, based on the foregoing results, peptide loaded but not Ad5-NY-
BR-1 infected target cells are recognized by the newly generated murine HLA-DR-
restricted, CD4+ T cell lines, thus endogenous processing of the newly identified
NY-BR-1-specific T cell epitopes could so far not be confirmed in human cells. This
finding is most likely due to an exhausted phenotype of the tested T cell lines as well
as a potential lack of affinity of these T cell lines for their cognate peptide at the time
point of the performed EliSpot assay. Moreover, it has to be further investigated, if
the relevant NY-BR-1-specific epitopes are processing products in the tested target
cell lines Ma-Mel79b, Ma-Mel21 and SK-BR-1 upon infection with Ad5-NY-BR-1.
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5.6.3 Confirmation of endogenous processing of NY-BR-1-specific candidate epi-
topes in human cells using HLA-matched, human DCs loaded with lysate
generated from Ad5-NY-BR-1 infected tumor cells
Due to the fact that human HLA-matched in vitro generated Ad5-NY-BR-1 infected dendritic cells
(DCs) failed to be specifically recognized by all murine CD4+ T cell lines (fig. 36, C), we set out
and altered the experimental design. In vitro generated HLA-matched human DCs loaded with
cell lysates containing NY-BR-1 protein might serve as a source to verify endogenous processing
of the newly identified NY-BR-1-specific, HLA-DR-restricted epitopes in human cells.
NY-BR-1 containing cell lysates were generated by repeated thaw freeze cycles of Ma-Mel73a
cells infected with Ad5-NY-BR-1. The melanoma cell line Ma-Mel73a showed stronger NY-BR-1
protein expression at 48 hrs after infection (MOI=100) of cells with Ad5-NY-BR-1 (fig. 39), when
compared to panel of melanoma and breast cancer cell lines tested previously (fig. 33).
Figure 39: Western blot analysis of NY-BR-1 protein expression in Ad5-NY-BR-1 infected target cell line Ma-Mel73a. Ma-
Mel73a were infected with Ad5-NY-BR-1 of Ad5, (MOI=100). 15 µg of cellular protein was analyzed for each sample by Wester blot
analysis.
HLA-matched in vitro generated dendritic cells were loaded with the NY-BR-1 protein con-
taining cell lysate over night, followed by co-culture with CD4+, HLA-DR-restricted murine T cell
lines. Lysates processed from Ma-Mel73a cells infected with Ad5, as well as lysates of uninfected
Ma-Mel73a cells were included as control lysates for loading of human dendritic cells.
As shown in figure 40 A, T cell line BR1-1347 specifically recognized dendritic cells loaded
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with NY-BR-1-containing cell lysate (mean of 163 IFN-γ-spots), whereas no IFN-γ secretion was
detectable for dendritic cells loaded with cell lysate generated from uninfected Ma-Mel73a cells
or Ma-Mel73a cells infected with Ad5. Moreover, only dendritic cells pulsed with the cognate
epitope (over-saturated IFN-γ signal) but not with the irrelevant Trp-2 epitope were recognized
by T cell line BR1-1347 (fig.40 A).
Confirming specificity and HLA-DRB1*0301-restriction, T cell line BR1-88 recognized HLA-
matched dendritic cells loaded with lysate of Ma-Mel73a-AdV-NY-BR-1 cells, indicated by IFN-γ
secretion detected by IFN-γ EliSpot assay (mean of 153 IFN-γ-spots) (fig. 40 A). Importantly,
dendritic cells loaded with cell lysate originating from uninfected Ma-Mel73a cells as well as from
Ma-Mel73a cells infected with Ad5, did not promote any IFN-γ secretion of T cell line BR1-88.
Exogenous pulsing of dendritic cells with the epitope BR1-88 elicited greatest IFN-γ secretion
by T cell line BR1-88 (over-saturated IFN-γ signal), which on the other side was absent in case
of dendritic cells pulsed with an irrelevant HLA-DRB1*0301-restricted epitope derived from the
melanoma associated antigen Trp2 (fig.40 A).
Similar results could be obtained within the HLA-DRB1*0401-restricted system. Figure 40
B shows the results on specific recognition of in vitro generated dendritic cells, obtained from a
HLA-DRB1*0401 positive healthy donor, loaded either with cell lysate of Ma-Mel73a cells infected
with Ad5-NY-BR-1, or dendritic cells pulsed externally with the epitopes BR1-537 and BR1-1242,
by the corresponding T cell lines. T cell line BR1-537 specifically recognized dendritic cells loaded
with cell lysate generated from Ad5-NY-BR-1 infected Ma-Mel73A cells (mean of 96 IFN-γ-spots),
albeit dendritic cells loaded with cell lysate of cells infected with Ad5 also induced IFN-γ secretion
of T cell line BR1-537 upon encounter (mean of 35 IFN-γ-spots), this signal has to be considered
background activity for the T cell line BR1-537. Uninfected Ma-Mel73a cells were not recognized
by T cell line BR1-537. Besides, T cell line BR1-537 specifically detected BR1-537 peptide pulsed
on dendritic cells (mean of 82 IFN-γ-spots) but not the irrelevant HLA-DRB1*0401-restricted
epitope BR1-1242 (fig.40 B). Similarly, T cell line BR1-1242 specifically recognized dendritic cells
loaded with cell lysate originating from Ma-Mel73a cells infected with Ad5-NY-BR-1 (mean of 163
IFN-γ-spots) and dendritic cells exogenously pulsed with the BR1-1242 epitope (over-saturated
IFN-γ signal). Dendritic cells loaded with irrelevant cell lysate originating from uninfected Ma-
Mel73a cells or Ma-Mel73a cells infected with Ad5, as well as dendritic cells externally pulsed with
the irrelevant HLA-DRB1*0401-restricted epitope BR1-537 did not lead to specific recognition by
T cell line BR1-1242 (fig.40 B).
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Figure 40: Recognition of human dendritic cells loaded with lysate generated from Ad5-NY-BR-1 infected tumor cells, by
murine HLA-DR-restricted T cell lines. In vitro generated human dendritic cells were externally loaded with cell lysate originating
from Ma-Mel73a cells infected with either Ad5 or Ad5-NY-BR-1 or pulsed with 1 µg of the relevant peptide. 2 X 104 in vitro generated
dendritic cells were incubated with 1 X 105 cells of either the HLA-DRB1*0301-restricted T cell line BR1-88 and T cell line BR1-1347
(A) or with HLA-DRB1*0401-restricted T cell line BR1-1242 and T cell line BR1-537 (B) for 18 hrs on an IFN-γ EliSpot assay.
Columns, mean of duplicate determination; bars standard error of the mean.
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To sum up, endogenous processing of HLA-DRB1*0301-restricted, NY-BR-1-
specific CD4+ T cell epitopes BR1-88 and BR1-1347, as well as endogenous process-
ing of HLA-DRB1*0401-restricted, NY-BR-1-specific CD4+ T cell epitopes BR1-1242
and BR1-537 in human cells was proven by specific recognition of HLA-matched den-
dritic cells loaded with lysate generated from Ad5-NY-BR-1 infected tumor cells, by
murine HLA-DR-restricted T cell lines BR1-88, BR1-1347, BR1-1242 and BR1-537.
After all, the milestone IV on verification of processing of NY-BR-1-specific epitopes
in human cells was reached.
5.7 Detection of NY-BR-1-specific CD4+ T cells in breast cancer
patients and healthy donors
5.7.1 Selection of NY-BR-1+ HLA-matched breast cancer patients
A total of 120 breast tumor biopsy specimens from breast cancer patients were collected at the
Heidelberg University Hospital and NY-BR-1 protein expression was confirmed by immunohisto-
chemical stainings, performed at the Pathology department at the Heidelberg University Hospital.
24 Patients with NY-BR-1 positive tumor biopsies were selected, and HLA-genotyping of PBMCs
revealed three HLA-DRB1*0301 (BC-1, BC-2, BC-3) and five HLA-DRB1*04 (BC-4, BC-5, BC-6,
BC-7, BC-8) positive breast cancer patient samples which were used in the following experiments
(Supplement table. 36).
5.7.2 NY-BR-1-specific CD4+ T cells were detected among PBMCs of breast cancer
patients and healthy donors after peptide stimulation in vitro
Next, we wanted to determine the spontaneous T cell response specific for the NY-BR-1-derived
CD4+ T cell epitopes identified in HLA-DRtg mice within the peripheral blood of breast cancer
patients and healthy donors.
a) NY-BR-1-specific CD4+ T cells were detected among PBMCs of breast cancer
patients
PBMCs obtained from three HLA-DRB1*0301 positive breast cancer patients (samples: BC-1,
BC-2, BC-3) and four HLA-DRB1*0401 positive breast cancer patients (samples: BC-4, BC-
5, BC-6, BC-7) were in vitro stimulated with the relevant HLA-DR-restricted NY-BR-1-specific
peptides for 24 days. To detect NY-BR-1-specific CD4+ T cells among the in vitro stimulated
PBMC cultures, cells were analyzed by immunoflourescent staining. A panel of different markers
was investigated, including three cellular surface markers (CD3, CD4, CD8) and one cytokine
(IFN-γ).
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As shown in figure 41 A, elevated levels of CD4+IFN-γ+ T cells could be detected among
PBMCs of all three HLA-DRB1*0301+ breast cancer patients (BC-1, BC-2, BC-3) upon in vitro
stimulation with the respective NY-BR-1-derived peptides. Between 0.14% and 2.77% of antigen-
specific CD4+IFN-γ+ T cells were detected among PBMCs of HLA-DRB1*0301+ breast cancer
patients (fig. 41 A), when compared to the medium control (m), for all NY-BR-1 derived peptides
investigated.
Most elevated levels of antigen-specific CD4+IFN-γ+ T cells could be detected among PBMCs
of three HLA-DRB1*0301+ breast cancer patients, for CD4+IFN-γ+ T cells specific for the NY-
BR-1-derived peptide BR1-1347 (BC-1: 2.77%, BC-2: 0.43%, BC-3: 1.88%), when compared
to elevated amounts of activated CD4+IFN-γ+ T cells specific for peptides BR1-88 (0.24% -
1.24%) and BR1-1238 (0.03 - 0.49%) detected in these patients (fig. 41 A), when compared
to the medium control. Collectively, antigen-specific CD4+ T cells for all three NY-BR-1-derived
peptides analyzed (fig. 41 A) could be detected among in vitro restimulated PBMCs of HLA-
DRB1*0301+ breast cancer patients BC-1 and BC-3. However, no elevated levels of CD4+IFN-γ+
T cells specific for peptides BR1-1238 and BR1-88 could be detected among PBMCs of breast
cancer patient BC-2 (fig. 41 A).
As shown in figure 41 C, results obtained in the second experiment (Experiment 2), confirmed
the absence of CD4+IFN-γ+ T cells specific for peptide BR1-1238 and BR1-88 among PBMCs of
breast cancer patient BC-2 (fig. 41 C). Moreover, detection of CD4+IFN-γ+ T cells recognizing
their cognate peptides BR1-1347 and BR1-88 was confirmed in the second experiment (fig. 41
C) among PBMCs of BC-2. Albeit, in contrast to the first experiment (Experiment 1), no
CD4+IFN-γ+ T cells specific for peptide BR1-1238 could be detected among PBMCs of breast
cancer patient BC-3 (fig. 41 C). As shown in figure 41 B, CD4+ T cells specific for NY-BR-
1-derived peptides BR1-537, BR1-1242 and peptide BR1-656/-775 could be detected among
PBMCs obtained from HLA-DRB1*0401+ breast cancer patients (BC-4, BC-5, BC-6, BC7).
However, differences regarding the frequency of activated, NY-BR-1-specific CD4+ T cells and the
immunogenicity of the three NY-BR-1-derived peptides, were observed among individual patients
(fig. 41 B). Among PBMCs obtained from HLA-DRB1*0401+ breast cancer patients, highest
immunogenicity was observed for peptide BR1-537 with elevated levels of CD4+IFN-γ+ T cells
between 0.97% and 1.42% detected among PBMCs of HLA-DRB1*0401+ breast cancer patient
BC-4 and BC-7 (fig. 41 B) compared to the medium control. Albeit, no elevated amounts of
activated CD4+IFN-γ+ T cells specific for peptide BR1-537 could be detected among PBMCs
of breast cancer patients BC-5 and BC-6. However, elevated amounts of CD4+IFN-γ+ T cells
specific for the remaining analyzed HLA-DRB1*0401-restricted, NY-BR-1-derived peptides BR1-
1242 and BR1-656/-775 up to 0.28% and 0.43% could be detected among PBMCs of patient
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BC-5 but did not stimulate CD4+IFN-γ+ T cells among PBMCs of BC-6 (fig. 41 B), when
compard to the medium control.
Figure 41: Detection of NY-BR-1-specific CD4+ T cells among PBMCs of breast cancer patients. PBMCs obtained from
HLA-DRB1*0301 (A, C) and from HLA-DRB1*0401+ breast cancer patients (B, D), BC-1 to BC-7 were in vitro stimulated for 24
days with the indicated peptides. Antigen-specific CD4+IFN-γ+ T cells were detected upon stimulation of PBMCs with the relevant
peptide for 24 hrs in the assay by immunoflourescent staining of the PBMCs for the surface markers CD3, CD4 and the cytokine IFN-γ.
Within the assay, in vitro stimulated PBMC cultures were either again stimulated with the relevant peptide (p), or left unstimulated
medium control (m). Data were acquired on a FACS canto and analyzed by using the Flow Jo software. Depicted are percentages
of CD4+IFN-γ+cells among live CD3+ cells.
Upon in vitro stimulation of PBMC-samples BC-4 and BC7 with peptide BR1-1242 and BR1-
656/-775, CD4+ T cells recognizing their cognate antigen could be detected in both patients for
the peptide BR1-1242, with elevated frequencies of CD4+IFN-γ+ T cells from 1.34% to 1.5%
in comparison to the medium control. Among PBMCs obtained from patient BC-7, increased
amounts of CD4+IFN-γ+ T cells specific for peptide BR1-656/-775 (0.26%), but no difference
in the frequency of CD4+IFN-γ+ T cells specific for peptide BR1-1242, were detected when
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compared to the medium control (fig. 41 B).
In a second experiment (Experiment 2), as shown in figure 41 D, PBMCs obtained from
HLA-DRB1*0401+ breast cancer patients BC-4 and BC-5 were screened for the presence of NY-
BR-1-specific CD4+ T cells. Results obtained were in line with the first experiment (fig. 41
B), except for the detection of CD4+ T cells specific for the peptide BR1-656/-775 (elevated
fequencie of CD4+IFN-γ+ T of 0.97% ) in BC-4 (fig. 41 D) and the absence of CD4+IFN-γ+ T
cells specific for peptide BR1-1242 among in vitro restimulated PBMCs of patient BC-5 (fig. 41
D), in comparison to the medium control.
Overall, the HLA-DRB1*0301-restricted NY-BR-1-derived peptide BR1-1347 and
the HLA-DRB1*0401-restricted NY-BR-1-derived peptide BR1-537, stimulated the
highest frequencies of CD4+IFN-γ+ T cells among tested PBMCs of breast cancer
patients after in vitro stimulation of PBMCs over a time period of 24 days.
In parallel to the immunoflourescent staining of in vitro stimulated PBMCs of breast cancer
patients (BC-1 to BC-7), IFN-γ+ EliSpot assays were performed with the PBMCs used in ex-
periment 1 (supplement fig. 46) and experiment 2 (supplement fig. 47). However, the results
did not correlated with the data obtained by immunoflourescen staining (fig. 41), due to high
background activity of the analyzed samples in the IFN-γ+ EliSpot assays.
B) NY-BR-1-specific CD4+ T cells were detected among PBMCs of healthy donors
PBMCs obtained from two HLA-DRB1*0301 positive healthy donors (samples: HD-1, HD-2)
and from two HLA-DRB1*0401 positive healthy donors (samples HD-3, HD-4), were stimulated
in vitro with the relevant MHC-restricted NY-BR-1-derived peptides.
Among PBMCs of HLA-DRB1*0301+ healthy donors (HD-1, HD-2), in vitro stimulated with
peptide BR1-1347, elevated frequencies of antigen-specific CD4+IFN-γ+ T cells of 1.5% (HD-1)
and 0.43% (HD-2) (fig. 42 A), were detected compared to the medium control. CD4+IFN-γ+ T
cells specific for peptide BR1-88 could be detected among PBMCs of HD-1 (fig. 42 A). The results
obtained for the detection of CD4+IFN-γ+ T cells specific for peptide BR1-88 among PBMCs of
healthy donor 2 (HD-2) in the medium control, most likely presents an artifact due to technical
problems during data acquiring. Results obtained in the second experiment for PBMC-samples
of healthy donors HD-1 and HD-2, are in line with date obtained in the the first experiment
(Experiment 1) (fig. 42 A).
As depicted in figure 42 B and figure 42 D, elevated frequencies of activated CD4+IFN-γ+
T cells specific for the HLA-DRB1*0401-restricted peptide BR1-537 could be detected in both
experiments among PBMCs obtained from HLA-DRB1*0401+ healthy donor HD-3, compared to
the medium control . However, no increased frequencies of CD4+ T cells specific for the NY-BR-
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1-derived peptides BR1-1242 and BR1-656/-775, in comparison to the medium control, could be
detected in any of the PBMC-samples obtained from HLA-DRB1*0401+ healthy donors (fig. 42
B, D).
Figure 42: Detection of NY-BR-1-specific CD4+ T cells among PBMCs of healthy donors. PBMCs obtained from HLA-
DRB1*0301 (A,C) and from HLA-DRB1*0401+ healthy donors (B,D), were in vitro restimulated for 24 days with the relevant
peptide. Antigen-specific CD4+IFN-γ+ T cells were detected upon stimulation of in vitro stimulated PBMCs with the relevant
peptide for 24 hrs, by immunoflourescent staining of the PBMCs for the surface markers CD3, CD4 and the cytokine IFN-γ. Data
were acquired on a FACS Canto and analyzed by using the flow Jo software. Depicted are percentages of CD4+IFN-γ+cells among
live CD3+ cells.
To sum up, CD4+IFN-γ+ T cells specific for the NY-BR-1-derived HLA-DRB1*0301-
restricted peptides BR1-1347, BR1-88, BR1-1238 and HLA-DRB1*0401-restricted
peptides BR1-537, BR1-1242 and BR1-656/-775 were detected in the peripheral
blood of breast cancer patients upon in vitro stimulation for 24 days of PBMCs with
the relevant peptide.
Moreover, CD4+ T cells specific for NY-BR-1-derived peptides BR1-1347 and
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BR1-537 were also detected among PBMCs of HLA-matched healthy donors upon
in vitro stimulation for 24 days of PBMCs with the relevant peptide.
5.7.3 NY-BR-1-specific CD25+FoxP3+CD127- T cells and CD25+FoxP3+CD4+ T
cells secreting IFN-γ could be detected among PBMCs of breast cancer pa-
tients and healthy donors.
Among CD4+ T cells of PBMCs obtained from HLA-DRB1*0301+/*0401+ breast cancer patients
and healthy donors, we could detect CD25+FoxP3+CD127- T cells (Tregs).
As shown in figure 43 A, frequencies of total Tregs from 9.53% to 13.80% could be detected
among PBMCs obtained from breast cancer patient BC-1, whereas the highest frequency of Tregs
was observed in PBMC cultures of patient BC-1 which had been stimulated with peptide BR1-88.
In contrast to this findings, highest frequencies of Tregs (7.08%), were detected among PBMCs
obtained from BC-2 which were in vitro stimulated with peptide BR1-1238 (fig. 43 A). Numbers
of total Tregs detected among PBMCs obtained from BC-3 with frequencies of 7.08%, 7.20% and
7.09% were similar for all three PBMC cultures analyzed, irrespectively of the NY-BR-1 specific
peptide used for in vitro stimulation for the PBMC cultures (fig. 43 A). Similar tendencies
of total Treg frequencies being independent of the peptide applied for in vitro stimulation of
PBMC cultures, were observed for the detection of total Tregs among PBMCs obtained from
HLA-DRB1*0301+ healthy donors HD-1 and HD-2, hence frequencies of total Tregs varied only
from 7.39% to 8.89%, and from 3.37% to 4.00% among PBMCs obtained from HD-1 and HD-
2, respectively (fig. 43 A). Collectively, the overall highest frequencies of Tregs among PBMCs
obtained from HLA-DRB1*0301+ donors, was detected among PBMCs of breast cancer patient
BC-1.
Figure 43 B, shows the frequencies of total Tregs detected among PBMCs of HLA-DRB1*0401+
breast cancer patients and healthy donors. Among PBMCs obtained from breast cancer patient
BC-4, 12.% and 11.2% of total Tregs could be detected upon stimulation with peptides BR1-
537 and BR1-656/-775, respectively. Whereas, after stimulation of PBMCs obtained from BC-4
with peptide BR1-1242, the lowest frequency (6.31%) of total Tregs among PBMCs of patient
BC-4, was detected (fig. 43 B). Interestingly, frequencies of total Tregs among PBMCs obtained
from BC-7 were in comparison lower than frequencies of total Tregs detected among PBMCs ob-
tained from BC-4, but showed the same distribution. The lowest frequency of regulatory T cells
(2.66%) was detected among PBMCs of breast cancer patient BC-7 which had been stimulated
with peptide BR1-1242 (fig. 43 B). In line with this findings, the lowest number of total Tregs
of 3.86% among PBMCs of HD-4 was also detected after stimulation of the PBMC sample with
peptide BR1-1242. Frequencies of total Tregs detected were similar for all PBMC cultures tested
obtained from BC-5, BC-6 and HD-3, irrespectively of the peptide used for in vitro stimulation
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of the PBMC cultures (fig. 43 B). As depicted in figure 43 B, total numbers of Tregs detected
among PBMCs obtained from BC-5, BC-6 and HD-3 varied from 7.66% to 8.13%, from 4.09%
to 5.90% and from 10.9% to 12.4%, respectively.
Collectively, frequencies of total CD25+FoxP3+CD127- T cells among CD4+ T cells de-
tected ranged from 2.66% (BC-7) to 13.80% (BC1-) independently of the NY-BR-1-derived
antigenic stimulus applied during the 24 days of in vitro stimulation. Total frequencies of
CD25+FoxP3+CD127- T cells among CD4+ T cells did not exceed 14% in any of the analyzed
samples.
Next, we investigated the presence of CD25+FoxP3+CD4+ T cells (Treg-like cells) which
secreted IFN-γ, among NY-BR-1-specific CD4+IFN-γ+ T cells detected in PBMCs of breast
cancer patients and healthy donors by immunoflourescent staining of PBMCs. As depicted in
figure 43 C, frequencies of CD25+FoxP3+CD4+ T cells secreting IFN-γ among total NY-BR-1-
specific CD4+IFN-γ+ T cells, varied between 4.49% and 17.05% in PBMC-samples obtained from
HLA-DRB1*0301+ breast cancer patients and healthy donors. Even though differences, regarding
the total amount of Treg-like cells secreting IFN-γ varied among patient PBMC-samples, total
numbers of Treg-like cells were similar among CD4+IFN-γ+ T cells in all patient PBMC-samples
and healthy donor PBMC-samples, irrespectively of the NY-BR-1-derived peptide used for in vitro
stimulation.
Frequencies of CD25+FoxP3+CD4+ T cells secreting IFN-γ detected among CD4+IFN-γ+ T
cells of BC-1 varied from 12.42% to 16.82% and from 11.93% to 14.31% among CD4+IFN-γ+
T cells in the PBMC-sample of BC-2, upon stimulation of PBMC cultures with NY-BR-1-derived
peptides BR1-88, BR1-1347 and BR1-1238 (fig. 43 C). In line with this findings, we detected
similar amounts (13.43%, 9.04% and 12.42%) of Treg-like cells secreting IFN-γ among CD4+IFN-
γ+ T cells in the PBMC sample of BC-3 , which had been in vitro stimulated with NY-BR-1-specific
peptides for 24 days (fig. 43 C).
One exception being, PBMC samples obtained from HLA-DRB1*0301+ healthy donors, HD-1
and HD-2, which displayed low levels of CD25+FoxP3+CD4+ T cells secreting IFN-γ ( from 4.49%
to 12.27%) among CD4+IFN-γ+ T cells, after in vitro restimulation of the PBMC sample with the
NY-BR-1-derived epitope BR1-1347 and BR1-1238, but displayed higher amounts of Treg-like cells
secreting IFN-γ among CD4+IFN-γ+ T cells upon stimulation of PBMCs with NY-BR-1-derived
epitope BR1-88 (from 17.05% to 18.33%), (fig. 43 C). Thereby, indicating a potential peptide
specific induction of CD25+FoxP3+CD4+ T cells secreting IFN-γ upon stimulation of PBMCs
obtained from HD-1 and HD-2 with the NY-BR-1-specific peptide BR1-88.
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Figure 43: Detection of CD25+ FoxP3+CD127- and Treg-like cells secreting IFN-γ among CD4+ T cells of breast cancer
patients and healthy donors. PBMCs obtained from HLA-DRB1*0301+ breast cancer patients BC-1, BC-2, BC-3 and healthy
donors HD-1, HD-2 as well as PBMCs obtained from HLA-DRB1*0401+ breast cancer patients BC-4, BC-5, BC-6, BC-7 and healthy
donors HD-3, HD-4, were in vitro stimulated for 24 days with the NY-BR-1-derived epitopes BR1-1347, BR1-88, BR1-1238 and
BR1-537, BR1-1242, BR1-656/775, respectively. Results depict the frequency of total Tregs (CD25+ FoxP3+CD127-) of CD4+ T
cells among PBMCs of HLA-DRB1*0301+ PBMC samples (A) and among HLA-DRB1*0401+ PBMC samples (B). Frequencies of
CD25+FoxP3+CD4+ T cells (Treg-like cells) secreting IFN-γ of CD4+ T cells are depicted for HLA-DRB1*0301+ PBMC samples
(C) and HLA-DRB1*0401+ PBMC samples (D).
As shown in figure 43 B, D, CD25+FoxP3+CD4+ T cells secreting IFN-γ could also be detected
among CD4+IFN-γ+ T cells of PBMCs obtained from HLA-DRB1*0401+ breast cancer patients
BC-4, BC-5, BC-6, BC-7 and healthy donors HD-3, HD-4.
In PBMC-samples obtained from breast cancer patient BC-4, BC-5, BC-6 and BC-7, total
variations in frequencies of Treg-like cells among CD4+IFN-γ+ T cells from 0.7% (BC-%) up to
23.81% (BC-4) were observed.
Similar amounts of Treg-like cells secreting IFN-γ among CD4+IFN-γ+ T cells, varying from
5.3% to 6.04%, irrespectively of the peptide used for in vitro stimulation of the PBMC cultures,
were detected among PBMCs of breast cancer patient BC-5. CD25+FoxP3+CD4+ T cells secret-
ing IFN-γ detected among CD4+IFN-γ+ T cells in the PBMC-sample of BC-6 varied from 6.37%
after stimulation of the PBMCs with peptide BR1-537 to 11.52% and to 10.15%, after stimulation
with peptides BR1-1242 or BR1-656/-775. Furthermore, Treg-like cells secreting IFN-γ (17.6%)
could be detected among CD4+IFN-γ+ T cells upon stimulation of PBMCs, obtained from BC-7
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with peptide BR1-537. In comparison, amounts of Treg-like cells detected upon stimulation of
PBMCs obtained from BC-7 with peptide BR1-1242 and BR1-656/-775 were lower with detected
freqeuncies of 8.99% and 8.62%, respectively. Important to note, in vitro stimulated PBMCs
of breast cancer patient BC-4, displayed the overall highest variation in the frequency of Treg-
like cells secreting IFN-γ (44.14%), detected among CD4+IFN-γ+ T cells, after stimulation of
PBMCs with the peptide BR1-656/-775, when compared to 20.33% and 17.68% of Treg-like cells
secreting IFN-γ after stimulation of PBMCs with peptides BR1-537 or BR1-1242 (fig. 43 D).
Amounts of Treg-like cells secreting IFN-γ detected among CD4+IFN-γ+ T cells of healthy
donor HD-4 varied from 4.57% to 18.36% after stimulation with the peptides BR1-1242 and BR1-
656/-775 (fig. 43 D). Whereas, frequencies of Treg-like cells secreting IFN-γ among CD4+IFN-
γ+ T cells were similar (10.27%, 10.30% and 9.38%), after the stimulation of PBMCs with the
peptides BR1-537, BR1-1242 and BR1-656/-775, respectively (fig. 43 D).
To sum up, we could detect CD25+FoxP3+CD4+ T cells (Treg-like cells) se-
creting IFN-γ among CD4+IFN-γ+ T cells of breast cancer patients and healthy
donors, whereas frequencies of Treg-like cells secreting IFN-γ were in all stimu-
lated PBMC-samples below 20%. One exception being the detection of 44.14%
of CD25+FoxP3+CD4+ T cells secreting IFN-γ among CD4+IFN-γ+ T cells in the
PBMC-sample of breast cancer patient BC-4, upon stimulation with the NY-BR-
1-derived peptide BR1-656/-775. This finding might indicating an antigen-specific
stimulation of Treg-like cells in this particular case.
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6 Discussion
6.1 Comparison of a global vaccination approach versus in silico
epitope-prediction used for the identification of antigen-specific
T cell epitopes
To identify NY-BR-1-specific T cell epitopes, a number of different methods are available for the
exact mapping of antigen-specific epitopes within the amino acid sequence of the antigen. In this
work, a global vaccination approach was applied, followed by in silico epitope-prediction, using
the SYFPEITHI algorithm. In the following paragraph, advantages and disadvantages of both
methods are going to be elucidated.
The global vaccination approach applied in this work was based on immunizing HLA-transgenic
mice with a global NY-BR-1 encoding expression vector and followed by the screening of a NY-
BR-1-specific peptide library. Hence, the complete NY-BR-1 amino acid sequence was covered
by the NY-BR-1-specific peptide library, one advantage of the global approach certainly is the
potential of theoretically detecting every possible NY-BR-1-derived T cell epitope. Furthermore,
the global vaccination approach allows to investigate candidate epitopes which might be neglected,
due to low prediction scores and thresholds of the in silico epitope-prediction algorithm. This
particular advantage of the global screening approach became especially obvious in the case
of identifying NY-BR-1-specific epitopes in DR3tg mice, as candidate epitopes with in silico
SYFPEITHI algorithm prediction scores < 20 were identified (fig. 35 A). These NY-BR-1-specific,
MHC-restricted candidate epitopes would have been neglected relying on reverse immunology.
On the other hand, several limitations of the global vaccination approach used in this project
appeared: e.g the antigen-specific candidate epitopes identified in DR3tg mice and DR4tg mice
(fig. 35 A,B), could not explain immunogenicity for all peptide pools detected in DR3tg mice
(fig. 13) and DR4tg mice (fig. 16).
Moreover, a cascade of matrix screenings had to be applied in DR4tg mice to identify immuno-
genic NY-BR-1-derived library peptides (fig. 9). Possible reasons for the limitations of the global
vaccination approach might be insufficient uptake and expression of intramuscularly injected DNA
by muscle cells, since Dupuis et. al described that the distribution of DNA vaccines determines
their immunogenicity after intramuscular injection in mice [64]. In addition, high numbers of
individual library peptides (13 peptides), composing the NY-BR1-library peptide pools K1-13 and
L1-13, might cause the observed limitations of the global vaccination approach applied in this
work. One explanation being a potential competition of individual library peptides included in
one peptide library pool. As crude NY-BR-1 library peptides were used, an accumulation of pep-
tide synthesis byproducts, such as peptide fragments, might lead to poor immunogenicity of the
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affected NY-BR-1 synthetic library peptide pool.
Global vaccination strategies using an attenuated adenovirus (Ad5) encoding the NY-BR-1
antigen might be one fruitful alternative to using a global DNA vaccination approach regarding to
the immunogenicity of the applied vaccine. Osen et al. [183] showed, that antigen-specific T cell
epitopes could be identified successfully in HLA-tg mice after immunization with an adenovirus
encoding the melanoma tumor associated differentiation antigen Trp-2. Furthermore, reduction
in numbers of individual library peptides composing the peptide library pools, as well as the
addition of adjuvants, such as additional CpC motives, which enhance immunogenicity of the
DNA vaccination by activation of innate immunity [253], might elevate the immunogenic impact
of the global vaccination approach.
Overall, application of the global vaccination approach led to the identification of NY-BR-1-
derived, immunogenic library peptides in HHDtg mice, DR3tg mice and DR4tg mice (fig. 35), thus
this approach might be considered to be suitable for the identification of tumor antigen-derived
T cell epitopes in HLA-tg mice.
Even though the global vaccination approach was successfully applied for the identification of
immunogenic NY-BR-1-library peptides (20mers), we subsequently relied on in silico SYFPEITHI
algorithm, to predict candidate epitope sequences within the identified immunogenic NY-BR-1-
derived library peptides (fig. 35).
Algorithms available for in silico prediction are for example the SYFPEITHI database [204],
predicting human and mouse MHC-I and MHC-II human restricted T cell epitopes for a number
of MHC-I and MHC-II alleles of several species. The database Rankpep [205] predicts MHC-I
and MHC-II epitopes, as well as the proteasomal digestion of given peptides. Epitope-prediction
by the SYFPEITHI database is based on the preferential binding of particular amino acids at
anchor positions of the MHC-molecules, for example the HLA-A2 molecule most likely binding
9mer amino acid residues with a Leu at position 2 and a Val or Leu at position 9 [189]. In silico
prediction scores of the SYFPEITHI algorithm are described to be 80% accurate for prediction
of MHC-I-restricted epitopes, thus naturally presented epitopes should be among the top-scoring
2% of all predicted epitopes. In case of MHC-II restricted epitope motifs, prediction reliability is
estimated to be only 50%, due to the degenerated binding motives and promiscuity of MHC-II
ligands [204].
In the present case, limitations of the SYFPEITHI algorithm were especially observed regard-
ing the in silico epitope prediction of HLA-DRB1*0301-restricted peptides. HLA-DRB1*0301-
restricted NY-BR-1-derived epitope BR1-88 has a very high prediction score by the SYFPEITHI
algorithm (SYFPEITHI score: 34) when compared to the HLA-DRB1*0301-restricted epitopes
BR1-1238 (SYFPEITHI score: 15) and BR1-1347 (SYFPEITHI score: 22), but did not present
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the strongest antigen-specific IFN-γ response among splenocytes obtained from immunized DR3tg
mice (fig. 23 A, fig. 24 A). Discrepancies between the in silico prediction of antigen-specific HLA-
DR-restricted epitopes using the SYFPEITHI algorithm and the observed immunogenicity of the
predicted epitopes in HLA-tg mice, might be due to species-specific differences in the MHC-II
epitope processing machinery or selection of the T cell repertoire, which will be discussed in the
next paragraph.
6.2 Potential limitations and advantages of HLA-tg mouse models
for the identification of human tumor antigen-specific T cell
epitopes
In this work, we observed differences among the immunogenicity of individual NY-BR-1-derived
peptides investigated in mice or humans. The published NY-BR-1-derived, HLA-A*0201-restricted
epitopes p158-167, p960-968 [112], did not stimulate splenocytes obtained from HHDtg mice
after DNA-vaccination in an antigen-specific manner. In fact, it was expected that HHDtg mice,
expressing the HLA-A*0201 molecule, are capable of presenting these epitopes after global DNA-
vaccination. Lack of antigen-specific IFN-γ response upon stimulation of murine splenocytes with
the epitopes p158-167 and p960-968, can be potentially explained by differences in MHC-I antigen
processing machinery among mouse and human species.
It has been described in the literature by Falk et al., that antigen processing for MHC class I
restricted presentation is conserved between mouse and humans [70], demonstrated for example by
the ovalbumin peptide SIINFEKL being processed in both, human and murine H-2Kb expressing
cells [69]. However, interspecies differences among the murine and human MHC-I processing
machinery are also described in the literature available. The ATP-dependent transporter associated
with antigen processing (TAP) shows differences regarding peptide binding in mouse and humans.
Murine TAP are described to preferentially bind peptides with a hydrophobic C-terminus, whereas
the human TAP transporter is less selective [224, 165].This difference is also reflected by different
peptide anchor residues required by the MHC-I alleles for peptide binding. Murine MHC class I
alleles require unvaryingly hydrophobic or aromatic C-terminal residue whereas binding of peptides
with either a hydrophobic, aromatic or basic anchor residue is described for human MHC class I
alleles [93, 204]. One exception is the HLA-A*0201 motif which also requires, similar to the murine
MHC-II molecule, hydrophobic amino acids at the C-terminus of the peptide ligand. Moreover,
the length of MHC-peptide ligands, cleaved by the ERAP peptidase which trims precursor peptides
to generate peptides with the appropriate length required for binding to the MHC-I molecules,
differs among humans and mice, thus generating a different MHC-I-restricted epitope repertoire
within these two species [19].Evidence for the differences among human and murine MHC-I ligand
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processing has been given by a study conducted in mice transgenic for the human HLA-A*0201
molecule (HHDtg mice), which reported, that certain HLA-A*0201-restricted antigen-specific
epitopes found among the peptide repertoire in human cells are not processed in HHDtg mice
[243].
Up to now, interspecies differences in the MHC-II antigen-processing pathway among mouse
and human are poorly investigated.
Regarding our results obtained in DR3tg mice, even though predicted by the SYFPEITHI
database with a high score, HLA-DRB1*0301-restricted NY-BR-1-derived candidate epitope BR1-
88 (SYFPEITHI algorithm score 34), did not elicit a strong antigenic response among splenocytes
obtained from immunized DR3tg mice, determined by Elispot assay (fig. 23 A) and by IFN-γ-
secretion assay. This might be attributed to differences in the presented MHC-II peptide repertoire
among mice and humans or differences in T cell selection. The immunogenicity of candidate
epitope BR1-88 among PBMCs obtained from breast cancer patients (fig. 41 A), which was
detected in the following, supports the assumed inter-species differences in the presented MHC-II
peptide repertoire, since the presence of CD4+ T cells specific for the peptide BR1-88 among
PBMCs of breast cancer patients clearly indicate that the peptide BR1-88 is presented on MHC-II
molecules in humans.
Classical MHC class II molecules do not associate with peptides in the endoplasmic reticulum
since the peptide binding groove is shielded by the invariant chain (Ii). The invariant chain Ii is
degraded in mice and humans by the protease cathepsin S, generating the CLIP (Class II-associated
invariant chain peptide), preventing peptide binding to the MHC-II molecule, before the MHC-II
peptide repertoire is fully assembled in the endosomal compartment. Cathepsin S later on further
facilitates processing of CLIP and MHC-II restricted epitopes in the endosomal compartment [106].
Apart from Cathepsin S being the major protease in MHC-II antigen processing [15] in humans,
several other Cathepsins (Cat) have been described in mice to facilitate cleavage of the invariant
chain and peptide loading, such as Cat L, Cat F and Cat K [10]. Subsets of murine antigen
presenting cells (APCs) are described to use Cathepsin F to mediate MHC class II invariant chain
cleavage and peptide loading [231]. Recruitment of different Cathepsins for peptide cleavage might
alter the peptide repertoire presented on murine MHC-II molecules, leading to differences among
the NY-BR-1-specific T cell repertoire in mice and humans, which might explain interspecies
differences observed regarding the immunogenicity of peptide BR1-88.
However, there are many examples where DR3tg mice have been successfully used to identify
human CD4+ T cell epitopes [183, 214, 229]. Since no murine analogue of the human NY-BR-1
protein has been described in mice, it has to be expected that induced NY-BR-1-specific murine
T cells are not eliminated due to central tolerance mechanisms. This might enhance NY-BR-1-
125
Discussion
specific T cell responses in HLA-tg mice, when applying the global vaccination approach discussed
above.
6.3 Chimeric screening for human T cell epitopes using murine
CD4+ T cells
A chimeric screening system of using murine CD4+ T cells to verify HLA-DRB1*0301-/*0401-
restriction and endogenous processing of the newly identified NY-BR-1-derived peptides was ap-
plied in this project. One advantage of this approach is good general feasibility of establishing
antigen-specific murine CD4+ T cell cultures, which were used for the generation of murine
HLA-DR-restricted, antigen-specific CD4+ T cell lines (fig. 27). Established murine HLA-DR-
restricted T cell lines showed high peptide affinity when recognizing their cognate peptide on
human MHC-molecules (fig. 28). Nevertheless, peptide affinity differed among the five estab-
lished, NY-BR-1-specific murine, HLA-DR-restricted CD4+ T cell lines since amounts between
62.5 ng/ml and 1000 ng/ml of peptide (fig. 28), externally loaded on human T2/DR3, T2/DR4
cells, were required to elicit specific recognition of the target cells by murine T cell lines. Cloning
of the T cell lines by limiting dilutions would probably help to select for high affinity T cell clones,
specific for peptides BR1-88, BR1-1347 and BR1-656/-775. Moreover, the protocol of in vitro
restimulation of murine CD4+ T cell lines should be optimized to minimize the risk of inducing
CD4+ T cell lines to become exhausted T cells, which are characterized by a state of T cell dys-
function, commonly observed after chronic antigen-exposure [270]. In our work we might have
detected a stage of an exhausted T cell phenotype when applying the murine CD4+ T cell lines for
the specific recognition of Ad5-NY-BR-1 infected melanoma cell lines and breast cancer cell lines
(fig. 38). A potential exhausted phenotype of the murine CD4+ T cell lines during the performed
IFN-γ-EliSpot assay might be indicated by reduced recognition of the positive controls (peptide
loaded T2/DR3, T2/DR4 cells) included in this experiment, compared to specific recognition of
peptide loaded T2/DR3, T2/DR4 cells by these T cell lines in earlier experiments (fig. 27).
In addition, insufficient interaction of co-stimulatory molecules during priming and of further
accessory molecules, such as lymphocyte function-associated antigen 1 (LFA-1) during restimula-
tion might occur due to interspecies barriers, leading to an impaired T cell activation. It has been
described, that murine LFA-1 does not bind to human intercellular adhesion molecule (ICAM),
although binding-specificity can be mapped to the human LFA-1 alpha subunit [119].
Moreover, the interaction of the CD8-molecule and the MHC-I complex works in a species
dependent manner, thus suboptimal interaction of the CD8-molecule with the alpha 3 domain
of xenogenic MHC-I molecules may be an important contribution to poor xenoreactivity [109].
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Furthermore, it was described in humans, that interaction of the HLA-DR molecule and the human
CD4 molecule requires specific amino acid residues at position 110 and 139 of the β2-domain of the
human class II molecules, for proper binding [186]. Experiments in HLA-DRtg mice, have shown,
that amino acid 110 of the second domain of human HLA-DR-molecules contributes also to the
interaction between murine CD4+ T cells and human class II [127], thus inter-species binding of
human MHC molecules and murine CD4+ T cells can be successful. However, interspecies barriers
were reported for the interaction of human CD4+ T cells and murine H2-E β2-domain [203], thus
possible xenogenic barriers might also exist (vice versa) for the interaction of murine CD4+ T
cells and HLA-DR-molecules.
The DR4tg mice used in this thesis express a chimeric HLA-DRB1*0401 molecule with a
murine α2- and β2- domain, in comparison to DR3tg mice which express the complete human
HLA-DRB1*0301 molecule. Therefore, potential interspecies differences in binding of murine
CD4+ T cells to the relevant transgenic HLA-DR molecule were expected to be more pronounced
in DR3tg mice compared to an effect in DR4tg mice. Our results show that IFN-γ responses
determined by EliSpot assay, upon screening of the synthetic NY-BR-1-specific peptide library,
were suboptimal in DR4tg mice (fig. 16) compared to DR3tg mice (fig. 13). Furthermore,
the amounts of antigen-specific CD4+ T cells detected ex vivo among splenocytes of immunized
HLA-DR transgenic mice, were on average greater in DR3tg mice than in DR4tg mice (fig. 24
A, B). This might indicate a suboptimal activation of murine CD4+ T cells by the chimeric
HLA-DRB1*0401 molecule expressed in DR4tg mice. In line with this findings are the results
obtained on recognition of lysate loaded human HLA-matched dendritic cells by the relevant
HLA-DR-restricted T cell line. We could observe on average a higher IFN-γ secretion in HLA-
DRB1*0301-restricted murine CD4+ T cells lines compared to HLA-DRB1*0401-restricted CD4+
T cell lines upon recognition of NY-BR-1 protein containing cell lysate loaded human DCs (fig.
40 A, B).
However, signal intensity might have been additionally reduced for some established NY-BR-
1-specific T cell lines due to impaired interaction between accessory molecules such as LFA-1 and
ICAM. One example for impaired LFA-1 and ICAM interaction might be the T cell lines BR1-
656/-775, which showed low affinity for recognition of the cognate HLA-DR-restricted peptide
on peptide loaded T2/DR4 cells (fig. 28). It is conceivable, that optimal interaction of co-
stimulatory and accessory molecules probably are required to achieve maximal T cell activation
upon antigen-recognition in the case of T cell line BR1-656/-775.
In summary, the conclusion can be drawn that the compatibility of the human HLA-DRB1*0301
and HLA-DRB1*0401 molecules is sufficient for binding and activation of murine HLA-DR-
restricted CD4+ T cells.
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6.4 Multiple approaches applied to confirm endogenous processing
of the newly identified HLA-DRB1*0301- and HLA-DRB1*0401-
restricted NY-BR-1-specific epitopes in human cells
Given the fact that endogenous processing of the newly identified NY-BR-1-derived peptides
needed to be verified in human cells, this work we took advantage of the already established NY-
BR-1-specific murine HLA-DR-restricted CD4+ T cell lines to examine this scientific question.
The overall strategy aimed at the chimeric approach of antigen-specific recognition of NY-BR-1
expressing human target cells by murine T cell lines.
Up to now, no human cell line endogenously expressing NY-BR-1 in vitro is available, thus
we firstly focused on the generation of NY-BR-1 expressing human target cells on the relevant
MHC-background. Melanoma cell lines and breast cancer cell lines were infected with an at-
tenuated adenovirus encoding the NY-BR-1-protein (Ad5-NY-BR-1). Surface-expression of the
CAR-receptor (fig. 31), one major receptor associated with infection of target cells by adenovirus
Type 5 [284], as well as surface-expression of HLA-DR molecules (fig. 31) was confirmed, double
positive tumor cells (CAR+, HLA-DR+), were considered as promising NY-BR-1-protein expressing
target cells upon Ad5-NY-BR-1 infection. However, no antigen-specific recognition of Ad5-NY-
BR-1 infected, HLA-matched target cells could be observed (fig. 37) for any of the investigated
murine T cell lines, although, NY-BR-1-protein expression in the tumor cell lines was confirmed
by Western blot analysis (fig. 38). Possible reasons for the observed results might be insufficient
processing of MHC-II-restricted peptides in the tested target cell lines, since the melanoma and
breast cancer cell lines tested, do not belong to the group of professional antigen-presenting cells,
which might impair processing of the relevant epitopes in these cell lines. Moreover, MHC-II
surface expression needed to be induced by IFN-γ treatment, resulting in a maybe only transient
effect leading to suboptimal amounts of MHC-II surface molecules and subsequently to insufficient
antigen-specific stimulation of the CD4+ T effector cells, in combination with impaired interaction
of the MHC-DRB1*0301/*0401 molecule and the murine CD4+ T cell line.
Furthermore, persistent antigenic stimulation of the murine CD4+ T cell lines might have
induced an “exhausted” phenotype in these T cell lines [280]. T cell exhaustion is defined by poor
effector functions and expression of molecules associated with immune-suppressive pathways, such
as the PD1 molecule [270]. In line with this thought, murine HLA-DR-restricted CD4+ T cell lines
used in this experiment, only showed poor recognition of the included positive control (peptide
loaded T2/DR3, T2/DR4 cells),(fig. 38). However, to confirm induction of T cell exhaustion, an
immunofluorescent staining for T cell exhaustion markers such as CD244, CD160 and PD1 [283]
of the murine CD4+ T cell lines would have been to be performed additionally.
Failure of recognition of HLA-matched human target cell lines, endogenously expressing the
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NY-BR-1 protein upon infection with Ad5-NY-BR-1(fig. 38), might also have been due to the
fact that IFN-γ is a suboptimal cytokine used as read out for potential CD4+ T cell stimulation.
Taken into consideration that CD4+ T cell responses might potentially be a Th2 associated T
cell response, cytokines characteristic for a Th2 CD4+ T cell response, such as IL-4 and IL-13,
should also be investigated. Moreover, NY-BR-1 expressing target cells might induce antigen
specific Tregs, thus cytokines associated with stimulation of regulatory T cells such as TGF-β
or IL-10 might be an important additional cytokine read out for this assay. Taken together, so
far we could not demonstrate recognition of NY-BR-1 protein expressing, HLA-matched human
tumor cell lines, by the established murine CD4+ T cell lines, probably due to the various reasons
discussed above.
The following attempts of infecting human PBMCs and human dendritic cells with Ad5-NY-
BR-1 did not reveal NY-BR-1-protein expression in infected cells (fig. 34, 36). We could show,
that expression of the CAR-receptor was absent in human dendritic cells, which gives a reason for
insufficient infection of human dendritic cells with Ad5-NY-BR-1 (fig. 36).
It has been described previously, that human PBMCs, depleted of CD3+ lymphocytes, are
specifically recognized by human CD4+ T cell lines after incubation with antigen-encoding Ad5-
constructs [183]. Reasons for inefficient infection of human PBMCs, depleted of CD3+ lympho-
cytes, with Ad5-NY-BR-1 in this work remain unexplained. Application of an antibody detecting
Ad5-derived protein could be included in the Western blot analysis to discriminate between un-
successful infection of target cells and lack of endogenous epitope processing, thereby elucidating
the capacity of Ad5-NY-BR-1 to infect human PBMC fractions.
Finally, endogenous processing of the HLA-DR-restricted, NY-BR-1-derived epitopes BR1-88,
BR1-1347, BR1-537 and BR1-1242 was verified by the use of human dendritic cells loaded with
NY-BR-1-protein containing whole cell lysate. In vitro generated mature human dendritic cells
(fig. 35) loaded with cellular lysate containing the NY-BR-1-protein (fig. 39), were specifically
recognized by murine HLA-DR-restricted CD4+ T cell lines in an antigen-specific manner (fig.
40). In fact, due to our findings, endogenous processing of the above mentioned epitopes can
be postulated in human cells. Nevertheless, it remains questionable if the epitopes are processed
in the melanoma cell line Ma-Mel73a or by the human dendritic cell from whole cellular lysate,
containing NY-BR-1 protein, used for exogenous loading of the dendritic cell. Blockade of the
MHC-II processing machinery within the human dendritic cells, for example by using simvastin
which inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily
GTPases [86], could give first insights to resolve this question.
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6.5 Differences in frequencies of NY-BR-1-specific CD4+IFN-γ+ T
cells in the peripheral blood of breast cancer patients and healthy
donors
A collective of PBMC samples of three HLA-DRB1*0301+ (BC1 to BC-3) and four HLA-DRB1*-
0401+ breast cancer patients (BC-4 to BC-7) was analyzed for the presence of NY-BR-1-specific,
CD4+IFN-γ+T cells, after 24 days of in vitro stimulation with the relevant NY-BR-1-derived
peptides.
Analysis of PBMCs obtained from breast cancer patients indicated the presence of CD4+ T
cells specific for the identified NY-BR-1-derived peptides BR1-1347, BR1-88, BR1-537, BR1-1242
and BR1-656/-775 in the peripheral blood of tested breast cancer patients (fig. 41). Peptide
specific stimulation of CD4+IFN-γ+ T cells was detected in at least 1/3 tested PBMC sam-
ples obtained from HLA-DRB1*0301+ breast cancer patients upon stimulation with the HLA-
DRB1*0301-restricted, NY-BR-1-specific peptides BR1-1347 and BR1-88. Based on these find-
ings, we assume that the NY-BR-1-specific peptides BR1-1347 and BR1-88 identified in HLA-
transgenic mice, are among the presented MHC-II peptide repertoire in NY-BR-1+ breast cancer
patients, which is indicated by the presence of CD4+IFN-γ+T cells in the peripheral blood of these
patients. Interestingly, the frequencies of CD4+IFN-γ+ T cells specific for the peptide BR1-88
detected among splenocytes obtained from immunized DR3tg mice were very low compared to
the detected frequencies of CD4+IFN-γ+ T cells specific for peptide BR1-1238 (fig. 24). In
contrast, we could detect CD4+IFN-γ+ T cells specific for the peptide BR1-88 with a higher fre-
quency (2.06% CD4+IFN-γ+ T cells) than CD4+IFN-γ+ T cells specific for the peptide BR1-1238
(1.29% CD4+IFN-γ+ T cells), in the peripheral blood of breast cancer patients (fig. 41). This
finding, might demonstrate inter-species related differences in frequencies of NY-BR-1-specific,
CD4+IFN-γ+ T cells due to differences in the peptide repertoire presented on MHC-II molecules in
mice and humans, as discussed above. So far, we could not demonstrate the endogenous process-
ing of the NY-BR-1-derived HLA-DRB1*0301-restricted peptide BR1-1238 in human cells, hence
this epitope might not be among the peptide repertoire presented on MHC-II in breast cancer
patients. Therefore, potentially explaining very low to non-detectable amounts of CD4+ T cells
specific for this antigen detected among PBMCs of HLA-DRB1*0301+ breast cancer patients.
Moreover, CD4+IFN-γ+ T cells specific for the HLA-DRB1*0401-restricted, NY-BR-1-specific
peptides BR1-537, BR1-1242 and BR1-656/-775 were also detected among PBMCs in at least
1/4 tested breast cancer patient samples. Frequencies of CD4+IFN-γ+ T cells specific for peptide
BR1-537, were the highest (1.34% CD4+IFN-γ+ T cells) among all HLA-DRB1*0401-specific
CD4+ T cell responses detected, which correlates with our data obtained in DR4tg mice (fig. 24
B).
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It was expected to detect NY-BR-1-specific CD4+ T cells in the peripheral blood of breast
cancer patients with NY-BR-1+ tumors, since NY-BR-1-specific immunogenic peptides might be
released by dying tumor cells into the tumor stroma, and further on processed and presented
on MHC-II molecules for example by dendritic cells or tumor associated macrophages (TAMs).
Notably, it should be taken into considereation that frequencies of NY-BR-1-specific CD4+ T
cells in the peripheral blood of breast cancer patients might be low, as observed within the PBMC
sample of BC-6 (fig. 41 B), since mature CD4+ T cells show enhanced migratory properties
toward the bone marrow, thus the bone morrow might function as a secondary lymphoid organ
[54]. Thereby, withdrawing NY-BR-1-specific CD4+ T cells from the peripheral blood, leaving no
or very low levels of antigen-specific CD4+ T cells behind which could not be detected by the
immunofluorescent staining applied in this project (fig. 41).
NY-BR-1-specific CD4+ T cells were not only detected in PBMCs obtained from breast cancer
patients, but were also detectable among PBMCs obtained from healthy donors (fig. 42).
In this work, we detected frequencies from 0.77% to 3.66% versus from 0.8% to 2.7% of
CD4+IFN-γ+ T cells specific for the NY-BR-1-derived peptide BR1-1347 in PBMCs obtained
from HLA-DRB1*0301 positive breast cancer patients and healthy donors, respectively (fig. 41
A, 42 C). In line with these findings, elevated numbers from 0.6% to 3.23% versus from 0.3%
to 2.81% of CD4+ T cells specific for their cognate antigen BR1-88 could be detected among
PBMCs of breast cancer patients compared to healthy donors (fig. 41 C, 42 A).
In the case of HLA-DRB1*0401-restricted NY-BR-1-specific epitopes BR1-537, BR1-1242
and BR1-656/-775, frequencies of antigen-specific CD4+IFN-γ+ T cells were higher in PBMCs
obtained from breast cancer patients in comparison to PBMCs obtained from HLA-matched
healthy donors (fig. 41 B, D; fig. 42 B, D), except for antigen-specific CD4+ T cells detected
in PBMCs obtained from healthy donor HD-3 (fig. 42 C, D). In this case we would postulate
high frequencies of CD4+ T cells specific for the NY-BR-1-derived peptide BR1-537 in healthy
donor HD-3, due to cross-reactivity of CD4+ T cells with a different antigen-specificity. Overall, it
needs to be further investigated if antigen-specific CD4+ T cell responses detected among PBMCs
obtained from healthy donors are true NY-BR-1-specific CD4+ T cell responses or are based on
cross-reactivity of CD4+ T cells in a NY-BR-1 independent manner.
It has been described in the literature, that frequencies of circulating antigen-specific CD8+
T cells were found to be higher in CML patients compared to healthy donors [209]. Moreover,
frequencies of CD4+ T cells specific for the melanoma associated differentiation antigen Trp-2
were described to be elevated among PBMCs of melanoma patients in comparison to healthy
donors [183]. The data obtained in this thesis might support the fact, that frequencies of NY-
BR-1-specific, CD4+ T cells circulating in the peripheral blood of healthy donors, are reduced in
comparison to frequencies of NY-BR-1-specific, CD4+ T cells detected in the peripheral blood of
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breast cancer patients.
Overall, conclusions are difficult to be drawn due to very limited numbers of breast cancer
patients and healthy donors available for our studies. Further experiments are required to confirm
the so far obtained data on the detection of antigen-specific CD4+ T cells in the peripheral blood
of NY-BR-1+ breast cancer patients and healthy donors.
6.6 Breast cancer cells as direct targets for NY-BR-1-specific CD4+
T cells
Breast cancer cells might be a direct target for antigen-specific CD4+ T cells with cytotoxic
effector function, such as secretion of perforin and FasL-mediated cytolytic activity [27]. Specific
targeting of tumor cells by cytotoxic CD4+ T cells has been described to be efficient in tumor
control in melanoma [166]. However, in contrast to melanoma cells, which are described to express
MHC-II molecules on there cell surface [25], this might not be the case in breast cancer cells.
In the literature, MHC molecules are described to be down regulated in 20% to 50% of primary
breast tumors and cell lines, and MHC-II expression could only be detected in around 30% of breast
tumors [29]. Given this fact, also the majority of NY-BR-1 expressing breast tumors are most
likely to be MHC-II negative. Reduction of MHC-II expression might be due to unresponsiveness
of the tumors to IFN-γ caused by defects in the class II transactivator (CIITA) synthesis at
the transcriptional or translational level [170]. Moreover, cell surface exposure of MHC-II can
be down regulated by the interaction of ubiquiting ligases of the membrane-associated RING-
CH family [180]. Hereby, addition of ubiquitin molecules to the cytoplasmic tail of the MHC-II
molecules, enhances intracellular sequestration and degradation of the MHC-II molecules, leading
to reduced MHC-II surface expression [263].
Our data obtained on the MHC-II surface expression in breast cancer cell lines has indicated,
that most of the tested tumor cell lines were negative for MHC-II expression (fig. 31). In vitro,
MHC-II surface expression could be induced by IFN-γ-treatment, however, this would not be
applicable in vivo in breast cancer patients, due to severe side effects, such as cytokine-storms
anticipated. In conclusion, tumor cells might not be targeted by NY-BR-1-specific CD4+ T cells
directly due to the absence or down regulation of MHC-II surface expression.
6.7 Potential targets of NY-BR-1-specific CD4+ T cells within the
tumor stroma
Immune cells of the tumor stroma such as tumor associated macrophages (TAMs), myelo-derived
suppressor cells (MDSCs) and regulatory T cells (Tregs) might represent direct interaction partners
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for antigen-specific CD4+ T cells.
Tumor associated macrophages (TAMs) reside in the tumor microenvironment and can con-
stitute up to 50% of the tumor-mass of breast cancers [121]. Especially, when considering a
NY-BR-1-specific CD4+ T cell based immunotherapy, antigen-presenting cells within the stroma,
such as TAMs might be the link for a CD4+ T cell mediated anti-tumor response. However,
TAMs display a dual face of firstly classically activated macrophages (M1) and secondly tumor
promoting macrophages (M2-like) .
M1 macrophages can be induced by the influence of IFN-γ and bacterial products [154].
Once activated, M1 macrophages function as antigen presenting cells, thus being considered to
promote anti-tumor immunity by e.g. activating NY-BR-1-specific CD4+ Th1 cells. Moreover,
activated M1 macrophages can directly eliminate tumor cells by activation of the inducible NO
synthase (iNOS) gene leading to the production of nitric oxide (NO) [179]. Phenotypically, M1
macrophages can be characterized by the expression-markers iNOS and IL-12p70 [101].
M2-like macrophages, or alternatively activated macrophages, are activated in association with
the cytokines IL-4, IL-10, IL-13 and glucocorticoid hormones [154]. Under hypoxic conditions in
breast cancer tumors, M2-like macrophages secrete IL-10 which inhibits immune effector T- cells
[168][179]. Moreover, IL-10 secretion drives the development of Th2 cells and enhances Treg ac-
tivity, supported by the expression of chemokine ligand 22 (CCL22) on M2-like macrophages which
recruits Tregs into the tumor microenvironment [201, 47]. Furthermore, it has been described,
that M2-like macrophages may affect the clinical course of breast cancer patients by non-immune
mechanisms, such as induction of angiogenesis via secretion of VEGF[196] and promotion of tumor
cell invasion and metastasis [200, 142]. Breast cancer cell invasion and metastasis is potentiated
by M2-like macrophages via the production of several enzymes which can degrade the extracellular
matrix (ECM), one example being the metalloproteinases MMP-2 and urokinase-type plasminogen
activator (uPA) [169]. Breast cancer patients with primary tumors and high levels of uPA were
reported to have a significant shorter disease-free interval when compared to patients with normal
uPA levels [62].
Recently it has been described that interaction of M2-like macrophages with tumor infiltrating
Th1 CD4+ T cells can favor a re-polarization of M2-like macrophages to a M1-like phenotype,
thus promoting anti-tumor immunity [100]. Re-polarization of M2-like macrophages is achieved
by exposure of the cells to IFN-γ-secreting and CD40-ligand expressing Th1 cells, indicated by
elevated expression of co-stimulatory molecules, elevated IL-12 secretion and loss of typical M2-
like markers, such as CD206 and CD163, in affected M2-like macrophages [100]. To sum up,
cognate interaction of M2-like macrophages and IFN-γ secreting Th1 cells in synergy with CD40
activation, can initiate a switch of tumor-promoting M2-like macrophages to classical M1-like
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macrophages with anti-tumor capacities. NY-BR-1-specific CD4+ T cells activated in vitro or
NY-BR-1-TCR transduced CD4+ T cells, used for an adoptive cell transfer in breast cancer
patients, could maybe promote a phenotypic-switch of tumor-promoting M2 macrophages into
classical M1-like macrophages, reducing immune-suppressive capacity orchestrated by the breast
tumor stroma. However, this implies the uptake and processing of exogeneous NY-BR-1 antigen,
for example originating from necrotic tumor cells, by M2 macrophages [11].
Further experiments will have to be performed to gain more profound knowledge on the
composition of the tumor-miroenvironment in NY-BR-1+ breast tumors. Currently an orthotopic
NY-BR-1 tumor model is established in DR3tg mice in the group of Prof. Eichmueller, which will
be applied to investigate not only a possible CD4+ T cell mediated support for an NY-BR-1-specific
CD8+ T cell anti-tumor response, but can also be further used to investigate the composition of
the NY-BR-1+ tumor stroma in mice.
6.8 Role of Tregs in breast cancer
As depicted in figure 43 A, B, we could detect CD25+ FoxP3+CD127-CD4+ T cells (Tregs)
among CD4+ cells of HLA-DRB1*0301+/*0401+ breast cancer patients and healthy donors. Total
frequencies of Tregs among CD4+ T cells of breast cancer patients and healthy donors did not
exceed 13% and were independent of the NY-BR-1-derived peptide used for in vitro stimulation
of the PBMC cultures (fig. 43 A, B).
In this work we did not detect overall differences regarding the frequencies of total Tregs
among CD4+ T cells among PBMCs of breast cancer patients and healthy donors.
However, it was described in the literature that in patients with breast cancer, regulatory
Tregs are increased in both, peripheral blood and malignant effusions [146][50]. Furthermore,
Treg numbers are reported to increase in the peripheral blood of breast cancer patients with
developing progression of a stage I breast cancer into a stage IV classified breast tumor [264]. In
line with this, it has been described that total frequencies of tumor associated Tregs in breast
cancer patients can be directly associated with disease progression in invasive and non-invasive
breast tumors, whereas invasive tumors display greater numbers of Tregs than non-invasive tumor
specimens [14].
We further on investigated the frequency of CD25+FoxP3+CD4+ T cells (Treg-like cells)
secreting IFN-γ among CD4+ T cells detected among PBMCs of breast cancer patients and
healthy donors (fig. 42). This experiment was performed to elucidate the possible induction of
antigen-specific Treg-like cells by the NY-BR-1-derived peptides BR1-1347, BR1-88, BR1-1238,
BR1-537, BR1-1242 and BR1-656/-775. To confirm a true regulatory T cell phenotype, further
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assays addressing the functional activity of Treg-like cells, for example antigen-specific suppression
of CD4+ effector cells or the release of Treg associated cytokine such as IL-10 and TGF-β upon
antigenic stimulation, should be performed.
Total numbers of CD25+FoxP3+CD4+ T cells secreting IFN-γ among CD4+IFN-γ+ T cells,
did generally not exceed numbers higher than 20% in both, breast cancer patients and healthy
donors. Furthermore, frequencies of Treg-like cells among CD4+IFN-γ+ T cells of breast cancer
patients and healthy donors were independent of the NY-BR-1-derived peptide used for in vitro
stimulation of the PBMC cultures (fig. 43 C,D). One exception was, that elevated amounts of
Treg-like cells up to 44.14%, specific for the NY-BR-1-derived peptide BR1-656/-775 could be
detected among CD4+IFN-γ+ T cells obtained from breast cancer patient BC-4 versus 9.38%-
18.36% of T cells with the same phenotype detected among CD4+IFN-γ+ T cells of healthy
donors (fig. 43 B). In this particular case, amounts of potential antigen-specific Treg-like cells
among CD4+ T cells are higher in the peripheral blood of breast cancer patients, compared to
healthy donors. Based on this finding, we assume an NY-BR-1-specific induction of Treg-like cells
among PBMCs obtained from breast cancer patient BC-4.
Especially when considering for example a NY-BR-1-specific anti-tumor vaccine for the treat-
ment of NY-BR-1+ tumors in breast cancer patients, it is crucial to consider a potential antigen-
specific induction of regulatory T cells. In the literature it has been described, that antigen-specific
Tregs develop from CD4+CD25-Foxp3- T cells by activation with an immunogenic antigen and
TGFβ, in a non-inflammatory environment [94]. There is evidence that antigen-specific Tregs are
superior in their immunosuppressive function when compared to natural Tregs, hence antigen-
specific Tregs suppress the immune response at ratios below 1:10 (CD4+CD25+: CD4+CD25-)
T cells, whereby natural T cells are described to induce tolerance in a 1:1 ratio [95, 96]. Even
though, IFN-γ not being the classical cytokine associated with regulatory T cells, it has been de-
scribed in mice, that antigen-specific Tregs can acquire an effector phenotype of IFN-γ secreting
cells upon antigen-encounter [182].
Recently Schmidt et. al, reported that mammaglobin-reactive, antigen-specific Tregs can
be found in the peripheral blood of breast cancer patients. The authors postulated, that pre-
existing antigen-specific regulatory T cells are induced by encounter of their cognate antigen
on professional antigen presenting cells, such as dendritic cells [222]. Moreover, regulatory T
cells expressing IFN-γ were described to be found selectively expanded in the peripheral blood of
patients with metastatic melanoma upon peptide vaccination, impairing an effective Th1 effector
response [116].
When considering to apply a NY-BR-1-specific vaccine as a therapy to treat breast cancer,
a potential activation of antigen-specific regulator T cells should be very closely monitored, to
prevent an overshooting activation of suppressive antigen-specific Tregs, which might even result
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in tumor-progression.
6.9 NY-BR-1 as a target for immunotherapy approaches against
breast cancer
HLA-DRB1*0301-restricted epitopes BR1-88, BR1-1347 and HLA-DRB1*0401-restricted epi-
topes BR1-537, BR1-1242 were identified as NY-BR-1-specific epitopes naturally processed in
human cells (fig. 40). Promising results in cancer immunotherapy have been reported combining
CD4+ T cell epitopes and CD8+ T cell epitopes by generating long synthetic peptides leading to
profound immunity against human papilloma virus [269]. So far two HLA-A*0201 restricted NY-
BR-1-specific epitopes have been identified by Jaeger et al. [112], thus combining these MHC-I
restricted epitopes with the newly identified MHC-II epitopes might result in fruitfully anti-cancer
treatment. NY-BR-1-specific epitopes could be combined for composition of a synthetic long
peptide used for peptide vaccination of NY-BR-1+ breast cancer patients. Immunotherapy of ma-
lignant tumors has been described using synthetic long peptide vaccines, here delivery of peptides
to antigen presenting cells (APCs) plays a pivotal role [160]. Hence, a possible NY-BR-1 pep-
tide vaccine should not only include MHC-I and MHC-II restricted NY-BR-1-specific epitopes but
also a signal to enhance delivery of the vaccine to dendritic cells as described for DNA-vaccines,
one example being the fusion of antigenic DNA to a dendritic cell direct single chain antibody
fragment (scFv) specific for a DC-restricted surface molecule (DEC-205) [30].
Moreover, identified HLA-DR-restricted, NY-BR-1-specific epitopes deliver antigenic-sequences
for generating NY-BR-1-specific tetramers. Tetramers could be used for monitoring a NY-BR-1
specific immune response in patients ex vivo and after NY-BR-1 specific immunotherapy. MHC
class II specific tetramers allow detection of very low frequency of antigen specific CD4+ T cells
circulating in the peripheral blood. Biophysical studies identified tetramers of pMHC superior to
monomeric and dimeric forms of pMHC, since off-rate analysis suggested that multivalent binding
of tetrameric pMHC is most effective for reliable T cell imaging and isolation of antigen-specific
T cells by fluorescence-activated cell sorting (FACS) [173].
As discussed above in paragraph 6.5, we could detect activated NY-BR-1-specific CD4+ T
cells in the peripheral blood obtained from breast cancer patients (fig. 41), thus adoptive cel-
lular transfer presents a possible treatment approach for breast cancer patients with NY-BR-1
expressing tumors. We suggest, that detected CD4+ T cells specific for the newly identified NY-
BR-1-derived, HLA-DR-restricted T cell epitopes circumvent mechanism of peripheral tolerance
in the breast cancer patient and could therefore possibly be further restimulated and expanded in
vitro. Successful expansion of NY-BR1- specific CD4+ T cells could be achieved by co-incubation
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of purified CD4+ T cells and in vitro generated dendritic cells loaded with cognate antigen in
vitro. Expanded cell-populations could be subsequently used for an adoptive T cell transfer in
breast cancer patients. Moreover, genetically engineered T cells could be designed encoding a
NY-BR-1 specific T cell receptor (TCR). Currently, RNA isolated from HLA-DR-restricted, NY-
BR-1-specific murine T cell lines BR1-88, BR1-1370, BR1-537, BR1-656/-775 and BR1-1242 is
sequenced for identification of the TCRs α-chains and β-chains. Once NY-BR-1-specific murine
TCR-sequences are available, they could be applied for retroviral insertion of TCR-genes into
autologous lymphocytes obtained from HLA-matched breast cancer patients. Similar as described
by Voss et al. it might be favorable to generate a chimeric antigen-specific TCR, expressing a
murine constant α-domain (Cα) and human variable α domain (Vα), variable β domain (Vβ) and
human constant β (Cβ). Voss et al. report, that the chimeric TCR showed superior functional
T-cell avidities compared to a double transgenic TCR. Moreover, human CD8+ T cells transduced
with a chimeric T cell receptor, specific for the melanoma antigen gp100, did show superior delay
in tumor-growth in a engrafted melanoma model in NOD/SCID mice compared to a double chain
transgenic TCR [261].
Collectively, the breast cancer associated antigen NY-BR-1 might therefore present a suitable
target for anti-tumor immunotherapy by various approaches discussed above.
6.10 Conclusion and outlook
In this work, we identified two novel NY-BR-1-derived, HLA-DRB1*0301-restricted CD4+ T cell
epitopes and two novel NY-BR-1-derived, HLA-DBR1*0401-restricted CD4+ T cell epitopes as
natural processing products in human cells, which could be directly implemented in the design
of NY-BR-1 targeted anti-tumor immunotherapies. However, immune escape mechanisms, such
as reduced MHC-molecule expression on the tumor and establishment of a suppressive tumor
microenvironment, hamper a successful anti-tumor response. To overcome these limitations,
targeting of the tumor stroma, for example by induction of a more M1 macrophage dominated
tumor stroma, would be one possible approach. Moreover, we would like to gain more insight
into the cellular composition of the tumor-microenvironment in a NY-BR-1-expressing breast
tumor, with special regard on understanding the plasticity of tumor associated macrophages,
possibly influenced by NY-BR-1-specific CD4+ T effector cells. Furthermore, NY-BR-1-specific
anti-tumor immunotherapy might be most effective when administered as an adjuvant therapy in
combination with negative checkpoint blockade, such as blockade of the CTL-A4, PD-1, CD39
and CD73 associated pathways. We would like to further investigate the immunogenicity of
adoptively transferred HLA-DR-restricted, NY-BR-1-specific murine CD4+ T cell lines, also in
combination with blockade of suppressive pathways as indicated above, in transplantable murine
tumor models. We are especially interested in the contribution of NY-BR-1-specific CD4+ T cells
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to an effective anti-tumor response. Relevance of the newly identified HLA-DR-restricted CD4+
T cell epitopes should be further confirmed in humans by incorporating larger numbers of breast
cancer patients and healthy individuals. Furthermore, we would be interested in investigating
the repertoire of pre-existing antigen-specific CD4+ T cells and antigen-specific regulatory T
cells among PBMCs obtained from breast cancer patients and healthy donors. Finally, it would
be desirable to translate our so far gained immunological knowledge regarding the breast cancer
associated antigen NY-BR-1 into the clinics by launching a first clinical study on NY-BR-1-specific,
anti-tumor immunotherapies in breast cancer patients.
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7 Supplement material
7.1 Arrangement of the NY-BR-1 peptide library in the first matrix
Figure 44: Arrangement of the NY-BR-1 peptide library in the first matrix. 174 single NY-BR-1 library peptides were organized
in 26 pools (K1-K13, L1-L13), each pool containing 13 individual peptides. Library peptides #24, #146, #166, #171, #173 were
not included in the NY-BR-1 matrix but screened as individual library peptides directly.
7.2 Screening of a second NY-BR-1-specific library in DR4tg mice
Figure 45: Screening of a second level NY-BR-1-specific library in DR4tg mice. IFN-γ EliSpot assay result on an experiment
conducted with splenocytes of DR4tg mice vaccinated with global NY-BR-1 DNA. Splenocytes isolated from DNA-immunized DR4tg
mice were incubated with peptide pools (A1-A7, B1-B8) for 18 hrs. Each column represents one individual mouse; bars, standard
error of the mean upon duplicate determination.
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7.3 HLA-phenotype of enrolled breast cancer patients and healthy
donors
PBMC samples HLA-phenotye gender
BC -1 HLA-DRB1*0301 female
BC -2 HLA-DRB1*0301 female
BC -3 HLA-DRB1*0301 female
BC -4 HLA-DRB1*0401 female
BC -5 HLA-DRB1*0401 female
BC -6 HLA-DRB1*0401 female
BC -7 HLA-DRB1*0401 female
BC -8 HLA-DRB1*0401 female
HD -1 HLA-DRB1*0301 female
HD -2 HLA-DRB1*0301 male
HD -3 HLA-DRB1*0301/
HLA-DRB1*0401
male
HD -4 HLA-DRB1*0401 male
Table 36: HLA-phenotype of enrolled breast cancer patients and healthy donors. Out of 24 HLA-typed breast cancer patients,
eight HLA-matched breast cancer patients (BC 1-8) which were tested for a NY-BR-1 positive tumor lesion and five healthy HLA-
matched donors (HD 1- 5) were selected.
7.4 Detection of activated NY-BR-1-specific CD4+ T cells among
PBMCs of breast cancer patients and healthy donors by IFN-γ
EliSpot assay
In parallel to the immunoflourescent staining of in vitro stimulated PBMCs obtained from breast
cancer patients and healthy donors (fig. 41), IFN-γ EliSpot assays were performed with the same
PBMC-samples. Significant amounts of CD4+IFN-γ+ T cell specific for the peptide BR1-1242
could be detected among PBMCs obtained from breast cancer patient BC-7. Indicated by elevated
IFN-γ spots/well, tendencies for the presence of preexisting NY-BR-1-specific CD4+ T cells could
be detected for peptide BR1-1347 among PBMCs obtained from breast cancer patient BC-3 and
for peptides BR1-1242 and BR1656/-775 among PBMCs obtained from breast cancer patients
BC-6 and BC-8, respectively.
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Figure 46: Experiment 1: Detection of NY-BR-1-specific T cells in breast cancer patient samples 24 days after in vitro
stimulation with NY-BR-1-specific peptides. 1 X 105 isolated breast cancer PBMCs were incubated with 5 µg/ml of the indicated
peptide for 18hrs in an IFN-γ-EliSpot assay. PBMCs were in vitro stimulated for 24 days with the same peptide used in the IFN-
γ-EliSpot assay. Colums, mean of duplicate determination; bars standard error of the mean. (Statistic analysis: unpaired t test,
significant (*) if P < 0.05)
In the IFN-γ EliSpot assay performed in parallel to the second experiment of detecting NY-
BR-1-specific CD4+ T cells among PBMCs of breast cancer patients (fig. 41 ), significant levels
of CD4+ T cells specific for their cognate antigen BR1-1347 could be detected among PBMCs
obtained from breast cancer patient BC-3 (fig. 47 A), indicated by significantly elevated IFN-γ
spot numbers/well compared to the medium control (no. pep.). Moreover, significantly elevated
levels of CD4+ T cells specific for the NY-BR1 derived peptide BR1-1242 could be detected
among PBMCs of breast cancer patient BC-6 (fig. 47 B).
As depicted in figure 47 D, significant elevated levels of BR1-1242 antigen-specific CD4+ T
cells could be detected among PBMCs obtained from healthy donor HD-3, indicated by elevated
IFN-γ spot numbers in the IFN-γ EliSpot assay.
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Figure 47: Experiment 2: Detection of NY-BR-1-specific T cells in breast cancer patient samples 24 days after in vitro
stimulation with NY-BR-1-specific peptides. 1 X 105 isolated breast cancer PBMCs were incubated with 5 µg/ml of the indicated
peptide for 18hrs in an IFN-γ-EliSpot assay. PBMCs were in vitro stimulated for 24 days with the same peptide as used in the
IFN-γ-EliSpot assay. Columns, mean of duplicate determination; bars standard error of the mean. (Statistic analysis: unpaired t test,
significant (*) if P < 0.05)
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To sum up, antigen-specific secretion of IFN-γ among PBMCs obtained from breast cancer
patients could be obtained, but results are not consistent within two independent IFN-γ Elispot
assays performed (fig. 46,47), and do not correlated with the data on antigen-specific CD4+ T
cells among PBMCs of breast cancer patients and healthy donors obtained by immunoflourescent
staining of the cells (fig. 41, 42). Background IFN-γ signal was very hight in this IFN-γ EliSpot
assay, to obtain more reliable data, firstly background IFN-γ signals should be reduced and secondly
the assay should be repeated with a greater amount of PBMC-samples obtained from HLA-
matched breast cancer patients and healthy donors.
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Familie angereist ist um mich in meinem “Projekt-Doktorarbeit” zu unterstützen.
Letztendlich wäre ohne die stetige Unterstützung meiner Familie auf meinem bisherigen Lebensweg
diese Arbeit nicht entstanden. Voran möchte ich meinen Eltern und meinem Bruder danken, die
es mir ermöglicht haben eine wissenschaftliche Laufbahn einzuschlagen und es immer wieder
geschafft haben mich in meinen Zielen zu bestärken und zu unterstützen. Ein großer Dank geht
auch an meine beiden Großelternpaare, die mir auf vielfältige Weise sehr geholfen haben das große
Ziel des Erlangens einer Doktorwürde, zu erreichen. Besonders hervorheben möchte ich auch den
unermüdlichen Einsatz seitens meiner Tante und Onkel, Danke für die zur jeder Zeit verfügbare
Unterstützung, die ich von Euch erfahren habe. Besonderer Dank gilt Benny, ich danke Dir von
Herzen dafür, dass Du mich nicht nur in der Zeit meiner Doktorarbeit immer unterstützt hast,
sondern auch sonst immer zu mir stehst und mir das wunderbare Gefühl gibst geliebt zu werden.
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